Transform

Action
Patients People

Environment Social Governance

ESG REPORT 2022 Biocon 5.0

Transform
Action
Biocon’s problem-solving spirit has
led it to harness the
transformational power of
biotechnology-led innovation to
improve the health and well-being of
humanity. Over the past four
decades, we have leveraged our
knowledge of modern molecular
biotechnology to engineer organisms
with beneficial traits, thus enabling
new solutions to the challenges of
disease.
From our origins as a pioneering biotechnology enterprise, we inculcated a
research-driven strategy to introduce eco-friendly, enzyme-based solutions
in industrial processing. Our innovation-led healthcare solutions that
provide affordable access to patients who battle cancer, diabetes, and
autoimmune diseases, are propelled by a clear sense of business purpose
and responsibility.
Environmental, Social and Governance (ESG) is at the core of our business
purpose and responsibility. By serving patients, protecting the environment,
and promoting business integrity, we are taking ‘sustainable action’ every
day, reinforcing our commitment to building an equitable and viable future.

We are putting new, research-driven insights into action to develop cost-

effective therapeutic products that address unmet patient needs and
reduce health inequities.

We are leading the transformation of patient ecosystems in collaboration

with partners and disruptive operating models.

We are unleashing the power of technology to improve the quality of

performance, increase efficiency and enable the highest levels of quality
compliance.

We are building a diverse, equitable, and inclusive workplace through

affirmative action, from recruitment to career and leadership development.

We are transitioning to renewable energy, reducing our carbon footprint,

conserving natural resources, and safeguarding ecological diversity to ensure
long-term environmental sustainability.

We are building resilient solutions that enable and empower disadvantaged

communities to live better, every day.

We are implementing globally benchmarked standards of governance to

create trust with patients, employees, customers, shareholders, and society.

It is transformation in action.

The challenges facing humanity remain significant. The past two-years have
been a stark reminder of our fragility as a species. In the face of a deadly
viral pandemic, climate disruption and economic standstill, embracing ESG
is now, more than ever, imperative for a responsible corporate citizen like
Biocon.

We are committed to taking bold and transformative action for the planet,
people, and prosperity.
About the Report

Report overview Reporting scope and boundary

As a company committed to achieving The FY22 ESG Report includes disclosures on
sustainable growth with positive social and the non-financial performance of Biocon Limited
environmental impacts, it is with immense pride and Biocon Biologics Limited, excluding Syngene
that we present Biocon’s first ESG Report in International, for the period 1st April 2021 to 31st
FY22. The purpose of this report is to share our March 2022. The reporting boundary further
value creation journey with all our stakeholders extends to include discussions on sustainability
and provide insights into the non-financial factors that impact the company’s ability to
performance of Biocon. Through this report, create long-term value.
our aim is to uphold the values of
accountability, responsibility and transparency Responsibility statement
that resonate across everything that we do.
We believe that this Report offers a balanced
Reporting standards view of our ESG performance and our efforts to
make a difference to all our stakeholders.
This report has been prepared in accordance
with the Global Reporting Initiative (GRI) The Board of Directors confirms that the
Universal Standards and the Securities Exchange content of this report has been developed
Board of India’s (SEBI) Business Responsibility under the guidance of the senior leadership and
and Sustainability Reporting (BRSR) guidelines the support of the various business functions.
and attempts to provide a holistic overview of
our ESG management practices and
performance.
4 | ESG Report 2022
 Biocon Limited

Contents
To view or download 02 TransformAction 58 Responsible Action Towards
our online reports, Environment
please log on to 06 Our Transformative Story
biocon.com 66 Transforming our Communities
10 Statements from the
Leadership 72 ESG Scorecard
20 Transformational Progress in 81 GRI Standards Index
Action
89 BRSR Index
24 Transforming Patient Lives
30 Governance in Action
40 Partnership in Action
46 Transforming the Workplace
TransformAction | 5
Our Transformative Story

Biocon was set up in 1978, as a joint venture Over the years, Biocon has periodically re-
with an Irish biotech company to manufacture invented its business model to usher in
bio-enzymes for the brewing industry for its transformational change.
partner’s global customers. Beginning with a
modest investment of Driven by a strong belief that the pharmaceutical
` 10,000 and operating out of a garage in industry has a humanitarian responsibility to
Bengaluru, Biocon has steadily evolved over the enable access to essential drugs for patients and
years, from being an entrepreneurial enzymes to do so with the power of innovation, Biocon
enterprise, to a globally recognized, innovation- has focused on building a new model of
led biopharmaceuticals company. innovation that adds the condition of
affordability to ensure accessibility.

Vision

To enhance global healthcare through innovative and affordable

biopharmaceuticals for patients, partners and healthcare systems
across the globe

Mission Values

To be an
integrated
biotechnology
enterprise
of global
distincti
on

Management of research and business partnerships Customer relationship through outstanding products and services

Intellectual asset creation through discovery, research, and Human resource development through training, mentoring and
empowering
development New medical insight through disease specific clinical
research
State-of-the-art manufacturing capabilities

Internationally benchmarked quality and regulatory systems 6 | ESG Report 2022

 Collaboration, teamwork, and

mutual respect Integrity and

ethical behaviour
Performance-driven work culture

Value creation through innovation and

differentiation Quality through compliance

and best practices
 Biocon Limited

Biocon is a differentiated player in own label in the U.S. and are gradually
the global pharmaceutical space expanding our reach to other geographies.

We have built a pipeline of niche, difficult-to-

make formulations with high barriers to entry.
120+ 14,750+ This, coupled with our excellence in execution,
will enable us to help address the needs of
patients, partners, and healthcare systems
countries1 worldwide.
employees1

Biosimilars

1,300 To address the global challenges associated

with non-communicable diseases (NCD), Biocon
1,060 rapidly moved up the pharmaceutical value chain
patents from small molecules to recombinant proteins
granted1 and antibodies in the early 2000s. We enabled
registered trademarks1
competition for expensive innovator biologics
through our biosimilars for diabetes and cancer.
Generated
We invested in cutting-edge Research and
revenues of
Development (R&D) and commercial scale
globally compliant manufacturing facilities
$1.1 across diverse technology platforms spanning
billion insulins, monoclonal antibodies, and conjugated
50+ recombinant proteins.

in FY221
cGMP approvals from
International regulatory
agencies

Generics

When we entered the biopharmaceutical sector

in the early 2000s, we made the strategic
choice of leveraging our core competence in
fermentation sciences to produce small molecule
Active Pharmaceutical Ingredients (APIs). As a
result of this focus, we were able to command a
significant market share for our portfolio of
APIs, initially comprising of statins and later,
increasingly dominated by immunosuppressants
and other specialty small molecules. For over 20
years, our global portfolio of APIs has catered to
over 700 pharma companies, with an
impeccable track record of quality, safety, and
reliability. To capture a larger portion of the
value chain in the Generics business, which was
a key anchor of Biocon’s initial success in
biopharmaceuticals, we forward integrated into
complex formulations such as injectables and
oral solids that incorporated our differentiated
APIs. We have successfully commercialized
several generic formulations under our
1
Includes
Syngene
TransformAction | 7
Biocon Biologics, which is an independent Biocon’s ground-breaking work in novel biologics
subsidiary of Biocon, is leveraging cutting-edge has enabled the company to address unmet
science, advanced R&D capabilities, innovative requirements for the treatment of cancer and
tech platforms and global-scale manufacturing autoimmune ailments. Our current portfolio
capacities to develop and manufacture high- includes molecules that we are developing in-house,
quality biosimilars for a global patient as well as, those that are driven by external
population. collaborations.

We established global credibility as a serious

biosimilars player through several ground-
breaking achievements, starting with the Indian
approval for the world’s first bTrastuzumab in
2014 and the Japanese approval for bGlargine
in 2016. We were the first in the world to obtain
U.S. approvals for bTrastuzumab in 2017 and
bPegfilgrastim in 2018.

Our biosimilar monoclonal antibodies and

therapeutic proteins are significantly impacting
cancer care worldwide. Our portfolio of affordable
recombinant human insulin and insulin analogs
are benefiting millions of people with diabetes
globally. In FY22, we touched 5.3 million
patients’ lives worldwide through our biosimilars
portfolio for diabetes, oncology, and
immunology.

Our investments in building global scale

manufacturing have led us to be among
the world’s Top 15 bio-manufacturing
companies. We are one of the leading insulin
producers worldwide and have global scale
antibodies manufacturing capacities as well.

To make a greater impact on global health, Biocon

Biologics executed two strategic transactions in
FY22. This included acquisition of Viatris’ global
biosimilars business will create a fully, vertically
integrated world-leading biosimilars company
with direct commercial presence in developed
and key emerging markets. The strategic
alliance with Serum Institute Life Sciences
provide Biocon Biologics an ‘asset light’ by
accelerating entry into vaccines. These
strategic developments will create a business
that will not only be able to expand our reach,
but also transform patients’ lives by delivering
affordable access to innovative and inclusive
healthcare solutions, thereby addressing the
issue of health inequity.

Novel Biologics
We are proud to be pioneers in the cutting-edge therapies for cancer. We are
development and launch of BIOMAb-EGFR confident that synergies between the scientific
(Nimotuzumab), India’s first indigenously teams in Boston and Bengaluru will pioneer rapid
manufactured novel monoclonal antibody for and cost-effective breakthrough innovation.
the treatment of head and neck cancer.
Furthermore, we developed and launched Research Services
ALZUMAb (Itolizumab), the world’s first
novel anti-CD6 monoclonal antibody, for Started in the early 1990s, Syngene was India’s
psoriasis and other indicators. Our proven first Contract Research Organization (CRO), set
capabilities in discovery, process, and product up with the aim of catering to the R&D needs of
development, translational and clinical the global pharmaceutical industry. Syngene’s
sciences, maximize the overall probability emergence as India’s leading contract
of our success. development and manufacturing company
(CDMO) triggered its successful public listing in
In the next few years, we are expecting 2015. Today, Syngene is well-positioned with its
results from studies involving our novel capabilities and infrastructure to leverage the
assets. strong market demand for the development and
manufacturing of drugs. The company is
Bicara Therapeutics, an associate of Biocon moving beyond a traditional service outsourcing
based in Boston, U.S., is developing a model toward true end-to-end collaborations,
pipeline of bifunctional antibodies that accelerating innovation for its clients across the
exploit the recent advances in immuno- drug R&D continuum. It is building expertise in
oncology. Bicara enables access to the immuno-oncology, CAR-T, mRNA, and small
thriving innovation ecosystem in the U.S. interfering RNA (siRNA) platforms for
which accelerates our development of researching next-generation therapies.

8 | ESG Report 2022

 Biocon Limited

TransformAction | 9
Statements from the Leadership

Transformative Action for Sustainable Outcomes

Chairperson’s Statement
Kiran Mazumdar-Shaw,
Executive Chairperson
Biocon and Biocon
Biologics
Innovation that delivers
affordable access to life-saving
therapeutics for patients
worldwide is at the core of our
business ambition. Our
philosophy of ensuring health
equity resonates with our
Environmental, Social, and
Governance or ESG aspirations.
In a world where ESG is
increasingly becoming a
“biomarker” of business
purpose, Biocon has adopted
practices to demonstrate
conscious capitalism,
environmental stewardship,
talent diversity, and equitable
governance within its
stakeholder ecosystem.

In FY22, Biocon made strategic

moves to further its purpose of
catalyzing transformative
change to address health
inequities across the world. We
charted new growth paths and
made a mega acquisition,
fostered alliances, and made
multiple new investments.
10 | ESG Report 2022
 Biocon Limited

Transformative Investments Through usage of solar and wind energy, the

share of ‘green power’ in total energy purchased
Our landmark decision to acquire the global across Biocon and Biocon Biologics India rose to
biosimilars business of our long-term partner, 58% in FY22. We achieved 117,697* tonnes of
Viatris, will enable full vertical integration across carbon dioxide equivalent (tCO2)
the biosimilars value chain from ‘lab to market’
and take us closer to patients, payors, and
*
BL + BBL (Excluding Malaysia)

healthcare providers in developed and emerging

markets.

Our quest to impact global healthcare steered us

towards a strategic expansion into adjacencies
such as vaccines. In FY22, Biocon Biologics
entered an alliance with India’s largest vaccine
maker, Serum Institute to join the effort of
addressing the inequitable access to vaccines.

Mission Insulin for Health Equity

As we commemorate 100 years of the discovery

of Insulin, we are positioning ourselves to build
global leadership through unlocking equitable
access to insulin and meeting varied patient
needs through our comprehensive portfolio.

We are proud of the historic approval we

received for the world’s first interchangeable
biosimilar in the US. In FY22, the launch of our
interchangeable Glargine is in line with our
aspiration to provide our biosimilar to ‘one-in-
five’ insulin-dependent people with diabetes,
globally.

Saving Lives During the Pandemic

At the height of the pandemic, we were able to

realize the potential of bio-therapeutics in the
fight against Covid-19 induced cytokine storm.
Our repurposed novel biologic ALZUMAb-L
(Itolizumab) benefited over 40,000 COVID-19
patients so far.

Practicing Environmental Empathy

As a company, we believe that health equity is

embedded in restoring ecological balance. This
belief has driven us continuously to identify
opportunities to increase the share of
renewables in our energy mix, improve energy
efficiency, innovate to drive productivity across
our value chain, implement the principles of a
circular economy, and adopt digital solutions
that minimize inefficiencies.
reductions in the year as a result of our green TransformAction | 11
power initiatives and the use of clean fuel
(natural gas) for steam generation.

We recorded 680,000 liters of incremental water

savings per day from water conservation
initiatives across the global manufacturing
operations of Biocon and Biocon Biologics.

Working Towards Gender Equity

As a woman entrepreneur, I have inculcated a strong

sense of purpose and commitment to diversity,
inclusion, and social equity at Biocon. This is
reflected in our aspiration to get to a 50:50
gender ratio by 2030. To achieve this target, we
are refining our policies and increasing career
opportunities for women through initiatives that
include management and leadership
development programs.

We were certified by Great Place to Work® India

as a Workplace with Inclusive Practices,
acknowledging our investment in our people
and our inclusive culture.

Digital transformation: A key strategic initiative

ESG is foundational for Biocon’s digital

transformation initiative. We are making
significant investments to transform the Biocon
Group into a data and digital-led global
biopharmaceuticals organization. These initiatives
are enhancing quality and compliance while
augmenting productivity through enhanced
operational excellence. They are also enabling
data integrity through technology-led data
transparency. Digitalization, we firmly believe,
can build higher standards of governance and
build greater levels of trust with all
stakeholders.
 ESG is foundational for Biocon’s digital
transformation initiative. We are making
significant investments to transform the Biocon
Group into a data and digital-led global
biopharmaceuticals organization.

Corporate philanthropy in action Building Hallmarks of Trust and Reliability

Biocon’s corporate philanthropy aims to build At Biocon, we believe in building trust with
resilient and innovative solutions that enable patients, customers, shareholders, and society
and empower disadvantaged communities to is the anchor for long-term success.
live better. In FY22, the Biocon Foundation
implemented several initiatives targeted at We are evolving and expanding our sustainability
increasing access to healthcare for underserved reporting and have captured our environmental
communities, improving the nutritional standing management, social impact, and corporate
of school-age children, promoting science & governance practices in our first GRI-aligned
technology, and sponsoring urban afforestation ESG Report.
initiatives.
Keeping with our focus on ESG issues, we are
Biocon Academy is the outcome of our endeavor taking transformative action to ensure
to build a talent ecosystem for biotech-related skills sustainable performance across operational,
in India. We have trained over 850 students over financial, environmental, social, governance
the last eight years, by augmenting their and humanitarian facets of our enterprise.
industry readiness and providing them with
value added employment opportunities in the
Indian life sciences sector.

Embracing ESG to drive the next phase of Kiran Mazumdar-Shaw

transformative action Executive Chairperson
Biocon and Biocon
Our business purpose is deeply intertwined with Biologics
ESG. By protecting the environment, serving
patients globally, and promoting business
integrity, we are reinforcing our commitment
to building a sustainable future. Our recent
entry in the Dow Jones Sustainability Index
(DJSI) Emerging Markets Index, where we
achieved a 93rd percentile position with a Total
Sustainability Score of 45, is a testimony to our
responsible and sustainable business practices.
12 | ESG Report 2022
 Biocon Limited

Sustainability is Integral to Business Strategy

Q&A with Siddharth Mittal,
Managing Director and CEO, Biocon Limited

How is the Indian landscape evolving from

the perspective of industry in achieving
UN Sustainable Development Goals?

Companies have started realizing that

sustainability is a serious business driver. They
now understand that profitability and growth
depend upon how effectively they are able to
meet the expectations of different stakeholders,
who are more aware and concerned about
sustainability than ever before. Employees, for
example, want their work to have a purpose
that goes beyond a narrow professional
definition. They want to be part of a company
that believes in being socially responsible.
Investors are now recognizing this reality and
are asking questions about a business’
sustainability strategies. Customers, too, are
looking at a company’s track record on
sustainability and social commitment before
making their purchasing decisions.

An article published by McKinsey and Co stated,

“We looked at companies on the New York
Stock Exchange and Nasdaq that had strong
ESG records at the start of the pandemic, both
when markets started to collapse and from
March 2021 onward when the markets began to
recover. In both of those periods, companies
with better ESG records outperformed those
with low records.”

Not surprisingly, sustainability is now a critical achieve Net Zero emissions by 2070 and
part of business strategy that is driven at the Board declared that 50 percent of our electricity
level in several companies, including Biocon. This production will be from renewable sources
is aided and propelled by increasing regulatory within the next decade. These commitments
momentum as well. For example, SEBIs Business are sure
Responsibility and Sustainability Reporting
framework will help create a level playing field
to ensure transparency, consistency, and
comparability in non-financial disclosures.

At the 26th UN Climate Change Conference, also

referred to as COP26, India has committed to
 As a company, we believe in truly exploiting the
opportunity to invest in innovation and R&D.
With this, our purpose of promoting good health
to translate into policy action to incentivize and and well-being as well as reducing inequalities
support businesses that decrease their carbon in access to necessary healthcare across
footprint. spectrums is met.

TransformAction | 13
 Biocon
Limited

What are the objectives and targets of Biocon Limited and Biocon Biologics, the Board
your sustainability efforts in Biocon? formed an Environment, Social and Governance
Committee to drive positive impacts across the
Making ESG commitments and stating a entity.
purpose is easy. However, these become
meaningless without transformative action. One
has to have a clear ESG strategy, based on
which a coherent program can be created,
comprising specific action points and clearly
defined, realistic goals.

Sustainability is integral to Biocon’s business

strategy as well as necessary for fostering long-
term investment, financial stability, and
business continuity.

Environment – We have sharpened our focus

on climate action to understand, assess, and
manage climate-related risks. We have adopted
circular economy principles to reduce water
usage and improve the efficiency of resource
utilization. Our target is to ultimately transform
our operations and make them net water
positive, or at the very least, water neutral.
Environmental responsibility is also embedded in
our supply chain management practices.

Social – Social responsibility is intrinsic to our

corporate policies and work culture. Being an
equal opportunity employer, we believe
strongly in the power of diversity, equity, and
inclusivity. Our people policies and practices
foster a culture of mutual trust and respect.
Additionally, our actions are aimed at delivering
positive societal and environmental outcomes
and building intrinsic value in the community
that we are a part of. We regard these as part
of our business goals.

Governance – We have established high

standards of governance to build an
environment of trust, transparency and
accountability. To drive a top-down approach
for ESG integration, our Corporate Social
Responsibility Committee at the Board level
was reconstituted to ‘Corporate Social
Responsibility and Environment, Social, and
Governance Committee’ with the primary
objective of providing oversight, direction and
monitoring our ESG strategy and initiatives, as
well as to direct initiatives to embed integrated
thinking within Biocon’s culture. Additionally, at
Can you provide an overview of what strategize resource allocation accordingly.
Biocon achieved during FY22 in terms Demonstrating transparency and inclusion,
of ensuring stakeholder equity? while prioritizing key focus areas for our growth,
has enabled us to gain our stakeholders’ trust. I
The past two years were very challenging am delighted that the stakeholder priorities that
for the world at large with the COVID-19 emerged are aligned with Biocon’s business
pandemic almost bringing the world priorities. The details of the assessment can be
economy to a standstill. Being in the perused later in this report.
pharma sector, our responsibility was
multifold. We had to ensure that our This year we published our first Tax Transparency
patients continued to get our medicines, Report, demonstrating our commitment to
which they count upon to stay in good openness on tax matters. We also developed a
health. At the same time, we had to ensure Code of Conduct as a support program for our
the safety and well-being of our employees suppliers and partners that help them align
and their families, while also supporting the their operations and practices with our ESG
government and local authorities in their goals. This enables us to build synergies with
efforts to mitigate the pandemic’s impact. our suppliers.

However, amidst all this disruption, we We have published our first standalone Human
never lost sight of our ESG goals and Rights Policy*, which details our approach to
undertook several measures towards upholding human rights across our value chain,
achieving them. including our permanent and contractual
employees, suppliers, consultants and our
Last year, we conducted a detailed Board members.
Materiality Assessment (MA) covering as
many as 113 different stakeholders, both Embedding ethics and compliance in every
internal and external. The MA helped us aspect of our business has resulted in our CDP,
identify the most material issues to be DJSI CSA and EcoVadis scores improving
prioritized for creating long-term value and significantly.

*Similar principles applicable to Biocon Biologics, currently embedded

14 | ESG Report in its Code of Conduct, is being developed as an independent
2022 global policy document.
 Biocon
Limited

Our employees are our biggest asset and to

Due to the need of a highly-skilled
facilitate our commitment towards transforming
workforce, how do you focus on attracting
their career journeys, we have developed a
and retaining talent and building their
competency framework which acts as the
skills? Can you specify the efforts you are
foundation for all our people processes, covering
making to ensure diversity and inclusion?
talent acquisition, performance evaluation,
talent development, and succession planning. The well-being of our employees is of
We have also launched initiatives to build a paramount importance at Biocon, and we have
pervasive culture of excellence at Biocon and in place several initiatives and programs to
systematically incorporated tech-enabled tools enable them to stay in good health, physically,
into our processes to enhance efficiency, mentally, and emotionally. We foster a sense of
eliminate human error and ensure consistency of belonging and an ambience of mutual respect
quality. Our digitization journey is ongoing and and positive collaborative spirit through several
driven at the highest levels. employee engagement initiatives that cover
health and wellness and motivational sessions,
Can you provide an overview of what
to name a few.
Biocon achieved during FY22 in terms of
ensuring environmental equity? We hired 2,806 individuals as full-time
employees during FY22. We introduced several
We continue to build on the programs and
initiatives to enable our employees to learn,
initiatives undertaken over the last two years.
grow and develop their careers, such as
• With regard to energy purchased, we have departmental scorecards, career-pathing,
reduced our non-renewable energy from competency frameworks, and digital learning
141,700-megawatt hour (MWh) to 137,200 programs to facilitate the development of
MWh, and increased our renewable energy individuals in multiple domains. In this vein,
to110,000 MWh from 95,000 MWh. the total training hours for our employees stood
at over 178,000. We invested a total of ` 27
• We invested ` 80 million in a new 600 million for employee learning and development
kiloliters/day (KLD) capacity zero liquid in FY22.
discharge (ZLD) effluent treatment plant in
Bengaluru. This will gain us 680,000 liters of Biocon is an equal opportunity employer and
incremental water savings per day as 100 abides by a policy of equal pay for equal work.
percent of wastewater is recycled and reused Diversity and inclusion are intrinsic to our work
back in the process or in utilities.
culture and people. Our organization level
• We also sent over 5,500 tonnes of high- diversity ratio grew from 10.5 percent in FY
calorific waste for reuse as an auxiliary fuel to 2020-21 to 12.3 percent in FY 2021-22
cement factories. Besides, as much as 60
percent of solid waste generated at our facilities How would you sum up Biocon’s ESG
is recycled. journey in FY22?

• Approximately 58 percent of total electricity The significant improvement in our scores in

purchased for consumption at our India sites DJSI and CDP is a validation of the
in FY22 was from green sources for BL & BBL transformative actions being undertaken at
Indian operations. Biocon to embed ESG within and beyond the
All of these transformative actions have helped organization. As an ongoing journey, this aspect
us achieve reductions of over 102,000 tCO 2 in of our business has been accorded the topmost
FY21 and 117,000 tCO2 in FY22. priority and is overseen at the highest levels.
Going forward, we see ourselves delivering even
better results on the ESG front in the years to
come.
Siddharth Mittal
Managing Director and Chief Executive Officer, Biocon Limited

TransformAction | 15
 Biocon
Limited

Turning ESG Strategy into Action

Q&A with Dr. Arun Chandavarkar,
Managing Director, Biocon Biologics

How are you improving global patient

equity through Biocon Biologics’
biosimilars business?

At Biocon Biologics, we strongly believe that

healthcare must take many forms and should be
accessible to all in a cost-effective way. Biologics
have increasingly become the foundation of
innovative therapies in modern medicine. Given
the pipeline of therapies in clinical development,
it is evident that biological therapies will
continue to gain importance, if not dominate
the market.

Biosimilars, which are follow-on biologics manufacturing has allowed us to build a pipeline of
typically launched after the innovator molecules 20 biosimilar assets for the coming decade. We will
lose patent protection, have already continue to invest in R&D to develop quality
demonstrated their ability to broaden access to biosimilars for high-value therapeutics, enabling
several life-saving therapies, thus enabling wider patient access.
patient equity. Having entered this segment
more than 15 years ago, Biocon is a frontrunner
in biosimilars today. As an industry pioneer,
Biocon was amongst the first wave of
companies to address the global need for
biosimilars. Biocon Biologics, which is an
independent subsidiary of Biocon with its
management team, is leveraging strong
science, global scale and its long experience in
biopharmaceuticals to develop and
manufacture several high-quality biosimilars for
treating various chronic conditions for global
patient population. We have developed several
monoclonal antibodies and therapeutic
proteins, which are significantly impacting
cancer care worldwide. Our portfolio of
affordable recombinant human insulin and
insulin analogs is benefiting millions of people
with diabetes globally. In FY22, we touched 5.3
million patients’ lives worldwide through our
biosimilars portfolio for diabetes, oncology, and
immunology.

Our expertise in product development and

 How do you see Biocon Biologics
contributing to the global fight against
diabetes?

Diabetes is a worldwide NCD pandemic that

affects nearly half a billion people.
Unfortunately, ‘four out of five’ people with
diabetes live in low- and middle-income countries
(LMICs). Insulins help save the lives of millions of
diabetes patients each year, yet millions are
denied access to this life-saving therapy due to
its prohibitive costs.

16 | ESG Report 2022

 Biocon
Limited

Despite the capital-intensive nature of insulin investments in expanding its

production, Biocon Biologics has succeeded in manufacturing capacities. How do these
expanding access to insulin therapy in India and investments dovetail with your
key global markets by pursuing an innovation sustainability objectives?
strategy that is rooted in affordability. We have
built one of the largest insulin manufacturing Biocon Biologics has taken a modular approach to
capacities in the world, which we are using to capacity expansion. As we progress on our strong
shift the access paradigm for insulins, growth trajectory,
worldwide.

Biocon Biologics, through its proprietary Pichia

pastoris platform, has been able to disrupt the
insulins market globally. Our journey, which
started with recombinant human insulin in
India, has broadened to cover several global
markets including the U.S. We have
cumulatively supplied over 2.75 billion doses of
recombinant human insulin to patients globally
over the years.

Following the landmark commercialization of

bGlargine in the U.S. in FY21, we marked
another milestone by obtaining interchangeable
designation from the U.S. FDA for our
bGglargine in FY22. We are the first in the
world to obtain approval for an interchangeable
biosimilar product in the U.S. The
interchangeability approval, which allowed
substitution of our product for the innovator
at the pharmacy counter, demonstrated our
scientific, quality, and regulatory capabilities.
The interchangeability status is allowing us to
offer people living with diabetes in the U.S.
more treatment options, rationalize cost of
therapy and generate savings for the overall
healthcare system. Our insulins are widening
the treatment options available to patients
living with diabetes, as well as enabling local
healthcare systems to realize substantial
savings on diabetes care. With the aim of making
insulins affordable and accessible to patients in
LMICs, we have rolled out our ‘Mission 10 cents’
initiative to supply recombinant human insulin at
less than 10 U.S. cents per day to governments
in some countries.

With the EU approval of our bAspart, we now

have a broad portfolio, comprising basal, mixed
and rapid acting insulins to meet the varied
needs of people with diabetes worldwide.

Biocon Biologics has been making large

we will continue to invest in upgrading our industry, we have implemented targeted
facilities with new age technology and interventions to ensure all our manufacturing
capabilities to ensure that we meet our global operations in India are Zero Liquid Discharge
sustainability goals. Our new 340,000- square (ZLD) facilities equipped with advanced
feet, monoclonal antibodies manufacturing facility engineering systems to treat and reuse
received an honorable mention at the 2021 wastewater and effluents.
Facility of the Year Award (FOYA) from the
International Society for Pharmaceutical Biocon Biologics has multiple partners
Engineering (ISPE). This facility has been across the globe, including developed and
designed to be energy-efficient with green emerging markets. How do you ensure
building design features, thus reducing our stakeholder equity?
carbon footprint.
At Biocon Biologics, we believe synergistic
Conducting our business in the most responsible collaborations can help us capitalize on each
manner has always been in our DNA since others strengths to deliver on our objective of
inception. We continuously undertake initiatives enabling patient equity. Therefore, we have
across our facilities to ensure minimal entered global partnerships for research,
environmental impact. We have been increasing manufacturing, and commercialization. Our
the share of renewable energy across our long-standing global partnership with Viatris
operations through onsite solar installations and has enabled us to achieve many firsts, setting
the procurement of wind energy. Further, we new benchmarks for the global biosimilars
have adopted other innovative technologies like industry. In FY22, we made a strategic decision
energy efficient centrifugal air compressors, to acquire the global biosimilars business of
water chillers and motors, and rooftop solar Viatris to create a fully integrated biosimilars
panels to reduce energy consumption, thereby, business in Biocon Biologics. This deal provides
offsetting 63 percent of our total greenhouse several advantages, including expanded global
gas emissions across Biocon Limited and Biocon footprint, direct-to-market access, strategic
Biologics. agility and operational efficiencies. Once
concluded, this acquisition will enable us to
Bio-manufacturing being a water-intensive expand patient access to biosimilars and reduce
healthcare inequities worldwide.

TransformAction | 17
 Biocon
Limited

During FY22, we also entered into a strategic employees is evident through the various employee
alliance with Serum Institute Life Sciences engagement initiatives, which have been
(SILS) for vaccines to make a meaningful recognized through several awards both nationally
impact in fighting infectious diseases. Vaccines and internationally.
and antibodies for infectious disease are a
natural adjacency to Biocon Biologics’ existing
capabilities in biologics for non-communicable
diseases. Together with SILS, we believe we can
address patients’ needs for vaccines for various
infectious diseases, including COVID-19.

Our partnerships extend beyond our peers to

include our vendors and consultants who have
provided us with a continuous supply of raw
materials, equipment as well as technical
expertise when required. We are grateful for
their efforts, which have enabled us to scale our
operations and ensure business continuity, even
in difficult times.

Our investor community has been vital in

ensuring that we maintain a culture of
transparency and accountability. We have
received funding from four private equity
investors and will be welcoming SILS and Viatris
as shareholders post the completion of the two
strategic deals, which I am sure will support us
in building a world-class biosimilars company.

As a biopharma leader who has to deal

with the shortage of high-quality talent,
what are your key focus areas for talent
management?

Biocon Biologics’ workplace culture has been

built on a strong sense of purpose and values.

It is designed to foster a healthy, happy and

safe work environment where employees can
fulfill their career aspirations while contributing
to the organizational goals. We continuously
strive to build a culture of transparency,
openness, and innovation where people can find
solutions to address patients’ needs.

Biocon Biologics continues to make investments

for people development, in learning & training,
mentoring & empowering and enabling their
career growth, thereby accentuating their
contribution to the biopharma industry. We
pride ourselves on our people-centric approach.
Our concern for the health and well-being of our
What is Biocon Biologics doing to professional management team and
ensure diversity, equity and inclusion independent Board of Directors was not only to
especially with respect to gender ensure undivided focus on the biosimilars
parity? business, but also ensure better governance.
We have adopted globally benchmarked
Diversity and inclusion are at the core of standards of governance to foster long-term
our business strategy as we believe that investment, financial stability and business
everyone has unique strengths which can be integrity, which enable sustained and equitable
leveraged to create a culture of innovation growth. Our ethical business practices have
at Biocon Biologics. Over the years we have earned us a strong reputation and we continue
focused on diversity hiring and have a large to always uphold these through the highest
pool of women scientists who have level of compliance to our Code of Conduct and
partnered our science-led innovation Ethics. We have put systems and processes in
journey. We take pride in having a merit- place at Biocon Biologics that support the
based work culture and have ensured anticipated growth in business while protecting
gender parity in terms of compensation and the interests of our shareholders and other
benefits for similar roles. In order to ensure relevant stakeholders. In order to ensure
that women are well-represented in every consistent focus and drive our ESG strategy we have
team, we run special leadership designed a robust multi-tiered governance
development programs for women to take framework at the Board, management and
up larger roles. working group levels. As we bring global
investors and new partners on board, we will
Having already created a professional uphold our firm commitment to ethics and
management team and an values inherited from our parent company,
independent Board for Biocon
Biocon Limited.
Biologics, what additional measures
are you taking to reinforce corporate
governance in the entity?
Dr. Arun Chandavarkar
The premise of carving out Biocon Biologics Managing Director, Biocon Biologics
as an independent entity with its own

18 | ESG Report 2022

 Biocon Limited

TransformAction | 19
Transformational
Progress in Action
Our purpose, to champion change and make a
meaningful and tangible difference in the lives of our
patients and our people, forms the basis of all our
business decisions. To deliver on our purpose, we are
committed to a sustainable and equitable future
with a strong focus on employee wellbeing, enabling
development in the community and minimizing our
impact on the environment.
20 | ESG Report 2022
 Biocon
Limited

A purpose-led approach translates into stakeholders through online survey

integrating ESG considerations in the design questionnaires, and personal interviews. The
and execution phase of our business strategies. results of the assessment provided us with a
We have defined our vision and ambition priority list of ESG topics that are relevant to the
towards ESG integration, supported by clear long-term value creation potential of the
goals and commitments, and are transforming company. These ESG topics helped us develop
our business to better deliver shared value for our ESG focus areas over the next two to three
our stakeholders. Our approach to ESG pivots years.
around building trust, accountability, and
transparency to drive long-term value, minimize
risk and seize emerging opportunities.

Transformational Action on ESG

While the formal integration of ESG into our
business model has been a recent
development, its core ethos and principles have
always been a part of our business decisions.
We believe in doing business the right way and
over the years we have implemented a robust
framework of policies and processes that enable
us to be responsible corporate citizens.

The emergence of ESG standards and

frameworks coupled with rapidly evolving
regulations have provided an impetus at Biocon
to better understand and formulate our business
strategy to deliver a positive impact for our
stakeholders. The journey of recognizing ESG
principles as a key, standalone criterion for
business decisions underwent several steps:

• Conducted an ESG diagnostic: We started

our ESG journey by conducting a detailed
assessment to review and benchmark our
existing policies and processes, identifying
opportunities and strategies to build a more
sustainable company. The outcomes of the
exercise established a baseline and provided
insights into opportunities for further
improvement, which became integral
considerations to our ESG roadmap for FY22
and beyond.

• Assessed materiality: The ESG landscape is

dynamic and ever evolving. In order to
understand changing stakeholder
expectations and capture their perspective on
ESG priorities for our business, we conducted
a detailed materiality assessment, wherein we
engaged with over 110 internal and external
TransformAction 21
|
• Institutionalizing ESG into our stakeholder expectations demanding greater
governance structure: We recognize that in tax transparency, we have developed and
order to truly integrate ESG into our business published a comprehensive tax Policy, and
model, we need to identify ESG stewards we are also publishing our first ever ‘Tax
within the organization and assign roles and Transparency Report’. The purpose of the
responsibilities for implementing and Report is to provide an overview of our tax
monitoring our progress along the ESG strategy, our
transition. To provide adequate oversight and
accountability on ESG, we have instituted the
‘Corporate Social Responsibility and
Environment, Social and Governance
Committee’ and the ‘Environment, Social and
Governance Committee’ at Biocon Limited
and Biocon Biologics Limited, respectively.
The Committees report directly to the Board
and drive a top-down approach towards ESG
integration.

• Developing an ESG roadmap: We also

recognize that embedding ESG into everything
we do is a gradual process. Accordingly, we
have developed a pathway towards greater
ESG adoption by developing detailed actions
plans and business-function level roadmaps.
The roadmap sets out clear goals to achieve
our sustainable development ambitions and
will be tracked based on clearly defined
metrics under our established governance
process.

• Managing supply chain ESG risks: We

hold our partners and suppliers accountable to
the same set of expectations on ESG as we
hold ourselves. While we do have defined
processes for supplier assessments, we
developed a ‘Supplier Code of Conduct’, a
standalone charter which outlines
expectations from third parties, vendors and
suppliers towards fair treatment, ethical
behavior and safe and sustainable business
practices.

• We are publishing our first ESG Report for

FY22 in accordance with the Global
Reporting Initiative (GRI) Universal Standards
to enhance transparency on non-financial
performance. This report will also be our first
step to integrate SEBI’s BRSR guidelines for
ESG reporting ahead of its prescribed
statutory adoption in FY23

• Tax Transparency Report for FY22: In

lieu of the recent developments related to
 Biocon
Limited

governance, control and risk management Our ESG Highlights

framework and our contributions to the
exchequer. The publicly available Tax We have continued to improve our ESG initiatives to
Transparency Report is intended to improve ensure that the impact of our actions leads to
transparency and build a deeper sense of trust positive change. This is evidenced by our key
in our stakeholders regarding the highlights for FY21 and FY22, detailed below:
management of tax in our company.

• Human Rights Policy*: Demonstrative of

our values, this year we strengthened our
commitment to free and fair practices by
formulating our Human Rights Policy*. This is
in alignment with the ten-tier principles of the
UN Global Compact and the Universal
Declaration of Human Rights (UDHR). This
policy is aligned with Biocon’s Code of
Conduct and Supplier Code of Conduct and
imbibes the spirit of protecting human rights
in our operations and across the value chain.
The Policy confirms our commitment to equal
opportunity, non-discrimination, health and
safety, free employment, fair wage and
benefits, data privacy, corporate social
responsibility, etc. The Human Rights Policy*
applies to all employees of Biocon Limited
and its subsidiaries (excluding Biocon
Biologics, Syngene and their subsidiaries),
including business partners, contractual
employees, trainees, volunteers, consultants,
and members of the Board of Directors. We
intend to conduct appropriate training for
various stakeholders to ensure that they
understand and share the same commitment
towards this end.

• Improving our ESG ratings and scores:

We featured for the first time on the DJSI
Emerging Markets Index in 2021, with a total
sustainability score of 45 as against the
industry average of 18, thereby achieving a
93rd percentile position. We have also secured
‘B’ in the Carbon Disclosure Project (CDP) for
both Climate Change & Water Security
demonstrating disclosure, awareness and
management of climate change and water
related issues in our business, which is higher
than the global average of the biotech and
pharma sectors. We were awarded a Bronze
Medal by EcoVadis in FY22 for our ESG
performance.
TransformAction 23
|
• Biocon Biologics’ proposed acquisition of • Published our first Tax Policy and, voluntary
partner Viatris’ biosimilars business is a ‘Tax Transparency Report’ FY22
transformational deal that will accelerate
our mission of making biosimilars • Biocon Limited published a standalone Human
affordable, available and accessible to a Rights policy*
larger global patient pool.
• Published our Supplier Code of Conduct which
• Biocon Biologics has entered into an integrates ESG expectations such as Zero
alliance with Serum Institute Life Sciences tolerance for child labor
(SILS) to join the effort of addressing the
inequitable access to vaccines. • All employees trained in Adverse Event Reporting

• The landmark approval of • Continued digitization initiatives to

interchangeable bGlargine, co-developed strengthen the Quality Management System
with Viatris, will allow Biocon Biologics to and Learning Management
improve accessibility, availability and
Transforming Patient Lives
adoption of biosimilars in the U.S. for the
benefit of patients and the overall
• R&D Spend - ` 5,950 Million (FY22), 10%
healthcare system.
of total revenue**
Governance in Action
• Doses of rh-Insulin supplied to people with
diabetes globally since 2004 - ~2.75 billion
• Robust and globally benchmarked
corporate governance policies
• Patients benefitted through our biosimilars in FY22
- 5.3 million

*Similar principles applicable to Biocon Biologics, currently embedded

in its Code of Conduct, is being developed as an independent
global policy document.
22 | ESG Report
2022 **BL and BBL
 Biocon
Limited

Responsible Action Towards Environment4 for FY22 stood at 19.9. Furthermore, the
average amount spent per full-time employee
• Energy consumed - 511,354 MWh
on training and development stood at ` 3,033
• Water consumed - 1.71 million m3 in FY22

• Green Energy Purchased - 58 percent for BL • ISO 45001 (Occupational Health and Safety
& BBL Indian operations Management Systems) certified

• Total GHG offset - 117,697 tCO2 Transforming our Communities

• ` 113 million (BL and BBL) in Corporate Social

• ISO 14001 (Environmental Management
Responsibility (CSR) spending in FY22
Systems certified
• Investment in Hebbagodi Lake Rejuvenation
Transforming the Workplace
Project since inception is more than ` 82
• The number of women in the permanent million, with
workforce stood at 1,531 in FY22 while it was ` 5 million invested in FY22
1,354 in FY21.
• 120+ students graduated from Biocon
• 13 percent increase in women who constitute Academy in FY22 with 100 percent placement
the permanent workforce in FY22 as across leading pharma, biotech, and life
compared to FY21 sciences companies

• ` 12.8 million invested in activities such as • ~71,000 patient visits at the Biocon
annual health check-ups, employee Foundation-run eLAJ smart clinics in FY22
engagement initiatives, and RT-PCR testing
for our employees at Biocon Limited, India

• The total hours of training in FY22 stood at

178,264. The average training hours per
full-time employee

ESG highlights:
Carbon Disclosure Among Dow Jones Ecovadis assessment
Project (CDP) rating on Sustainability Index score increased from
Climate Change and (DJSI) score improved
Water Security
improved from
Top 15 from

35 to 52
Companies from India 18 to 45
C to B on Dow Jones
this year, compared
Sustainability
to last reporting
Emerging Markets in 2021 year
in 2021 Index in the 2021
Corporate

TransformAction 23
|
FY22
4
 Biocon
Limited

Transforming
Patient Lives
We discover, develop, and deliver affordable
medicines that help transform patient lives. Their
health and wellbeing are our top priority. Our
products have also helped enhance the healthcare
process in developing countries, furthering our goal
of achieving health equity for all.

TransformAction 25
|
24 | ESG Report 2022
 Biocon
Limited

Global health today is characterized by deeply This year began with two new formulation
entrenched inequities in access to quality product launches – Labetalol Hydrochloride
healthcare. Availability and accessibility of tablets and Esomeprazole Magnesium Delayed-
essential and life-saving medicines are a Release capsules. Labetalol is used to treat high
prerequisite to guarantee healthy lives and social blood pressure and helps in the prevention of
security for the majority of the world’s cardiovascular complications such as heart
population. Our commitment is to deliver attack and stroke, while Esomeprazole
medicines to a vast proportion of people and Magnesium, a proton pump inhibitor, is
ensure better patient outcomes. Over the past indicated for the treatment of gastroesophageal
20 years, Biocon has leveraged India’s value reflux diseases. This was followed by a key
advantage of scientific talent and advanced launch of our vertically integrated complex
manufacturing to deliver scale, speed, and formulation, Everolimus tablets in October
quality that enabled affordable access to 2021. Everolimus is a prescription medication
complex therapies for chronic conditions. that is used to treat certain types of cancers
Through our portfolio of generics, biosimilars and tumors. Further, we secured product
and novel biologics we have strengthened our approvals for Mycophenolic Acid, which is
value proposition to reflect our four strategic indicated for the prophylaxis of organ rejection,
pillars: accessibility, affordability, availability, and Posaconazole, an anti-fungal drug, as well as
assurance. Dorzolamide, an ophthalmic product. Before the
close of the fiscal, we were able to
Generics commercialize the latter two products.
Biocon is focused on delivering high-quality and
efficacious small molecule generic APIs and We continue to expand our portfolio and our
formulations across the globe. The cost savings regional presence while also building in-house
offered by generic drugs position them as manufacturing capabilities to support future
affordable alternatives to innovator drugs. They growth.
reduce the burden of healthcare costs for
patients, providers and healthcare systems. If
more prescribers substituted generics for
brand-name drugs, healthcare spending could
reduce substantially, especially for those in the Strengthening capacity and capabilities in API
middle to low-income brackets. manufacturing
We are close to completing the commissioning of our
greenfield, fermentation-based immunosuppressant API
Our global portfolio in APIs has grown During the fiscal year, we filed 34 DMFs globally,
significantly catering to ~500 pharma including 5 in the U.S. We also received
companies in 100+ countries, including approvals for 16 DMFs in various geographies
the U.S., Europe and large emerging across the U.S., Europe, and most of the world
markets. (MoW).

With a track record of excellence for over 20 years,

our APIs find application in high-quality drugs
that treat oncology, cardiology, CNS, neurology,
orthopedic, pulmonology, gastroenterology,
nephrology, ophthalmology, and endocrinology
conditions.

TransformAction 25
|
manufacturing facility in Visakhapatnam, Andhra
Pradesh. This is our first facility to be enabled with
Industry 4.0. transformative technologies and will
add much-needed capacities to serve our
customers’ demands. We are also investing in
synthetic, potent, and peptides API manufacturing in
addition to injectables in alignment with our
strategic priorities. Apart from manufacturing
capacity and capability expansion, we
strengthened our R&D capabilities as well through
an improved organizational structure.

26 | ESG Report
2022
 Biocon
Limited

Biosimilars Expanding into adjacent therapies

Biocon operates its biosimilar business through Whilst we have been primarily focused on bio-
its subsidiary Biocon Biologics Limited (BBL). therapeutics for non-communicable disease to
We develop high-quality, affordable biosimilars deliver on our vision of affordable, innovative
that can expand access to cutting-edge and inclusive healthcare solutions, we recognize
therapeutics for patients globally at our R&D that a strong presence in communicable
sites in Bengaluru and Chennai (India). These disease is an essential element to have a
are manufactured at scale for both developed holistic impact on patient lives.
and emerging markets in Bengaluru (India) and
Johor (Malaysia). Our products are marketed The rapid increase in the frequency of viral
globally through a hybrid commercial model, outbreaks such as Dengue, Zika, Ebola and more
wherein we have direct commercial presence in recently COVID-19, has had a devastating impact
a few countries and in others, we leverage on human life. Through our Covid-care portfolio,
partners such as Viatris to expand patient anchored by Alzumab-L (our novel antibody
reach. Itolizumab), we were able to realize the potential
of bio-therapeutics in the fight against infectious
FY22 was a transformational year for Biocon diseases.
Biologics. It marked several watershed events,
both strategic and operational, which have set Biocon’s more than 20 years of investments in
the stage for us to better deliver on our biologics provides a strong foundation to
commitment to serve patients and enhance contribute further to this fight, leading to our
global healthcare. strategic expansion into adjacencies such as
vaccines and antibodies.
Accelerating our vision of widening
access to biosimilars Biocon Biologics entered in a partnership with
Earlier this year, we signed a definitive Serum Institute Life Sciences (SILS) in September
agreement to acquire the global biosimilars 2021 for supply of about 100 million annual doses
business of our long-term partner Viatris for of vaccines per annum. The vaccines alliance
USD 3.3 billion. This acquisition, upon closing, with SILS strengthens Biocon Biologics’
will accelerate our strategy to create a fully, presence in infectious diseases, enabling it to
vertically integrated company with direct further its offering to patients.
commercial presence in the developed markets.
Gradually, we aim to establish a vaccine R&D
This transaction is unique as it brings together
division to support the strategic alliance in
the two companies’ teams, which have been
developing both vaccines and biologics for
collaborating on common projects, into a single,
communicable diseases, adding to our portfolio
integrated organization driven by a common
of life saving patient therapies.
vision and mission of improving affordability and
enabling greater access through lifesaving
Biocon also entered into a partnership with
biosimilars.
Adagio Therapeutics for manufacturing and
commercializing a novel COVID-19 antibody
Through this deal, we intend to integrate
therapy, ADG20 in India and select emerging
Viatris’ biosimilars commercial infrastructure
markets.
globally. We will gain from Viatris’ experience
on navigating the formulary positioning,
contracting, front end sales, regulatory
interface, and distribution in these markets.

As a vertically integrated enterprise, we will be quicker decision making, improved market insights
able to drive efficiencies in the system with and common focus across functions. This deal gives
TransformAction 27
|
us better strategic agility to improve overall cost
Aiming to make a difference
of supply chain, capital allocation and
with first-ever interchangeable
distribution, among others.
biosimilar Insulin Glargine in
U.S.
In July 2021, our biosimilar Insulin Glargine received historic
U.S. approval as the first interchangeable biosimilar
under the 351(k) regulatory pathways. Our partner
Viatris launched this first-ever interchangeable
biosimilar Glargine in the U.S. in November 2021,
thus providing a more affordable option for the
millions of Americans living with diabetes.

28 | ESG Report
2022
 Biocon
Limited

This is a matter of great pride for the country and for

all of us at Biocon Biologics. We believe this
Novel Biologics
interchangeable designation is a game-changing Our novel molecule, Itolizumab, is currently
development, as it will allow pharmacy- level being developed for indications such as acute
substitution of the reference product by our graft-versus-host disease (aGVHD) and systemic
biosimilar Insulin Glargine. It will maximize access
lupus erythematosus (SLE) or lupus nephritis (LN)
to an important therapy, regardless of financial
by our U.S.-based partner Equillium for the U.S.,
circumstances, insurance, or channel.
Canada, Australia and New Zealand.
Already, our interchangeable product has been
included in the National Formularies of two leading Itolizumab has been at the forefront of our fight
Pharmacy Benefit Managers (PBM) in the U.S., against COVID-19 in India, after we repurposed
Express Scripts and Prime Therapeutics, which it for the prevention and treatment of cytokine
together have a reach of over 60 million members. release syndrome (CRS) in moderate to severe
The product will also be offered through the acute respiratory distress syndrome (ARDS)
Walgreens Prescription Savings Club, saving patients due to COVID-19. In FY22, we completed
members up to 80 percent off the cash price of our Phase IV study of Itolizumab to treat CRS in
comparable long-acting insulins purchased at moderate to severe ARDS patients.
Walgreens.
In July 2021, the European Medicines Agency’s
We believe our biosimilar Insulin Glargine has the
Committee for Orphan Medicinal Products
potential to bring significant cost savings for
granted an orphan medicinal product
patients, employers and PBMs, making insulin-
based therapy affordable for a large number of designation to Itolizumab for the treatment of
people with diabetes in the U.S. both acute and chronic GVHD. This was
a milestone for us as we intend to develop this drug for
patients in Europe upon regulatory approval.

Our actions during the pandemic

Enabling affordable Through this initiative, Biocon Biologics focuses on
access to quality insulins implementing a continuum of care model
encompassing a diabetes patient’s journey from
In April 2022, the Ministry of Health (MoH), Malaysia awareness to early diagnosis and treatment.
awarded a three-year contract to Biocon Biologics
for its recombinant human insulin brand Insugen®.
As a result, our Insugen formulations will be
available to patients at all MoH hospitals, district
health offices and health clinics. This will further
expand affordable access to 400,000 patients with
diabetes and support the government in its journey
towards equitable access to diabetes care.

Since our entry into Malaysia in 2011, the prices of

human insulin have dropped by over 20 percent and
insulinization has improved by 30 percent. Being the
only insulin manufacturer in Malaysia, we play a
transformative role in insulin self-sufficiency, enabling
our mission towards increasing health equity.

We have designed a special program, ‘Mission 10

cents’, to offer our rh-Insulin to governments in
Low- and Middle- Income Countries for less than 10
U.S. cents a day. We have signed pacts to enable
access to rh-Insulin in the Philippines and Tanzania.
TransformAction 27
|
The unprecedented events of the past two As the COVID-19 pandemic swept through India,
years are reflective of the unique challenges Biocon responded to the need of the hour and
the world is facing. And the actions undertaken repurposed its novel biologic, ALZUMAb
by our employees and partners are a (Itolizumab) a first-in-class, anti-CD6 IgG1
testament to our ability to mitigate such monoclonal antibody. Itolizumab was used to
challenges. Powered by a culture of innovation, treat cytokine release syndrome (CRS) in
Biocon and its subsidiaries ensured that we COVID-19 patients experiencing moderate to severe
fulfilled our commitment of providing access to acute respiratory distress syndrome (ARDS).
life-saving medicines during COVID-19. Our top ALZUMAb-L benefited over 30,000 COVID-19
priority remained to protect human lives in a patients in FY22.
public health crisis and encourage all our
employees to relentlessly contribute towards We offered a comprehensive portfolio of
ensuring stability in our operations. products for treating COVID-19 patients at
different stages of the

28 | ESG Report
2022
 Biocon
Limited

disease spectrum, including RemWin

(Remdesivir) and ARAFLU (Favipiravir) for mild
to moderate patients, ALZUMAb-L for moderate
to severe patients and CytoSorb for critical
patients.

Our actions to combat the pandemic went

beyond supplying therapies for treating COVID-
19. We set up the necessary infrastructure
required to provide proper COVID care. During
the reporting period, we undertook the
responsibility of augmenting the COVID-19 care
infrastructure at the Anekal General Hospital
and supported the State Government in its
pandemic response efforts across over 20
Primary Health Centers in Karnataka. With
resources being diverted towards pandemic
management, our health interventions
addressed the need for prevention, screening
and control of common NCDs such as
hypertension, diabetes and common cancer.

In FY21, we had established a reverse

transcription– polymerase chain reaction (RT-
PCR) testing facility which is approved by NABL
and ICMR and adheres to the BSL-2 criteria. Over
100,000 samples have been tested at this
facility over the past two years.

In FY22, we implemented a COVID-19

vaccination drive covering several thousand
eligible individuals, including senior citizens,
people with co-morbidities and differently abled
individuals which was organised by the Biocon
Foundation.

TransformAction 29
|
 Biocon Limited

30 | ESG Report TransformAction | 29

2022
Governanc
e in Action
At Biocon, we live our values by demonstrating the
highest levels of ethics, compliance, and
governance. By further integrating ESG within our
governance and risk management framework, we
are expanding our field of view, assessing risks
holistically, implementing comprehensive controls
and identifying new opportunities to deliver
transformative outcomes to all stakeholders.
30 | ESG Report 2022
 Biocon
Limited

We implemented globally benchmarked maintain the highest standards of corporate

standards of governance to build trust with governance and enhance shared value.
patients, customers, shareholders and society.
With the aim to develop a culture of the best
management practices and compliances, sound
corporate governance rests on the pillars of
integrity, transparency, accountability, and the
highest standards of business ethics.

The commitment to adopt effective corporate

governance practices in all the spheres of
working, has always been an imperative factor
in the decision-making process, providing
immense value addition and a competitive
advantage.

Our continued success is driven by the trust,

commitment and faith, our stakeholders have in
our brand. To ensure this, we have built a highly
experienced executive leadership team,
professional management teams and
independent Boards for all our businesses, which
enables efficient governance across the Group.

Our Board of Directors are fully committed to

enhance and retain investor confidence while
creating a culture of transparency. We
established a multi-tiered governance structure
with defined roles and responsibilities for every
constituent to align with our management
philosophy.

As a company, we believe in going beyond the

requirements of the legal framework and
hence, while we adhere to all applicable
regulatory requirements, we also adopt global
best practices in corporate governance.

Board oversight
The Board of Directors provides oversight and
comprises a diverse and multidisciplinary group
of knowledgeable and experienced professionals.
Their objective is to ensure our success by
collectively driving and directing management
actions and reviewing overall performance,
ensuring that stakeholder expectations are
surpassed. Their guidance provides strategic
insights to steer the company in the right
direction and their expertise and counsel in
areas of risk, control and compliance helps us
TransformAction 31
|
Board diversity ensure holistic tracking of business
performance.
As a leading biopharmaceutical company, we take
pride in our commitment to embed diversity and • Encourage diversity of perspectives, thereby
inclusion across all levels of the organization. A fueling creativity and innovation.
diverse Board enables us to obtain different
perspectives that positively transform our • Supplement and enhance the skills,
decision-making process. We have formulated a knowledge, and experience of the Board.
‘Board Diversity Policy’ that creates a clear path
to more inclusive and collective corporate • Ensure effective corporate governance.
governance. It sets out an approach to have
diversity in terms of thought, experience, Composition and engagement
knowledge, perspective and gender in the
Board. At Biocon Limited, the Board consists of nine
directors, two executive directors, two non-
We believe that a diverse Board enables the executive directors, and five independent
following positive outcomes: directors. We have two women on our Board.

• Enhance the quality of decision making and The classification of the Board according to
various categories are as follows:

22%
Independent Non-Executive Executive

56%

22%

32 | ESG Report
2022
 Biocon
Limited

a candidate Board membership under Section

178 of the Companies Act and SEBI Regulations.
22%
The NRC assesses the composition and
diversity of the Board to ensure the appropriate
elements of skills, experience, independence
and knowledge for continued effectiveness. In
this case, diversity encompasses plurality in
78%
perspective, experience, education,
background, ethnicity, nationality, age, gender
and other personal attributes. These attributes
may extend to professional experience,
functional expertise, educational and
Men
professional background.
Women
The Independent Directors annually provide a
certificate of Independence, in accordance with
the applicable laws, which is recorded by the
Board. All Board members are encouraged to
22%
meet and interact with the management and
are also invited to key meetings to provide
strategic guidance as well as advice.

78%

The NRC selects suitable candidates

based on defined attributes and
expertise

After thorough screening, the NRC

recommends desired candidates to the
Promoter Non-Promoter Board

The Board recommends the

Our commitment to a diverse and equitable At Biocon, ofthe
appointment Nomination
the director to and Remuneration
workplace extends to Biocon Biologics Limited the shareholders
Committee (NRC) follows a disciplined process to
which is a material unlisted subsidiary of identify and evaluate
Biocon Limited and has a well-established
Board of Directors. At Biocon Biologics Limited,
the Board of Directors consists of eight directors,
with two being women and majority of them
being independent directors.

All Board members at Biocon are encouraged to

meet and interact with the management at
timely intervals. We ensure that the members of
the Board receive invites to key management
meetings to consider their advice and insights
for strategic guidance.

Board Membership Criteria and

Selection Process
TransformAction 33
|
 The proposal is placed before the
shareholders for their approval

Board Evaluation
A key function of the Board is to manage,
monitor, and review the Board evaluation
framework. The evaluation criteria for the
performance of the Chairperson, Board,
Committees and executive/non-executive/
independent directors have been laid down
by the NRC as well as the Board. This is
undertaken through peer evaluation,
excluding the evaluation of the director.

Additionally, to ensure transparency and

objectivity, the Board Evaluation is
conducted by an external agency, at least
once in three years. In FY21, this exercise
was conducted by Egon Zehnder, a
global management

34 | ESG Report
2022
 Biocon
Limited

consulting and search firm. In FY22, this activity Global Healthcare

was conducted through the deployment of self- Technology and Digital Perspective
evaluation questionnaires and focused on the
following aspects:

• Board dynamics and other aspects of Board

effectiveness

• Board Composition, quality, and culture

• Board meetings & procedures

• Execution & performance of specific duties

• Board & Management relations

• Succession planning

• Committee effectiveness

• Evaluation of Chairperson, Executive & Non-

Executive Directors.

The outcomes of this evaluation were

discussed at the Board of Directors meeting
and appropriate recommendations for
implementation were provided.

Key expertise and attributes of the

Board of Directors
In compliance with the SEBI Listing Regulations,
the Board has identified the following
competencies which are fundamental for the
effective functioning of the Company. These are
taken into consideration by the NRC while
recommending the appointment of any
candidate to the Board of the Company.

BOARD EXPERTISE
Research and Innovation

General Management

Finance and Risk Management

Corporate Governance and

Compliance Scientific Knowledge

TransformAction 33
|
Committees of the Board statutory requirements
Biocon Limited and Biocon Biologics Limited
have constituted various committees to focus on
specific areas and make informed decisions
within their authority. Each of these committees
meet periodically, along with members of the
management team, to deliberate over applicable
matters and monitor the same. Each committee
has its own charter which outlines the scope,
roles, and responsibilities. Decisions taken or
recommendations made by the committee are
placed before the Board for approval. Each
committee has the authority to engage outside
experts, advisors or counsel, to the extent
considered appropriate, to assist them in their
functioning. The committees call for various
details from the senior officers or function
heads, which are presented by them for review,
discussion, and deliberation.

Given the emerging importance of ESG, the

Board of Directors of Biocon Limited has
incorporated oversight for ESG related activities
under the ambit of its Corporate Social
Responsibility Committee, which has been
reconstituted as the ‘Corporate Social
Responsibility and Environmental, Social and
Governance Committee’.

The ESG key roles of the Committee comprise of:

• Embedding CSR & ESG into the business

• Developing action plans

• Mobilizing resources and expertise for the initiatives

• Building capacities for CSR & ESG at all levels

• Involving employees to volunteer for CSR & ESG

related activities

• Engaging stakeholders on a regular basis

• Building partnerships for scale

• Making strategic grants to support

worthwhile projects/programs

• Being transparent, consistent, and fair in

communication

• Carrying out periodic reviews and reporting

• Ensuring continuous compliance with

34 | ESG Report
2022
 Biocon
Limited

The Committee consists of a minimum of 3 to transform our CoC into an interactive document
Directors, of which at least one is an that helps create ‘buy-in’ and guide employees to
Independent Director. the most helpful information such as illustrations,
frequently asked situations, real life examples,
The Board of Biocon Biologics formally situations and solutions. To understand the ‘why’
approved the constitution of an ‘Environment, behind the policies, training on the CoC is provided
Social and Governance Committee’. The to all employees, including the new joiners who
Nomination and Remuneration Committee has are
assigned an Independent Director to be the
Committee Chairperson and appointed four
Board Directors as its members.

FAMILIARIZATION PROGRAM
FOR INDEPENDENT
DIRECTORS - FY22
In FY22, the members of the Board were regularly
updated with the relevant regulatory and policy
changes as well as the workings of the Company
and its operations under each business function by
the Senior Management Team. In addition to this,
the business function heads also presented their
respective performance and future strategy to the
Board.

The Board is also responsible for conducting strategy

meetings periodically to review the long-term plans
and growth of the Company.

The familiarization program for the Independent

Directors are also a part of the quarterly board
meetings of the Company. This year, our
Independent Directors spent approximately
148.25 hours in the programs cumulatively

The Code of Conduct (CoC)

Our Code of Conduct (CoC) that came into
effect in 2009, is one of the most important
ethics and compliance communications provided
to our employees. It doesn’t just outline policies
and acceptable behavior but also introduces
our compliance program to cultivate a positive
work culture and align all stakeholders with the
expectations of the company. Our CoC is
reviewed and amended periodically and was
most recently revamped in FY21, with the vision
TransformAction 35
|
subjected to a specific program on the Enhancing our ‘culture of ethics and
same as a part of their onboarding process. compliance’
How can an organization support large numbers
The Code of Conduct for Prevention of
Insider Trading of employees across locations in doing the right
thing when faced with an ethical dilemma?
Biocon Limited has a “Code of Conduct for
Prevention of Insider Trading” in place to This thought led to the creation of a specific
implement and practice the principles of program with the primary objective to
Corporate Governance based on fairness, proliferate a network of fully trained ethics
transparency, integrity, honesty and ambassadors throughout the business.
accountability. The observance of the Code
is a prerequisite to ensuring complete
confidentiality of all “Unpublished Price
Sensitive Information” and to build general
investor confidence and stakeholder
credibility. This policy is applicable to the
employees/designated persons of all the
subsidiaries, joint ventures and associates in
India as well as our global counterparts.

In addition to this, the company has also

adopted the “Code for Corporate Disclosure
Practices for Prevention of Insider Trading” to
ensure timely and adequate disclosure of
Price Sensitive Information with special
reference to analysts and institutional
investors.

Supplier Code of Conduct (SCoC)

In FY 22, we have developed a Supplier-

Centric Code of Conduct that outlines our
core values and expectations from our
business partners and suppliers. The
‘Supplier Code of Conduct’ covers suppliers,
service providers, customers, distributors,
wholesalers, resellers, and other business
partners and forms the foundation to build
a strong culture of collaboration and a
strong sense of purpose. The SCoC outlines
our partners’ expectations regarding
business ethics, human rights, business
practices, employee relations, health and
safety and other topics related to
sustainable and responsible business
practices. It encourages our business
partners to go beyond legal compliance,
drawing upon internationally recognized
standards.

36 | ESG Report
2022
 Biocon
Limited

The training sessions are designed, managed and

conducted 100 percent by women leaders from different
departments. Biocon’s Human Rights Policy*, 2022

Currently 700+ employees have been trained At Biocon, we endeavor to identify, prevent, and
across all departments and geographies. who mitigate any human rights violations within the
act as advocates for the ethics program and the organization as articulated in our Code of Conduct.
values of the organization. They also help in To further strengthen the process and demonstrate
this commitment, Biocon Limited has published its
communicating and disseminating information
Human Rights Policy* this year. While a detailed
that promotes a culture of compliance and good
global policy on similar lines is currently under
governance.
development at Biocon Biologics, the organisation
continues to abide by the principles through the
The CoC is communicated to the employees in CoC.
the form of a ‘Global Ethics and Compliance’
(GEC) policy designed to help foster a positive Biocon Limited’s policy focuses on fostering an
work culture which ensures necessary inclusive, safe, and open workplace. It is in line with
compliance and enables the employees to be the Code of Conduct which confirms our
aligned with our values of integrity and ethical commitment to abide by all applicable laws relating
conduct of business. to wage, benefit, safety, and Human Rights
principles. The focus areas are as mentioned
We also use the following tools to train our below:
employees on the policies within the CoC,
• Child labor and forced/complusory labor
including courses on anti-bribery and
corruption, prevention of sexual harassment at • Diversity, equal opportunity, and non-discrimination
the workplace and health and safety.
• Environment, health and safety
• Dedicated YouTube channel for micro-learning
videos • Wage, working hours, and benefits

• On the go, QR code based training video to • Data privacy

promote ethical behaviors
• Disciplinary measures
• Animated micro-learning videos covering all
industry specific topics • Corporate social responsibility

• Interactive learning platform ‘Kahoot’ to • Management systems

conduct live training through gamification
The Human Rights Policy* is a reflection of Biocon’s
and data analytics for focused training needs
values. We advocate and practice five values with a
Zero-Tolerance approach to violations. The guiding
Human Rights Policy* five values include integrity & ethical behavior,
As a pharmaceutical company, we recognize performance-driven work culture, value creation
that health is a human right and ensuring through innovation & differentiation, quality
access to medicines is vital. Beyond the core through compliance & best practices, and
collaboration, teamwork & mutual respect.
function of our company, we are
committed to upholding human rights to the highest
order. This includes taking action on issues pertaining to
child labor and forced/compulsory labor,
diversity, equal opportunity, and non-
discrimination, wage, working hours, and
benefits, and data privacy, among others.

This year, we formulated our Human Rights Policy*, which aims to

 prevent human rights violations by responding
promptly with appropriate action. Our policy is
further in alignment with global standards---this
includes the ten-tier principles of the UN Global
Compact (UNGC).
*
Similar principles applicable to Biocon Biologics, currently embedded
in its Code of Conduct, is being developed as an independent
global policy document. TransformAction | 35

38 | ESG Report
2022
Ethics and integrity demonstrating the highest levels of transparency
and accountability through voluntary ESG
The principles of integrity, transparency,
disclosures over and above statutory reporting
accountability, and business ethics are
requirements.
embedded in our DNA. At Biocon, we expect
adherence to the highest standards of ethical
conduct. To continuously be in alignment with
this vision, we have devised policies,
procedures, controls, and have implemented
global best practices in corporate governance
and risk management.

Integrity and whistleblowing policy

Biocon’s Integrity Committee (IC) or Audit
Committee (AC) governs the reporting and
investigation of allegations of suspected
unethical practices and enables the Board and
employees to report their grievances. Biocon’s
Integrity and Whistleblower Policy enables a
person to report an unethical practice in an
anonymous manner, without the fear of
retribution. The responsibility of the IC is to
assess the concerns raised by the whistleblower
and initiate appropriate corrective action. A
summary of key investigations is then
collectively presented on a quarterly basis to the
AC.

Transparency and accountability

Transparency and accountability are the values
that reinforce our pursuit of good governance
and fostering deep, long-standing trust with our
stakeholders. Increasingly, businesses are
facing scrutiny from stakeholders, including
customers, investors, employees, and
policymakers around ESG issues, driving the
demand for disclosure, transparency and
sustainable actions. At Biocon, ESG is very
much part of our Boardroom conversations and
we are committed to purposefully embracing
ESG aspects in our strategy and everyday
decision-making processes.

Considering the appropriate structures and

reporting systems in place to foster disclosure,
we have begun to engage with ESG rating
organizations and investors to better
understand their expectations and reflect their
priorities in our business activities and
disclosures. We are committed to
36 | ESG Report
2022
 Biocon
Limited

Tax strategy
As one of the leading and pioneering
healthcare providers, we have a
responsibility towards maximizing value for
our stakeholders and upliftment of our
communities across the geographies where
we operate. This responsibility also extends
to meeting our stakeholders’ expectations
on good tax governance. To promote trust
and credibility in our tax practices, we have
published our ‘Tax Policy’ and our first ever
‘Tax Transparency report’ for FY22. It
highlights our practices to balance tax
compliance with business activities while
meeting societal, ethical, and sustainability-
related expectations. The Report structure
and content are aligned with global trends
on tax transparency and with the GRI 207
standards on tax reporting.

Biocon’s Tax Transparency Report, 2022

With a focus on transparency in the tax realm,

our first ever Tax Transparency Report,
published in July 2022, is reflective of our
efforts to promote better visibility on how we
run our business. It elaborates on our
commitment towards adoption of responsible
tax principles and behavior to maintain high
standards of integrity with respect to tax
compliance and reporting, including:

• Complying with both the letter and spirit of

tax laws and regulations in jurisdictions and
countries we operate in, in a timely,
efficient, and accurate manner.

• Adhering to global standards and

regulations on transfer pricing, including but
not limited to ensuring that all transactions
undertaken with related third parties are in
line with the OECD guidelines.

• Maintaining a strong control environment

and tax risk framework to identify tax-
related risks and uncertainties and evaluate
how they can be addressed.

• Engagement with the tax authorities in fair,

transparent and co-operative manner.

TransformAction 37
|
 The responsibility of tax governance rests with our tax at a score to prioritize the 10 themes, which
function, in consultation with our Chief Financial are presented in the graph aside.
Officer (CFO). The Audit committee provides
oversight and guidance on tax governance and the
Risk Management Committee provides oversight
and guidance on effective tax risk management
respectively. Our Tax Policy has been
recommended by the Audit Committee and
approved by the Board of Directors.

The Tax Transparency Report is a voluntary initiative,

published on our website to provide insights to all
our stakeholders, including our patients,
employees, shareholders, vendors, customers,
government agencies, supply chain participants,
etc., and enable wider discussions around our tax
trends, tax legislation and tax transparency
matters.

Materiality Assessment and

Stakeholder Engagement
At Biocon, we believe in placing the utmost
importance on engaging with our stakeholders,
appreciating their views and, where applicable,
incorporating them within our business
operations. We are committed to designing an
effective ESG strategy that reflects and is
responsive to their expectations.

In FY22, we conducted a materiality assessment

to identify key ESG topics for Biocon and Biocon
Biologics. The process involved undertaking
extensive secondary research on ESG within the
biopharmaceutical industry and preparing an
exhaustive list of 50 topics. Through
understanding the macro business environment,
sector specific trends and challenges, as well as
benchmarking against peers, this list was
condensed to 30 of the most relevant issues with
respect to the company’s operations. These
issues were then categorized into 10 themes,
aligned with our strategic objectives.

The assessment was rolled out to diverse

internal and external stakeholders who were
asked to rate the importance of each topic on a
five-point scale ranging from low to very high.
Based on the responses received, the weighted
average of each topic was calculated, arriving

38 | ESG Report
2022
 Biocon
n = 113 Limited
Importance to business (Executive Leadership Team (ELT) + Board)
Product
Includes Biocon Limited and Biocon Biologics Limited Ethical quality
governance
Research &
Development
Key to the materiality matrix

Top priorities: The issues that fall under this category

Access &
are critical to both our stakeholders and our business.
affordability
An effective and externally visible managementSafe &
The material issues for Biocon have been defined response to these issues is vital for long-term
Digitizatio business
empowering
success. n
in line with the GRI guidelines and are linked with workplace
Key issues:
Supply These are medium to high priority issues
our value creation process. which require Environment
chain an effective and externally visible
management response for our end to address
sustainabili al them.
Inclusion and performanc
diversity
Hidden value creators: Although not of high
importance on our priority list, these issues are nonetheless
Community
important to our business. And it is our responsibility to
engagement
educate our stakeholders on the relevance of these
issues.
Hygiene
Ethicalfactors:
sales Issues that are regarded as high
priority
and for our stakeholders but are considered as low
priority for our business are categorised here. They
marketing
require a balance response from our end, keeping both
perspective in sight.
Monitoring issues: The last category addresses the
issues that are of low importance to our stakeholders and
also have limited impact on our business. Constant
vigilance is required to ensure these issues do not
become more prominent over time.

TransformAction 39
|
Risk management also incorporated into the ERM, including mitigation
measures for those risks identified. Our aim is to
From being managed in silos to being
align our corporate strategy, risk processes and
recognized as highly interconnected and
ESG, which will allow us to gain a complete view on
interdependent, the practice of risk
the risks and opportunities which are applicable to
management has shifted fundamentally. The
us.
new approach views all risks together, within a
strategic framework and encourages
transformational actions throughout the
organization.

At Biocon, risk management is a structured,

integrated, consistent, and continuous process
across the entire organization for identifying,
assessing, mitigating, and reporting on
opportunities and threats in a timely manner
and in alignment with our strategic objectives.

Our risk management process entails the

following:

• Risk identification and assessment

• Risk mitigation

• Risk monitoring and reporting

These aspects are aligned with the daily

operations of the company, thus ensuring that
the management of risks is embedded within
the processes and systems. With risk
identification being the first step, we undertake
the approach of ‘Treat, Terminate, Transfer and
Take’ to manage and mitigate the risk,
restricting the same to a tolerable level.

The risk monitoring and reporting provides

assurance that the risks identified have been
managed and all measures have been
undertaken to ensure that the company does
not face any negative consequences.

Risk governance
An enterprise-wide risk management
framework (ERM) is implemented with an
objective of timely identification of risks,
assessment and evaluation of risks which are in
line with the overall business objectives or
strategies and defining adequate mitigation
strategies. This year, risks associated or
impacting the ESG priorities or objectives were
40 | ESG Report
2022
 Biocon
Limited

The Risk Management Committee, formed COVID-19 related risks

by the Board, reviews critical emerging or
While the impact of the pandemic in FY22 was
existing risks on a rotational basis every
lower in comparison with the year before, the
quarter while also monitoring the de-risking
industry continued to witness risks related to
strategies and their implementation. This is
supply chain and logistics bottlenecks, delays in
in line with the risk management plan to
the development programs including regulatory
measure effectiveness of mitigation actions
reviews or approvals, delays in completion of
defined against critical risks and their
capex projects as well as workforce safety.
impact on overall risk exposure of the
company. All the critical risk areas are
covered at least once a year and the
identified risks are re-evaluated annually by
the company. During the year, as and when
required, changes are made to the risk
register, considering internal or external
changes.

Key risks identified

Due to the nature of the business, the
global pharma industry is potentially
exposed to inherent risks including product
safety and quality issues, intellectual
property tangles, regulatory delays and
inappropriate marketing practices, which
can lead to penalties, product recalls,
brand/reputation loss, and revenue loss.
These risks have been elaborated upon in
our Annual Report.

Electronic medical records, cloud-based

technologies, and data-sharing among
industry stakeholders have increased the
complexity of managing and ensuring the
safety of information assets, particularly
protecting patient health information and
intellectual property. However, with
digitization, we can control quality and
operations, bring in flexibility and
adaptability, and improve management
effectiveness.

We have identified the primary risks which

are material to the business. These include
product quality, environmental
performance, supply chain sustainability,
safe & empowering workplace and ethical
governance. For details on the impact of
these to the business and our mitigation
plan to address them, please refer to page
number 93 – of this Report.
TransformAction 41
|
 Biocon
Limited

With a transition to the “new normal” and to This internal control system aims to assure our
emerge stronger after the pandemic, we put in operational effectiveness and efficiency,
place key mitigation actions to continue our compliance with laws and regulations, asset
operations and support business continuity safeguarding and reliability of financial and
plans. These included but were not limited to: management reporting.
• Inventory buildup in case of supply chain We are staffed by experienced, qualified
disruptions
professionals who play an important role in
designing, implementing, maintaining, and
• Vaccination campaigns for workforce and
monitoring the internal control environment.
their family members
An independent firm of chartered accountants
• Virtual reviews by regulators
performs periodic internal audits to provide a
• Other safety precautions such as sensible assurance of internal control
continuous temperature monitoring, effectiveness and advises us on industry-wide
remote working options, etc. best practices. Our Audit Committee, consisting
of independent directors, reviews important
Internal controls issues raised by the internal and statutory
auditors regularly and the status of rectification
At Biocon, we have established a strong internal measures to ensure that risks are mitigated
control system, which comprises policies, appropriately on a timely basis. Our Compliance
guidelines and procedures adopted by us to Management System was reviewed by an
ensure orderly and efficient business conduct independent third party in FY 22. No major
including adherence to policies, asset deviations were identified and
safeguarding, fraud and error prevention and recommendations for improvement are being
detection, accounting records accuracy and incorporated
completeness, and the timely preparation and
presentation of reliable financial information.

TransformAction 39
|
40 | ESG Report
2022
 Biocon
Limited

Partners
hip in
Action
As the effects of the biggest health crisis in a century
continue to be felt across the globe, in communities
and within business, we are determined to honor our
commitment to patients and partners through unified
action and transformative measures. We believe that
by ensuring consistent and targeted action, we
effectively collaborate with partners, to improve and
enhance access, affordability, and reach. This is further
augmented by our integrated supply chain and strategic
partnerships, both local and international, which drive
efficiencies right from the procurement of raw
materials to last-mile delivery of life saving drugs.

TransformAction 41
|
40 | ESG Report 2022
 Biocon
Limited

It has been two years since the start of the COVID-19

pandemic, and while there has been relief in the form
of widespread vaccination drives and a Various partnerships and collaborations
reduction in daily cases, business as usual we have forged over the years*
continues to be disrupted, severely affecting
supply chains and delivery logistics. Despite
these challenges, we have worked closely with
our partners and suppliers to deliver the global patient
pool with our generic and biosimilar therapies.

The unwavering sense of purpose of our people

and partners to put ‘patients first’ ensured that
we delivered on our promise of providing
access to life-saving healthcare solutions
during COVID-19, globally. Our generic
formulations business in the US had zero back
orders throughout the pandemic and we were
able to act with efficiency and speed to ensure
crucial supplies of much-needed APIs and *Represents select key partnerships

formulations from India were distributed to over

70 countries. Our efforts to distribute medicines
contributed towards countering medicine
shortages during the pandemic.

For our biosimilars business, we have established

a strong foothold in developed markets like the
U.S., Canada, EU, and Australia through our
long-standing partner Viatris. Biocon Biologics
also has a wide commercial footprint across
many Emerging Markets, where we have
partnered with leading local pharma companies.

Creating value together with our

partners
We believe in forging strategic partnerships
that expand our ability to create value and
deliver quality products to patients across the
globe. Through the widespread reach of our
businesses, we are ensuring we lead from the
front, ensuring we strengthen our value
proposition of augmenting our four strategic
pillars: accessibility, affordability, availability
and assurance.

In FY22, we ramped up our presence in emerging

markets by signing 44 new partnerships across
50 countries for our biosimilar products,
enabling us to expand our reach.

TransformAction 41
|
In FY22, we continued to forge impactful
partnerships across our businesses:

• Biocon Biologics entering into a strategic

alliance with Serum Institute Life Sciences to
expand into vaccines.

• Biocon Biologics entering into a collaboration

with the Research Society for the Study of
Diabetes in India (RSSDI) to expand its insulins
access program to address the needs of young
people with Type 1 diabetes in India.

• Biocon Biologics partnering with US based

Adagio Therapeutics for an exclusive license
to manufacture and commercialize ADG20 in
India and select emerging markets. ADG20 is a
novel monoclonal antibody targeting the spike
protein of SARS-CoV-2 and related
coronaviruses.

• Strengthening an existing partnership by

acquiring Viatris’ Biosimilars Assets for up to
$ 3.335 billion to create a world leading fully
integrated biosimilars enterprise.

42 | ESG Report
2022
 Biocon
Limited

Our acquisition of Viatris will Partnering to address inequitable

transform our business and access to vaccines and biologics for
expand our reach: infectious diseases
Our belief in the strength of collaborations first led While Biocon Biologics continue to have a broad
us to partner with Viatris (previously Mylan) in 2009 and robust pipeline of biosimilars that target NCDs,
to co-develop a portfolio of biosimilar antibodies and it has made strategic alliances to expand its
recombinant proteins. We expanded this presence in communicable diseases, through two
collaboration to include insulin analogs in 2013. key partnerships, one with Serum Institute Life
Over the years, we synergized our frontier science Sciences (SILS) for vaccines and infectious disease
and robust manufacturing capabilities with Viatris’ antibodies, and the second with Adagio
regulatory and commercialization expertise to Therapeutics for a novel COVID antibody therapy.
deliver affordable therapies to patients in both The Serum Institute Life Sciences strategic alliance
developed and emerging countries. As it stands, we provides Biocon Biologics an asset-light and
have one of the most extensive biosimilars portfolio accelerated entry into the vaccines segment. This
with seven biosimilars from our joint portfolio alliance will complement the strengths and
commercialized in global markets. resources of the two leading players in vaccines
and biologics, with the objective of addressing
In February 2022, Biocon Biologics announced that inequitable access both in emerging and developed
it would acquire Viatris’ Biosimilar Assets for markets for life saving vaccines and biologics. SILS
$3.335 billion. This acquisition further builds on the will get about 15 percent stake in BBL enabling us
strategic global partnership that we have forged to work together to grow together. Thereby,
with Viatris over a decade. Our symbiotic through this alliance, both companies aim to make
partnership which will mature further after the a significant impact on global healthcare.
completion
of this acquisition, will allow us to share risks, lower costs,
maximize our efficiencies, expedite development, and expand
our reach. As we integrate the two businesses, we
will continue on our transformation journey under
one umbrella, creating operational efficiencies and
agility across value chain.
Transformative partnership with
Tabuk Pharmaceuticals to
commercialize specialty generic
drugs in the Middle East and North
Africa (MENA)
In December 2021, we announced a partnership
with Tabuk Pharmaceuticals Manufacturing
Company, a subsidiary of Astra Industrial Group, to
commercialise of specialty generic products in the
MENA region. As part of the agreement, Biocon will
develop and manufacture the products, while
Tabuk would commercialize them.

The partnership with Tabuk ensures that we are

synergizing with a leading pharmaceutical
company who understands the MENA market and
will enable us to register, import, and promote
specialty generic medicines in Saudi Arabia and
other Middle East countries, as they would hold
marketing authorization of these products. Through
TransformAction 43
|
 this partnership Biocon is laying the foundation to
expand into the MENA region, with a focus on
markets like Saudi Arabia, UAE, Kuwait, Qatar,
Oman and Iraq, Jordan, and Lebanon. Our plans to
expand into this region further corroborate our
commitment towards ensuring global availability of
affordable and accessible medicines.

44 | ESG Report
2022
 Biocon
Limited

Collaborating with suppliers to ensure the use of non-petrochemicals based ‘green

continuous delivery of quality and solvents’, which are environmentally friendly
value alternatives to petrochemical based solvents.

To ensure reliable supply of affordable We strive for a high level of conformance

therapies for patients and to make them towards environmental compliance for our
accessible globally, we leverage strong critical vendors. By evaluating various business
partnerships with our supply chain and and quality performance
logistics partners. Such strategic partnerships
help optimize cost, minimize resource
consumption, and increase the affordability of
our products. Our integrated supply chain
ensures uninterrupted medicine availability to
our customers, patients, partners, and
healthcare systems globally. Continuous focus
on cost effective and sustainable supply chain
remains a key priority to increase access and
affordability of the products to the patients.
Whilst we utilize both air and sea modes for
movement of our products, we are increasingly
focusing on sea freight to create a positive
impact on the environment.

Through the course of the pandemic, we strived

to maintain business continuity, and this is
something we are continuing to do via
collective action from within the organization as
well as outside. As a result, we are now well
versed in weathering the toughest challenges
and will continue to stand with our vendors and
collectively navigate global disruptions.

Responsible sourcing

For us, responsible sourcing is a key criterion

towards ensuring patient, people, social, and
environmental equity. As a result, we procure
our raw materials from approved vendors, both
local and international, and audit our critical
suppliers periodically on business sustainability
parameters. These parameters are closely
aligned with global frameworks and standards
to guarantee our products meet the
requirements of all 120 countries where we
supply the product.

We have made tremendous progress in moving

away from an animal-origin to a recombinant
supply base for some of our key products,
including insulins. The sourcing team focuses on

TransformAction 43
|
indicators, we ensure seamless supply across all
manufacturing plants. To encourage new ideas
and implement sustainable practices across the
supply chain, we organize periodic business
sessions with suppliers and logistics service
providers.

E-Sourcing has been implemented for our top

solvents to gain visibility in the market and
procure raw materials at competitive rates. We
are in the process of designing a vendor portal
to increase transparency and evaluate vendor
performance. This portal will also support Biocon’s
paperless initiative through seamless real time
SAP data integration, repository creation of
vendor documentation and process
simplification.

Effective alignment and action through our

Supplier Code of Conduct

To guide our value chain partners on the

behavioral and ethical standards we expect from
them, we have developed a Supplier Code of
Conduct in FY22. In alignment with our Code of
Conduct, we have zero tolerance for child labor
and have always ensured no children are
employed in any of our operations. During the
year, there were no reportable incidents of child
labor from any of our vendors.

Moreover, we are working towards ensuring ESG

is integrated within supplier and vendor
practices, and in this regard, we have
developed and designed a detailed ESG training
and development program. In FY22, we rolled
out the program for our key value chain
partners to guide them on applicable laws,
regulations, policies, and procedures, as well as
the behavioral and ethical standards we expect
from them.

44 | ESG Report
2022
 Biocon
Limited

Local Sourcing
Biocon prefers to collaborate and develop small
Biocon’s Supplier Code of Conduct
and medium enterprises (SMEs) around its area
At Biocon, we aim to adhere to the highest ethical of operations to foster local economy. Local
standards by operating within a framework of sourcing reduces carbon footprint from freight,
principles, guidelines and policies aligned with increases local employment and builds trust
ethical, social, and environmental responsibilities amongst local communities. With the disruption in
to deliver our brand purpose and promise. global healthcare delivery during the pandemic
Consequently, we seek to partner with third parties, and the Suez Canal blockage highlighting the
vendors and suppliers that are aligned with our
importance of local sourcing, we have further
values and are committed to operating ethically
strengthened our local vendor base throughout
and responsibly.
our value chain.
The Supplier Code of Conduct (SCoC) outlines our
expectations and guidelines with respect to Transparency and Traceability
responsible sourcing and calls for third parties,
Biocon engages with an extensive network of
vendors, and suppliers to commit to fair treatment
suppliers worldwide to ensure supply chain
and professional and ethical behavior along with
resilience. Supply chain teams collaborate with
safe, sustainable business practices.
stakeholders within and outside the
organization to anticipate and respond to
complex and interconnected risks that threaten
THE CODE COMPRISES OF THE FOLLOWING
ESG ASPECTS: the continuity of business operations. We focus
on product safety and integrity throughout our
Ethics & Labour & logistics channels and implement measures to
Qualit
business human
y ensure traceability of our products, whilst
integrity rights
strengthening compliance with Customs-Trade
Partnership Against Terrorism (C-TPAT) and Drug
Supply Chain Security Act (DSCSA).
Environment
Manageme
Health & al
nt
safety compliance
systems Periodic Vendor Evaluation
&
Periodic Reviews are done to address any
issues, based on metrics including OTIF (On-
Time, In-Full Deliveries) and number of quality
complaints. Third-party vendor evaluation is
carried out by international agencies such as
Dun & Bradstreet, as required.

TransformAction 45
|
 Biocon Limited

46 | ESG Report TransformAction | 45

2022
Transformin
g the
Workplace
At Biocon, we believe that organizational growth
hinges on the continued development of our
workforce. Our investments and strategy, therefore,
aim to create a diverse, equitable, and inclusive
workplace. Further, a performance driven work culture
based on transparency, integrity, teamwork, and
collaboration helps us drive innovation in our
thinking. This enables us to co-create
transformative solutions to real-world problems by
‘doing things differently’ and ‘doing different
things’. Leveraging this ethos, through our practices
and processes, we strive to develop the workforce of
tomorrow.
46 | ESG Report 2022
 Biocon
Limited

Repurposing our hiring and driven decision making on contractual

onboarding workforce, a Dashboard has been
operationalized which provides real-time
The company’s mission is to be an integrated
insights into budget, demographics, cost-
biotechnology enterprise of global distinction7. To
efficiency, and resource utilization of
achieve this, we place emphasis on our human
contractual workforce.
resource development, which starts with right
hiring and effective onboarding.

By recruiting the best talent, we actively seek

to create future leaders, who can further our
purpose of creating unparalleled impact.

We lay equal emphasis on the expertise of

potential hires and the alignment of their
aspiration with our values. Our hiring
philosophy is governed by transparency,
visibility, and respect for diversity across all
levels. It is imperative for us to onboard
passionate individuals, who are determined to
create transformational solutions for the
healthcare industry. This is exemplified with our
diversified Talent Acquisition strategies. In
FY22, we accessed skilled talent through our
targeted programs such as campus placements,
and other hiring initiatives across geographies
which includes attracting talent from Tier 2/Tier
3 cities. Our engagement framework with
various campuses provides support to students
through internship opportunities and multiple
knowledge sharing platforms that bridges the
gap between academics and industry know-how
for the students. This approach enables the
organization to deploy the young talent early on.

To ensure smooth navigation of our processes,

technology has been kept at the forefront of our
hiring strategy. Our approach leverages various
Artificial Intelligence (AI) interventions to
identify and attract talent from prestigious
institutions in India. As an example, at Biocon
Limited, the hiring efficiency increased through
the integration of AI-based tools to match the
Company’s requirements using talent
acquisition metrics. The tool ensures effective
tracking of timelines and quality of hires against
such metrics. This led to the creation of talent
acquisition scorecards that helped revamp our
recruiting processes. We have leveraged
technology for the entire pre-employment
medical examination. Similarly, to enable data
TransformAction 47
|
At Biocon, we place emphasis on leveraging the candidates undergo an in-depth interview as well
internal talent pool and have revamped our as panel assessments.
processes to promote career growth and
development. The job posting process allows Our hiring, onboarding and employee lifecycle
filling vacant positions internally first, before processes have been linked with technology to
expanding our search outside. The process is reduce human dependency and create an
managed by our newly launched in-house career efficient process. In FY22, we hired a total of
portal, MyCareer, that maps internal roles to 2,806 individuals as full-time employees. Of
employees based on aspirations, experience, these, we hired 594 full-time female employees.
skill, and competencies. This portal notifies the For FY22, an increase of ~94 percent has been
target population meeting the criteria for recorded for the number of full-time employees
internally advertised jobs. Post this, the selected hired, as compared to FY21 levels.

7
http://covid19.biocon.com/our-vision-mission-values

48 | ESG Report
2022
 Biocon
Limited

Strengthening performance management

Our dynamic environment requires our
employees to be adaptable, agile, and
passionate problem-solvers. For this reason,
performance management systems need to go
beyond the traditional approach toward
continuous feedback and evaluation of
performance.

During FY22, we strengthened our systems by

introducing the ‘department scorecard’ — a
process that supports individual business
functions to identify, prioritize and track their
strategic priorities in line with the organizational
goals. The integration of goal alignment in the
scorecards has resulted in proper measurement
of performance and achievement across the
organization. This leads to creation of a shared
sense of ownership across levels in the
organization through the goal cascading
process. This goal setting then forms the basis of
the promotion and career progression cycle and
provides periodic monitoring of performance and
progress against individual goals.

Furthermore, we have developed a robust

technical and behavioral competency
framework that is embedded in our
performance management process. One of the
key outcomes of our performance management
process is to identify the key development areas
for the employees and provide support for
improvement through learning and
development.

Identification of
Strategic Priorities

Creation of Department
Scorecards (Strategic
imperatives and other
initiatives)

Cascading of Organization
Objectives to the Departments

Quarterly Tracking and Scoring

TransformAction 49
|
 Biocon
Limited

To remain relevant and up to date in technical skills,

there has been a great emphasis on defining technical
competencies required for each role within the Senior Leadership
organization. We collaborated with Mercer Development Program
consulting to build a technical competency
framework. This initiative has assisted in The leadership development program aims to build
identifying technical competencies and future succession roles by developing a second line
of leaders. The program constitutes a two phased
proficiency levels for diverse roles across the
approach, wherein:
business functions of the organization. This
forms a core part of the overall talent and • Phase one involved the participants undergoing
organizational development strategy. extensive assessments conducted by SHL, an
external talent and HR consultancy firm. The
Transforming through learning assessment results form the foundation for
formulating individual development plans, in
To establish domain expertise and build
consultation with their respective
functional capabilities, we have partnered with
managers/mentors.
India’s prestigious educational institutes giving
higher education opportunity to employees while • Phase two focuses on Biocon’s defined
they continue to work. leadership competencies and identified learning
needs. This will be an immersive 10-month blended
We strive to support the skill development of learning format—leveraging online and offline
our people through meaningful interventions via tools. The program has been designed to be result-
Education, Exposure and Experiences Augmenting oriented, to ensure that leadership competency is
leadership capabilities and building a succession built in a contextualized and customized manner.
slate is one of the key focus areas for the To ensure that competencies are built, business
critical Action Learning Projects (ALP) are allocated to
organization.
participants which are reviewed by the senior
management. The key objective of phase two is to
At Biocon Biologics, to build future-ready
develop strategic ability, a mindset for
leaders and accelerate career development, we
collaboration, and team management skills for
have introduced a participants.
structured talent development program for the top talent
which aims to develop internal talent and
strengthen our
succession pipeline for leadership roles. In partnership
with the external parties, we have developed a in partnership with a global firm - Development
bespoke program with blended learning Dimension International (DDI), which includes
experiences that include coaching, cross- various master classes, group coaching, and
functional projects, and external market learning projects.
orientation thus enabling individual and group
learnings. Additionally, we also provide various
learning and development programs to support
the building of professional, digital, innovation
and managerial skills for our employees.

At Biocon Limited, senior leaders in the

organization underwent a behavioral competency
assessment program conducted by Saville and
Holdsworth Limited (SHL). Subsequently, ~ 40
leaders from senior management are
undergoing a 10-month development program

TransformAction 49
|
For our middle management level, we identified
a pool of 140 employees who underwent
assessments conducted by Basil Tree, a leading
talent assessment and development firm. The
assessments evaluated cognitive potential and
abilities based on our competency framework.
The outcomes of the evaluation were utilized to
develop customized individual development
plans. This will be followed by an 8–10-month
development journey in partnership with an
external facilitator. In addition, we implement
various initiatives to nurture and build technical
capabilities. A few noteworthy initiatives are
mentioned below:

• Lean Six Sigma Training: In FY22, we

conducted sessions in Bengaluru, training a
cohort of our employees as Green Belts (GB).
There are multiple green belt projects currently
underway, anchored by trained GB employees.

• Data Analytics Program: This has been

conducted for a group of our R&D scientists.
The training is divided into two phases, focused
on training the scientists on

50 | ESG Report
2022
 Biocon
Limited

data-backed decision making. Phase one of the effective teamwork.

training has been completed and phase two will
be concluded in FY23. Based on the collaboration roadmap, the IPQA training
was rolled out in a workshop-based format for capacity
• Customer Centricity workshops: These building
have been conducted for employees across IT and
Compliance teams.

We conducted a refresher program for our

Manufacturing & Quality team to build a quality
mindset and be audit-ready throughout the year.
Moreover, at Biocon Limited and Biocon
Biologics Limited, our employees have undertaken
mandatory trainings on the prevention of sexual
Harassment (POSH), Information Security
Management, Code of Conduct, Zero Tolerance,
and Employee Health and Safety, amongst
other function-based training.

The total hours of training in FY22 stood at

178,264. The average training hours per full-
time employee for FY22 stood at 19.9.
Furthermore, the average amount spent per full-
time employee on training and development
stood at ` 3,033 in FY22.

In-Process Quality Assurance

(IPQA Training)
Recognizing the business need to strengthen the
IPQA team’s existing skill sets, Biocon rolled out a
targeted training program to build synergies
between the quality and the production teams. To
identify the key concerns and challenges faced by
both teams, a stocktaking session was conducted.
Following this, a roadmap for collaboration was
built, which sought to address the identified
bottlenecks and create new opportunities for
TransformAction 51
|
and dissemination. The training focused on
enhancing the teams’ soft skills and creating
awareness of the importance of knowledge
acquisition and application in day-to-day
processes and work. A post-training
assessment was also conducted which
indicated visible improvement in the IPQA
team’s motivation levels and communication
skills.

Embedding diversity and inclusion

As a leading biopharmaceuticals company,
we recognize that diversity and inclusion are
the driving force for innovation, new ideas,
and perspectives. Our diverse employee base
reflects this recognition and are the carriers of
our success. As a result, we are investing in
building the next cadre of empathetic and
smart women leaders who will shape and
transform the business further. The share of
women in Biocon’s permanent workforce
stands at 17 percent. In absolute terms, the
composition of the total number of women
in the workforce increased to 1,531 in FY22
from 1,354 in FY21.

Our concerted and focused efforts have been

recognized by UN Women, as the winner in
the ‘Transparency and Reporting’ category
for exemplary practices in embracing
Women’s Empowerment Principles, Asia
Pacific.

In line with our ambition of being an equal

organization by 2030, we have undertaken
several initiatives to promote inclusion and
diversity. For example, we have an ‘Equal
Pay for Equal Work’ practice, where
employees are compensated based on
merit, rather than gender, race, or age. We
also ensure that women are well-
represented in every team, and therefore,
we undertake distinct developmental
programs to prepare them for managerial
and leadership roles.

52 | ESG Report
2022
 Biocon
Limited

Creating an Inclusive Workplace

An inclusive workplace is key to driving growth in
the organization. This enables higher employee
engagement, better innovation, and higher
employee recognition.

To bolster and action our commitment, we have

11
Parental leave is understood as maternity leave for
Biocon Limited, India.
focused on building and expanding our diversity
and inclusion networks. At Biocon Biologics, we
have institutionalized the diversity, equity, and
inclusion (DE&I) Council and launched a three-
structured employee resource group. This includes
creation of 6 Biocon Women Network chapters and
programs such as Back to Work and Old-Timers
Network. We also support women in science
through various activities, including mentoring.
Moreover, in FY22, we launched the Biocon Women
Mentors & Coaches Network for 300+ gender diverse
students across STEM colleges and universities in
India.

To ensure that our employees can manage and

perform their roles effectively, BioWin has been
operationalized to promote healthy work life
balance. A key pillar of BioWin is the maternity
leave benefit programs. In FY22, 1,299
employees were entitled to maternity leave 11
out of which, 53 employees availed the same
during the reporting year. The rate of return for
employees who took maternity leave stood at
84 percent, and 86 percent for Biocon Limited,
and Biocon Biologics India, respectively.

“When you have a strong support system to not

only guide you through your work but also
provide a sense of assurance, it helps you
rebuild your confidence”, says Lakshmi Bhavani,
who will soon transitioning back to work after
maternity leave, adding, “I had the full support
of my team, especially during the challenging
weeks before I went on leave.”

TransformAction 51
|
“Motherhood brings with it a tangle of responsibilities,
but I was allowed the space to explore the scope of
my work, helping me achieve a good balance
between work and home”, says Vineela A, who
made the shift to a new role that allowed her to
develop new skills and challenge herself.

52 | ESG Report
2022
 Biocon
Limited

Awards12 Empowering our employees

Great Place to Work has certified

Biocon Limited & Biocon Biologics
Limited among the top 10
12.8 (Million
companies in India for best
workplaces in Diversity, Equity, in `)
and Inclusion Employee
Employee Benefits
initiatives including

We pride ourselves on our people-centric

Jobs4her recognized Biocon Limited & approach. This is reflected in our practices for
Biocon Biologics Limited as the the health and well-being of our employees. We
“Top 20 Companies in DivHERsity deployed an app-based wellness initiative–
(Large Enterprises)” and “Top 20
BioPulse, which includes different programs
Most Innovative Practices —
DivHERsity Policies that focus on maximizing the physical, social,
environmental, and emotional well-being of our
employees. In FY22, we conducted various
webinars for health awareness through
BioPulse. This included webinars on eye care &
Working MOTHER & AVTAR has vision, coping with stress and anxiety during
awarded Biocon Limited as one of the pandemic, breast cancer awareness
the Best Companies for Women sessions, and awareness sessions on mothers
and was featured among the 100
returning to work after a maternity break,
Best Hall of Fame for winning
consistently for the 5 years among others. In FY22, a few notable programs
included the celebration of World Health Day,
#IBeatCOVID, yoga and meditation, cancer
awareness sessions, pregnancy care, and
sessions on women’s health concerns and
preventive measures.

TransformAction 53
|
 12
https://www.jobsforher.com/accelherate/DivHERsity-Showcase

54 | ESG Report
2022
 Biocon
Limited

Physical Emotion
Wellbei al
ng Wellbei
ng
• Annual health check ups • Unlimited access to
• Medical benefits counsellor via chat, email
and insurance & call
• Occupation health centre • Emotional
• Access to doctors wellbeing
and specialist awareness
• Gym facility session
• Yoga camps • Health & Iifestyle
• Zumba camps • Guided sessions burn out
• Aerobics and cardio • The wellness corner,
wellness portal and
mobile app to build a
healthy lifestyle

• lnterventions on
occupational hazards
• Health and Safety
guidelines
• Healthy work
environment
• Awareness and
• Preventive awareness
training sessions
session on a monthly
• Safety awareness session
basis
• ‘National Safety Week’
• Access to dieticians

TransformAction 53
|
 for a wing - Employee’s
healthy participation in
lifestyle actvities
• CSR

Environmen Soci
tal al
Wellbeing Wellbei
ng

54 | ESG Report
2022
 Biocon
Limited

At Biocon, we have created an environment a set of five GREAT behavioral traits that is weaved
where our employees are supported and cared into the DNA of our organization.
for beyond their professional aspirations. With
this resolve, we launched VEngage to interact
with and holistically celebrate our people. In
FY22, we undertook various webinars for health
awareness through VEngage. This included
webinars on eye care & vision, coping with
stress and anxiety during the pandemic, breast
cancer awareness sessions, and awareness
sessions on mothers returning to work after a
maternity break, among others.

PILLARS OF EMPLOYEE
ENGAGEMENT
HEALTH &
WELLNESS
Annual
Bioco
BioPuls Health
n
e Checku
Gym
p
VALUE ADDED SESSIONS
Health
Fun@ Knowledge
Awarenes
Bioco – driven
s
n forum
sessions
EMPLOYEE INTEREST GROUP
Biocon
Photograp Biocon
Adventure and
hy Club CSR
Sports Club
Wing
(BASC)

EMPLOYEE ONBOARDING &

SUPPORT
Pre-
Crech Inductio Employment
e n Medical
Check
AWARDS & EVENTS

Bioco Servic Bio

n Day e Contribut
Award e

In our transformative journey, we achieved a

significant milestone three years ago when we
shifted gears to design our ‘Good to Great’ or
g2G initiative. The aim of the initiative is to
establish a culture that embodies our values
while fostering excellence. The initiative includes
TransformAction 55
|
We have enhanced our employees’ skills, was launched across operations, including,
specifically in professional behavior and R&D, quality, supply chain management, IT. The
growth that has enabled them to achieve outcome/insights from the focus-group-
their aspirations and shaped rewarding discussion assisted us to understand employee
careers. concerns, suggestions for improvement and
action planning.

GO-GETTER
Have a Bias for Action

RESPECT every idea

Think Out of the Box

EMPATHY
Fosters Collaboration

APPROPRIATE
Walk the Talk

TRUTHFULNESS
Demonstrate Integrity

Furthermore, as part of our commitment to

bring affordable healthcare to all, we
introduced Biocare, a special access
program for our employees. Through a
digital platform, our people can request for
Biocon’s critical, life-saving medicines for
themselves and their immediate family
members.

Our progress for our employee initiatives

work work in parallel with accelerating
social transformation. In FY22, our
employees represented an extraordinary
drive for transformation. As an example,
Biocon Limited in association with
Narayana Health organized a blood
donation camp at Biocon Park and Campus.
This received a resounding response from
200+ donors at the drive.

Along with wellbeing initiatives, capturing

employee feedback is critical for enabling a
positive work culture. In view of this, we
rolled out the BioPulse Survey, to capture
employee feedback and sentiment. This

56 | ESG Report
2022
 Biocon
Limited

Employee health and safety define improvement measures. Walk through

surveys, measurement of noise levels,
At Biocon, we foster an environment where our illumination, indoor air quality and volatile
employees feel safe, healthy, and inspired. That organic compounds (VOC) monitoring are
is only possible by ensuring the highest degree carried out as a part of assessment in order to
of compliance with applicable laws and
locate various hazards of the workplace.
regulations while enhancing the mental,
Process safety improvement programs are
financial, and physical well-being of our people.
Creating an environment that prevents
accidents and incidents has positive impact on
our business productivity.

Our efforts to create a safe work environment is

evidenced by the facilities that are designed in
accordance with the highest safety standards
and state-of the-art safety controls. We
regularly assess risks through audits of our
equipment, systems, and processes across
various parameters to detect and mitigate
potential hazards. Process safety improvement
programs are regularly carried out across all sites
as part of the safety enhancement initiative.

All manufacturing areas are continuously

monitored in line with stringent industrial
hygiene protocols. For any new and existing
process, periodic safety risk assessment is done
to ensure safety interlocks and controls are
functioning as per the required standards. A
‘Zero Tolerance’ program is present to
strengthen discipline around workplace safety
and make it an integral part of the
organizational culture.

To identify the ground level safety issues, the

department heads periodically conduct GEMBA
walks at the manufacturing site. To undertake
any maintenance activity at the facility, a work
permit system has been established to
ascertain that equipment is isolated and
maintenance work can be carried out. Further,
Electrical safety programs such as lock out and
tag out (LOTO), Arc flash assessment &
Hazardous area classification are also
implemented. Fire safety measures include
maintaining a fire hydrant system, dry sprinkler
powder aerosol (DSPA) fire protection system,
fire extinguishers and an auto modular fire
extinguishing system at the facilities.

All operations undergo periodic third-party

audits to assess safety risks, identify gaps and
regularly carried out across all sites as part of the internal teams and external agencies and
the safety enhancement initiative. Process risk accordingly developed corrective action plans
register is maintained to manage and mitigate to modify our emergency response mechanism.
the residual risks, identified during safety Further, we organized ‘Advanced Firefighting’
assessments and those emerging during sessions conducted by KSFES for our employees,
operations. which focused on preventing fire emergencies
and acting responsibly in a contingency, in a
Our aim is to inculcate an efficient environment, manner that mitigates the risk of loss and
where managers and employees can injuries.
collaborate and drive the health and safety of
our people. To this effect, we also organize
internal and external training sessions on a
periodic basis, aimed at spreading awareness
on the health and safety aspects and guiding our A key event during the reporting period was
employees on prevention and mitigation ‘Red Tag’, an event where employees had to
measures. During the year, several safety- highlight potential workplace hazards. This event
related initiatives, awareness campaigns and was conducted as a part of the larger event of EHS
drives like ‘National Safety Week’ and ‘Fire Culture Building. Furthermore, the Dynamic
Services Week’ were conducted to advocate a Emergency Response Team (ERT) displays safety
“zero incidents” culture amongst employees. In performance boards across key manufacturing
alliance with the Karnataka State Fire and blocks to foster and increase emergency
preparedness and safety performance
Emergency Services (KSFES), we organized mock
awareness. At Biocon, we observed the
fire drills to assess the coordination between
*A Japanese term, which means a workplace walkthrough aimed at
observing employees, ask about their tasks, and identify
productivity gains. TransformAction | 55

58 | ESG Report
2022
 Biocon
Limited

‘Chemical Disaster Prevention Day’ in contractual employees, trainees, volunteers,

December 2021 and conducted awareness consultants, and members of the Board of Directors.
programs to emphasize the importance of At Biocon, we have zero tolerance for any kind of
chemical safety. The main aim of these discrimination or
programs was to commemorate the Bhopal Gas
Tragedy and disseminate information regarding
safe manufacturing, transportation, storage,
and use of chemicals to prevent accidents,
injuries, and loss of property. We also observed
the National Safety Week in March 2022 and
undertook activities such as a safety poster-
making competition and firefighting training.

We also provide our employees, including

workers, with non-occupational medical and
healthcare services at our occupational health
centers, equipped with a competent team of
paramedics and doctors. Our workers are also
provided with non-occupational medical and
healthcare services facilitated through various
initiatives driven by the HR and EHS teams. The
Company carries out a full annual health check-
up for all employees and contract workers,
aimed at identifying potential health problems
and raising awareness about potential
occupational illnesses.

In FY22, Biocon Biologics was

conferred the ’20th Annual
Greentech Safety Award 2021’ for
outstanding achievements in the
‘Safety Excellence’ category.

Over 124 companies, from both public

and private sectors, were in contention
for this national level award.

Actioning Compliance
At Biocon, we have reinforced our commitment
to adhere to our policies on Code of Conduct,
Prevention of Sexual Harassment (PoSH),
among others. We foster an ethical, fair,
equitable and responsible environment that
enables a culture of trust and transparency. This
year we have developed and released our
Human Rights Policy*, which is applicable to all
employees of Biocon Limited and its
subsidiaries, including business partners,
harassment and have instituted robust physical distance, and stay within their allocated
mechanisms for escalation and redressal. zones while working. We also conducted RT-PCR
tests for our employees and undertook contract
Actions to protect our employees tracing, where required. For our employees who
during the pandemic lived in shared residences, we provided additional
support and alternative accommodation, in case
Amid confusion and chaos caused by the
anyone on the premises was detected with
pandemic during the past two years, the
COVID-19.
world had its hopes pinned on the
pharmaceutical industry for recourse. While
our employees were up to the challenge of
providing for our customers, we were “As a scientist, I felt the urge to help those
equally cognizant of the importance of patients who are dependent on Biocon’s
protecting our employees. During the first therapies daily. At a time when COVID-19 cases
wave of the pandemic, even as the nation were surging in India, my family and friends
went into a lockdown, our facilities were concerned about my safety. I explained
remained operational. However, we to them the situation and my reasons for
ensured that the necessary protocols were reporting to work despite the challenges posed
implemented to ensure the safety of our by the lockdown. I was anxious too, but I
employees. We arranged transportation for believe my expertise helped patients, which
employees who were required to come to was the key motivation for me. I’m very
work. Our facilities were completely sanitized, humbled to be able to do my part. I encourage
and the employees underwent thermal everyone to embrace that passion, because
screening while entering the premises. Within we’re in a unique position to help fight this
the facilities, the employees were required pandemic, especially as a biotech company. I
to always wear their masks, maintain felt proud to be able to do my part.” – R&D
team personnel, Biocon Limited

*
Similar principles applicable to Biocon Biologics, currently embedded
56 | ESG Report in its Code of Conduct, is being developed as an independent
2022 global policy document.
 Biocon
Limited

To boost the morale of our frontline workers, we foster a sense of oneness at a time when teams
launched several campaigns like were working virtually.
#SmashCOVID-19Stigma, #BreakTheChain,
#YouAreImportant, Tribute to colleagues lost to COVID-19
and #UnitedAgainstCOVID
on our social media channels to appreciate the The last two years were extremely difficult for
efforts and contributions of our healthcare us, as we lost a few members of our family. We
warriors. Additionally, we launched a dedicated recognize the value of human life and take
microsite, ‘UNITED AGAINST COVID-19’, as a responsibility to support the families of our
one-stop resource for employees to receive all employees who have contributed to the
updates on government guidelines and health company immensely. In addition to the Group
advisories. We have also initiated several online Term Life Insurance and other applicable
programs to provide counseling, healthcare tips, benefits, we undertook additional actions to
and yoga to our employees. assist and support the families.

We have also launched a company-wide Our approach to human resource management

campaign called ‘Your Safety, Our Priority’ with can be described as holistic and forward-
the intent of reinforcing the importance of looking. The families were provided 50 percent
vaccination against the virus by sharing relevant of the employee’s gross salary for two years, up
details on approved vaccines, registration to a maximum payout of ` 5 Million. We also
process, and side effects as well as telling the facilitated a special education allowance that
facts from myths. We also launched a supports two children up to 18 years of age. In
vaccination drive for all our employees and addition, we provided support for the
their dependents. recruitment of either the spouse or the child in
any of our group companies or in another
We also ensured that there was continued suitable field depending on their qualifications
interaction between our leadership team and the and eligibility.
employees through shared videos, messages,
town halls and focus groups to

TransformAction 5
| 7
 Biocon
Limited

Responsible
Action
Towards the
Environment
As part of our commitment towards long-term
sustainability and climate change mitigation, we
aim to reduce our environmental footprint through
the implementation of strategic initiatives that will
bring about a transformative change in how we
interact with the environment. They include
identifying opportunities to increase the share of
renewable energy mix in our operations, improving
energy efficiency, innovating to drive productivity
across our value chain, implementing the principles
of circular economy and adopting digital solutions
which minimize inefficiencies.

TransformAction 5
| 7
58 | ESG Report 2022
 Biocon
Limited

As part of our responsibility towards the kilo litres per day (KLD) capacity zero liquid
environment, we also focus on collaborating discharge (ZLD) effluent treatment plant in
with stakeholders to promote environmental Bengaluru enabling 400,000 litres of
stewardship in communities, thereby ensuring incremental water savings per day and
responsible long-term action towards 680,000 additional savings achieved in FY22
sustainability and climate change mitigation. due to water offset initiatives at BBL facilities

Environmental stewardship has been a key

focus for Biocon since our inception and we
actively promote the same through judiciously
optimizing resources to enhance healthcare
outcomes and improve lives.

Most of our manufacturing processes have a

relatively lower environmental footprint as
compared to conventional pharmaceuticals.
This helps in ensuring we stand out as a
biopharma company that is more sustainable
and less resource intensive.

In order to limit our environmental impact, we

have taken progressive steps to accelerate our
transition towards renewable energy,
implemented efficient recycling of water and
waste and adopted responsible procurement
practices. Furthermore, as an environmentally
responsible company, we go beyond statutory
compliances and embrace responsible business
practices that focus on the judicious use of
natural resources.

We believe that creating a better business and

creating a better world are not conflicting
goals. They are both essential ingredients for
long-term growth and sustainability.

Our approach to managing the environmental

impact is holistic, transformative and inspired
by our desire to promote and strengthen
environmental stewardship. This starts by
managing the environmental impact of our
business including close collaboration and
coordination with our stakeholders, thereby
instilling environmental conscious decision
making in our day-to-day practices.

Key highlights
• 117,697 tCO2 reductions achieved in FY22*, a
12% increase from FY21

• ` 80 million invested in installing a new 600 TransformAction 59

|
• Over 5,500 tonnes of fermentation waste sent • We were awarded the ‘Best Safe industry in
for reuse as an auxiliary fuel to cement the category of Mega industries’ by the
factories* Department of Factories, Karnataka in March
2022
• 100 percent of treated wastewater is recycled
and reused in the process or in utilities • We won the prestigious ‘CII-SR EHS Excellence
Awards 2021’ for Bengaluru facilities for our
• 58 percent of total purchased electricity for commitment to EHS practices in March 2022
BL & BBL Indian operations in FY22 was green
power • In October 2021, we were awarded the
‘Greentech Environment Award 2021’ in the
• 60 percent of solid waste generated in our Environment Protection category for our
operations is sent for recycling Hyderabad facility

• 64,373 hours of EHS training

Awards
• We won the ‘Athyunnatha Suraksha
Puraskara’ from National Safety Council,
Karnataka in September 2021

* BL + BBL (excluding Malaysia)

60 | ESG Report
2022
 Biocon
Limited

and requires them to adhere to it. The Policy’s primary aim

is to ensure environmental stewardship, sustainability,
Biocon enters prestigious Dow and safety. Through this Policy we also aim to
Jones Sustainability Emerging minimize all safety incidents to achieve our
Markets Index target of zero incidents and keep our people
safe. Our EHSS Policy principally alludes to the
Biocon was selected to be in the Dow Jones
precautionary principle.
Sustainability Index (DJSI) in the Emerging Markets
(EM) category for progressive ESG practices, which
Furthermore, our aim is to identify and mitigate
underlines our commitment to the larger goal of
potential environmental impacts by ensuring
sustainable development. We made a formal
submission for Corporate Sustainability that all Biocon facilities meet strict
Assessment for its listing on the DJSI for the first environmental standards and our systems,
time in 2021 and made it to the DJSI EM Index with practices and processes are regularly upgraded
a total sustainability score of 45 as against an to align with leading industry standards.
industry average of 18, achieving a 93rd percentile
position. It is among the Top 15 companies from
India and one of the 12 companies from the pharmaceuticals,
biotechnology, and life sciences sectors to be featured in the
index for 2021. A total of 360 Indian companies Biocon’s mAbs facility
were invited to participate in DJSI in 2021. Biocon receives ISPE Award
has been listed amongst the Top 10 Global Biotech
Companies in 2021 and will strive to improve its We ensure that all new facilities constructed on our
position through future disclosures. campuses are designed with energy-efficient green
building features. Multiple elements of
Sustainability has been among our topmost sustainability were considered during the design of
priorities since inception and both Biocon and our new 340,000-sq. ft. monoclonal antibodies
Biocon Biologics are committed to provide insights (mAbs) manufacturing facility (B3) in Bengaluru to
into their ESG performance to their stakeholders. ensure minimal environmental impact, despite the
large size of the facility. We earned the distinction
The DJSI Index provides an important yardstick for of being the first biopharmaceutical company from
Biocon and Biocon Biologics to measure India to get an honorable mention at the
sustainability performance and continuously International Society for Pharmaceutical
improve reporting on ESG to address the growing Engineering’s (ISPE) Facility of the Year Award (FOYA)
interest of our global stakeholders. for this facility.

further supported by dedicated teams of 178 EHS

EHS governance specialists who are involved in the execution of EHS
management systems. The policy is extended to all
During FY22, Biocon introduced new
our internal and external stakeholders
governance mechanisms with regards to EHS in
the form of enhanced policies, procedures, and
management systems. This new mechanism
comprises the Environment, Occupational
Health, Safety, Sustainability (EHSS) policy which
is driven by the top management. The EHSS policy is
the foundation on which EHS governance is built
and is applicable to the entire Biocon Group.

The Policy is enforced and acted upon by the

EHS heads of BL and BBL, who in turn are
TransformAction 61
|
Additionally, with regards to the EHS
Management System, Biocon has extensively
bolstered it over the last two years by
implementing the PDCA Approach. This
approach is centered around the pillars of
1) Plan; 2) Do; 3) Check; and 4) Act. The
intention behind bolstering this system is to
ensure we are effectively and rapidly
addressing the climate emergency through
strategic transformative actions.

62 | ESG Report
2022
 Biocon
Limited

Bolstered EHS Management System

Plan Do Check Act
Implementation of and alignment Carrying out EHS related Conducting audits Incide
with EHSS policy trainings biannually nt
Development of EHS goals and manageme
Integrating EHS Carrying out
strategic objectives nt
procedures in our compliance
business processes evaluation Creation of action plans
assessments
Undertaking risk planning and Ensuring operational control Ensuring Continual improvement
assessment management
reviews are conducted
Ensuring leadership commitment Developing emergency
management systems

Biocon’s EHS Management System is ISO 14001:2015 and ISO 45001:2018 Certified

Addressing the climate emergency performance, aspirational goals are set as part of
our Environmental Management System (EMS).
Climate emergency is perhaps the biggest
challenge facing humanity in the 21st century Grid power, diesel, and natural gas account for
and requires collective action and transformative a significant share of our direct energy
change to mitigate the impacts. consumption and we are continuously
evaluating options to switch to cleaner sources
At Biocon, we are cognizant of our
of energy. As a result, over the years we have
responsibilities towards sustainable
development, and we are actively taking
necessary steps by collaborating both internally
and externally to ensure we are doing our bit to
address the climate emergency.

This begins by increasing investments to help

decarbonize our operations and build climate
resilience. As a part of our unceasing efforts to
lower carbon emissions over the long term, we
leverage opportunities to increase the share of
renewable energy across our operations through
onsite solar installations and procurement of
wind energy. These efforts have led to an
increase in the share of green power to 58
percent of our total power consumption for BL &
BBL Indian operations. All new facilities
constructed on our campuses integrate green
building design features to optimize resource
use.

To monitor our climate change related

initiatives, targets, objectives, priorities and
TransformAction 61
|
gradually reduced our dependence on traditional
sources of energy and are moving towards more
renewable forms. In FY22 we increased total
renewable energy by
13.6 percent compared to FY21. We strive to
continue increasing the share of clean energy in
our operations in the coming years.

Over the course of FY22, our total energy

consumption (direct and indirect) has increased
by 8.4 percent attributed to increased
production on account of greater demand.

Fig: Total energy consumption - Indirect Energy and Direct Energy

Indirect energy or grid electricity purchased has

increased by 4.2 percent over the course of FY22.
However, we have aimed to ensure we reduce
our electricity purchased from non-renewable
sources, and increase total renewable energy
purchased.

62 | ESG Report
2022
 Biocon
Limited

We have also adopted innovative technologies

like energy efficient centrifugal air compressors,
water chillers and motors to reduce energy
consumption, thereby reducing GHG emissions
from our own operations. Furthermore, the use
of variable refrigerant volume systems and
steam condensate recovery measures have also
helped us reduce our total energy consumption.
Lastly, installed energy efficient economizers in
boilers for steam generation, motors for air
compressors and ETP, and motors for chilled
water and cooling water pumps are also actively
being implemented across our operations.

Fig: Total indirect energy purchased - Renewable and Non- Greenhouse gas emissions (GHG) have
Renewable
increased marginally in FY22 by 1.1 percent on
account of an increase in production, compared
to FY21. The increase, however, is minimal and
Total direct energy consumption has increased our GHG intensity of production has reduced16
by 12.3 percent over the course of the last year compared to last year. This indicates that in
on account of increased production. relative terms we are reducing GHG emissions
across our operations, although our overall
energy consumption is increasing, by
implementing forward looking and
transformative initiatives.

Fig: Total Greenhouse Gas Emissions - Scope 1 and Scope 2

Fig: Total direct energy generation - Across LPG, HSD, Woodchips, Coal,
Furnace, Diesel, and Natural Gas

TransformAction 63
|
Furthermore, by increasing the
efficiency of our production, coupled
with incorporating renewable energy
technologies, we have substantially
decreased GHG emissions.
Increasing energy efficiency and
upgrading our energy mix has also
helped us offset a significant amount
of our total GHG emissions. In FY22
procurement of green power from the
grid has enabled us to offset
approximately 99,000 tCO2.

We also have switched to natural

gas, instead of using furnace oil to
produce steam. Natural gas, a
cleaner fuel, has considerably
lowered GHG emissions compared to
16
Please refer to the “GHG emissions” table in Biocon’s ESG
Scorecard

64 | ESG Report
2022
 Biocon
Limited

furnace oil, and this initiative alone has helped us This addition of solar power complements our
achieve a reduction of 17,045 tCO2. Through existing wind power and balances our renewable
other technological upgradations, such as energy requirements to cater to manufacturing
installation of energy efficient boiler all 24 hours a day throughout the year. Biocon is
economizers that reduce natural gas one of the first pharmaceutical companies to
2
consumption, we achieved a cumulative operate on hybrid renewable energy sources that
reduction of 117,697 tCO 17. includes both wind and solar.
In FY22, we were able to offset approximately 63
percent of our total GHG emissions through
technology upgrades, green power procurement
and fuel switchovers.

Accelerating the Clean Energy

Transition
To further our commitment to a greener and
sustainable future, we have commissioned the This image represents the first captive solar power plant of
first captive solar power plant of 20 MW over 60 20 MW over 60 acres in North Karnataka.
acres in North Karnataka in collaboration with a
leading renewable energy partner. It reduces
carbon emission by 25,000 tons annually.

Fig: Total greenhouse gas emissions offset through various initiatives at Biocon Limited and Biocon Biologics India Operations (tCO2)

Water management actions to mitigate the risks of water scarcity in

the region through responsible consumption.
As our offices and manufacturing units are in
regions that are projected to face moderate to We realize the impact our business has on the
extreme water stress by the mid-21st century, it communities we operate in, and we must be
is imperative for us to take the necessary cognizant of our duty
TransformAction 63
|
to optimally utilize and manage the scarce
freshwater resources that are available to us, as
these sources of water are essential for both
domestic consumption and agricultural use.
Therefore, we have deployed best-in- class
water management practices to appropriately
treat and reuse wastewater within our operations
and facilities, thereby eliminating discharges
into local water bodies and reducing our
demand for freshwater.

64 | ESG Report
2022
 Biocon
Limited

Our efforts to conserve water involve process communities to promote aquifer recharge in the
modifications and the adoption of new communities around our locations of operation.
technologies which allow us to undertake 100
percent recycling of treated wastewater. As our
manufacturing processes are water intensive
we have implemented targeted interventions to
minimize our water footprint.

One of our key initiatives is the introduction of

Membrane Bioreactor (MBR) technology which
improved our water quality in our wastewater
stream. MBR technology was introduced in the
newly installed 600 KLD capacity ZLD effluent
treatment plant in Bengaluru. Based on
advanced membrane bioreactor technology, this
ZLD effluent treatment plant facilitates the
recycling of an incremental 680,000 liters of
water per day and allows us to reuse the treated
permeate for boiler operations.

Furthermore, Multiple Effect Evaporator

(MEE) and biological treatment has been
expanded. Biological treatment is equipped
with Membrane Bioreactors at one of the
facilities to improve our treatment process as
well as to improve the quality of the treated
water.

Our transformative actions with regards to

water management have enabled us to proudly
state that 100 percent of our treated
wastewater is recycled and reused in different
processes and utilities at Biocon Limited and
Biocon Biologics India. We have made substantial
capital investments to upgrade to the latest
advancements in wastewater treatment. ZLD,
an innovative engineering system designed to
treat and reuse wastewater and effluents, is
implemented across all our manufacturing units
in India18.

Through water accounting, audits, demand

management, efficiency initiatives and risk
assessments, we ensure that we responsibly use
the scarce freshwater resources.

To further augment our water conservation

efforts, we have also installed rainwater
harvesting systems at our manufacturing units
to reduce our reliance upon external sources of
freshwater. We have also implemented several
catchment-based interventions in local
TransformAction 65
|
Waste reduction state regulations in India.
We strive to identify opportunities which
promote the circular use of our resources WASTE
Reusable
MANAGEMENT
Container Waste to
and reduce waste disposal in the INITIATIVES
Insulin pens:
Optimization:
Process in
energy:
Diversion of
communities we operate in. This is guided Innovative
which container 5500 tons of
product which
by our approach to waste management and allows
size is fermentation
determined
Digitalization waste to cement
governed by the principles of reduce, administration
Solvent based on the
Plastic
factories,
Free
where
of upto 80 : We have campuses:
reuse, and recycle. We extend our Recycling: volume80%
reduced of they are used
Various steps as
insulin shots
Solvents used
philosophy of circular economy across our product
of that
our paper fuel. Helps
have been
from ina single
need
wastetobybe reduce
taken to waste
phase
operations and within the business value pen, versus
manufacturing shipped.
migrating to a outgoing into
single use
using 80 single
are recovered
chain by actively engaging with our use
andpen.
Has digital
resulted in landfills
plastics onand
our
reduced plastic
platform. offsets
campuses
stakeholders, to effectively articulate our reintroduced
We are also including
desire to enhance environmental equity. into the
trying to adoption of
production
reduce layers reusable water
process. This
within our bottles and
Our EHSS policy clearly articulates reduces the
product recyclable
procedures to manage waste in an Fig: Waste management initiatives at Biocon

environmentally responsible manner.

Monthly reports track and categorize the In FY22, we recycled 60 percent ofthe total waste
waste generated, and our policies ensure generated at Biocon Limited and Biocon
that the waste is appropriately segregated, Biologics. Our approach to waste management
securely stored and safely disposed through involves chronological considerations of the
authorized waste handlers and recyclers, in principles of prevention, reduction, recycling,
compliance with applicable central and recovery, and disposal. We continue to
implement the

64 | ESG Report
2022

18
Only two manufacturing units are in Special Economic Zones (SEZ) where
wastewater and effluents are treated at a Common
Effluent Treatment Plant (CETP)
 Biocon
Limited

following initiatives within our operations and in overall carbon footprint, by designing products
our business value chain to minimize our waste that are not harmful to human or
generation and maximize the recycling and environmental health.’
recovery of wastes. It is our ongoing focus to
continuously reduce the fraction of our waste Environmental awareness and
diversion to landfills. We have introduced engagement
electric waste pickup vehicles as part of the We engage our employees in all aspects of
solid waste management initiative at our SEZ sustainability. From design and
facility in Bengaluru. manufacturing to community

Air emissions
The air emission levels from our operations are
significantly lower than the limits prescribed by
regional pollution control boards and we
monitor the air quality at our manufacturing
units every quarter to track nitrogen oxide (NOx)
compliance. Our transition to cleaner fuels such
as natural gas in our boilers at the two sites in
Bengaluru ensures minimum sulfur oxide (SOx)
and NOx emissions. The use of diesel generators
to generate power (which emits significant
amounts of air pollutants) is restricted to times
when grid power is interrupted. At our
Bengaluru facilities, we have installed state-of-
the-art continuous ambient air quality
monitoring stations (CAAQMS) to improve the
management of air quality parameters through
real time monitoring. Lastly, the partial
replacement of coal to biomass has also helped
reduce the air pollution.

Green Chemistry
Another key area of focus in our R&D
organization is ‘Green Chemistry’ that uses
sustainable or green chemical development
processes which, in turn, reduces or eliminates
the use of polluting substances.

We have initiated several measures in this

regard, including switching from solvent based
reactions to water-based reactions, replacing
hazardous solvents with harmless, greener
solvents, enhancing our solvent recovery
capabilities and improving our processes to
maximize the incorporation

of all materials used. These efforts extend to our

existing as well as new product molecules. Green
chemistry plays a key role in reducing our
TransformAction 65
|
outreach, we aim to embed a culture of we have also promoted conservation through
environmental care. EHS Learning Series, a celebration of the ‘World Environment Day’,
knowledge platform, was launched to share where Biocon employees, along with school
insights on various topics including children, planted 1,000 saplings to emphasize
environmental management. Sessions were the importance of safeguarding the
conducted by eminent speakers and subject environment and biodiversity.
matter experts. In FY22, our employees also
attended specialized EHS training sessions
conducted by reputed external agencies. 35
employees were certified as ISO Internal
auditors and 17 employees as ISO lead auditors
from Biocon Biologics by TUV Nord on ISO 14001
and 45001 standards.

Our employees clocked over 64,373 hours of EHS

training in FY22.

As we have in the past, this year too we

celebrated the World Environment Day to
spread environmental awareness amongst our
employees. To encourage environmental action
amongst employees, we have instituted a
program to recognize and reward innovative
projects that have demonstrated an impact on
emission reduction, energy efficiency and
environmental excellence.

Biocon Biologics has been conferred with the ‘20th

Annual Greentech Safety India Award 2021’ for
outstanding achievements in the ‘Safety Excellence’
category. Over 124 companies from both public
and private sectors were in contention for this
national level award.

Environmental stewardship in our

communities
As we work towards long-term environmental
sustainability, we are determined to create a
positive impact on the environment and
safeguard ecological diversity. As a result, we
have taken proactive steps to conserve
biodiversity around our manufacturing units and
other regions through our corporate social
responsibility (CSR) initiatives.

The ‘Namma Biocommunity’ initiative, which was

started in 2017 by Biocon employees, allows us
to implement change in local communities by
making the environment cleaner, greener, and
safer. Volunteers of the initiative engage with
the local communities through activities like
tree plantation drives, garbage cleanups and
environmental awareness programs. In the past,
 Biocon
Limited

Transforming
our
Communities
We believe that social transformation is only possible
by making a tangible difference in the lives of our
community members. Actions that promote
inclusive growth, such as equal access to
healthcare, education, and sustainable livelihoods,
enable a metamorphosis in the lives of our
beneficiaries. It is our firm belief that investing in
the growth of people is the best utilization of
financial resources.

TransformAction 67
|
66 | ESG Report 2022
 Biocon
Limited

We aim to make a positive impact on our communities. The beneficiaries of these

communities through our Corporate Social projects are primarily determined based on
Responsibility (CSR) arm, the Biocon their socioeconomic status, gender, age,
Foundation. We are acting by designing our information
programs to serve the needs of the
disadvantaged, vulnerable and marginalized
sections of society.

The community-centered approach of our

actions is reflected in the projects and
partnerships we have initiated with like-minded,
credible organizations. This has been undertaken
through signing of memorandum of
understandings and by providing grants to
NGOs, trusts, and academic institutions under the
Grant-in-Aid initiative for innovative and impactful
social projects. The Foundation works across the
following focus CSR areas:

OUR Vitalise preventive Mitigate

STRATEG and primary hunger,
healthcare poverty and
IC malnutrition
OBJECTIV
ES
Empower
Provide safe Ensure
communities
drinking protection of
through
water, the
equitable
sanitation environment
employment
and hygiene and natural
opportunities

Conserve
Reduce inequality traditional
Augment
and empower the art, culture
essential rural
marginalised and sites of
resources
national
importance

Support Contribute to
Facilitate the
projects that welfare funds
development
create and with
of sports
nurture statutory
science and approvals
technology

In FY22, our overall contribution stood at ` 113

million. We are focusing our resources on critical
projects where our engagement has made a
significant difference in the lives of our larger
TransformAction 67
|
asymmetry, infrastructure constraints, lab investigations, doctor consultation and
geographical challenges, and cultural barriers. counseling for lifestyle changes and medication
Armed with the knowledge that transformation adherence.
begins from the ground up, our initiatives are
currently carried out in and around our facilities,
a few remote rural areas with low-resource
settings and in one aspirational district as well. Focus
areas for our CSR activities

• Primary healthcare

• Environmental sustainability

• Rural development

• COVID-19 relief

Our efforts have been recognized at several

national as well as global platforms. We were
awarded the ‘Mahatma Awards 2021‘ on the
eve of Gandhi Jayanti, under the ‘Good health
and well-being’ category. We won the ‘Best
Corporate Foundation Award’ at the World CSR
Congress, 2021 and were bestowed with the
Jury Commendation Certificate for our oral
cancer screening program at the 18th FICCI CSR
Awards in the ‘Exemplary Innovation’ category.
In addition to these awards, the ‘Bengaluru
Women Achievers’ award was conferred upon Dr.
Anupama Shetty, Mission Director, Biocon
Foundation by the Bangalore Political Action
Committee. She also received the ‘South India’s
best CSR Leaders’ award at the National CSR
Leadership Congress & Awards.

Primary healthcare
eLAJ Smart Clinic services:

The Government of India formally launched the

Pradhan Mantri Digital Health Mission (PM-DHM)
on 27th September 2021, to enable unique
health ID for every citizen and build an
integrated digital health infrastructure in the
country. The Biocon Foundation has continually
invested in Information and Communications
Technology (ICT), enabled process innovations
by developing technology-enabled access to
healthcare.

Developed in-house, eLAJ Smart Clinic is a one-

stop solution that addresses the issue of
healthcare delivery in remote areas of the
country. Through these clinics, we provide free

68 | ESG Report
2022
 Biocon
Limited

This platform captures and securely stores appropriate technologies. This Task Force has
electronic patient records to enable the practice developed clear guidelines for the management
of evidence-based precision medicine and of head and neck cancer. It aims to develop a
ensure quality improvement in dispensing strategy to downstage oral cancer in India over
targeted, need-based care to the patient. the next decade.

A total of 20 government-run Primary Health As part of our oral cancer-screening program,

Centers (PHCs) and three Biocon Foundation- the Foundation organized screening camps in
operated health centers across seven districts of partnership with KLE Society’s Institute of Dental
Karnataka, transformed into eLAJ Smart Clinics, Sciences (KLESIDS) in and around Bengaluru and
remained operational in FY22. More than Homi Bhabha Cancer Hospital in Varanasi.
711,000 patient visits have been recorded at
eLAJ Smart Clinics since inception and Our mobile phone-based health technology
approximately 71,000 patient visits were platform captures data and intra-oral images of
recorded in FY22 alone. patients for recognizing the symptoms and
signs of oral cancer in high-risk groups. The
Outpatients exit survey: Six key performance Foundation has built extensive field experience
indicators (KPIs) were identified, and a five-point in early oral cancer screening, strengthening the
Likert scale was used to gauge the patient initiative through a mobile health-based
satisfaction. More than 1,100 patients were (mHealth) approach that equips the staff with
asked to grade their experience on a scale of smartphones to examine people in low-resource
one to five, , with five signifying a very positive settings.
experience.
Our mHealth platform innovation supports early
Oral cancer screening: Addressing the global detection and management of oral precancerous
burden of oral cancer, Biocon Foundation has lesions. The asymptomatic attribute of oral
formed an Oral Cancer Task Force composed of cancer in the early stages results in delayed
eminent national oncologists in 2018, with the presentation and late-stage diagnosis, and
objective of downstaging oral cancer through therefore, high morbidity and mortality. In a
preventive and promotive efforts on ground secure network, the mobile application creates
leveraging on research, advocacy and use of a robust electronic health record, which includes
intra-oral image-based data for active
treatment and surveillance. The frontline health
workers are trained for oral cancer prevention,
Conditions (eLAJ Dashboard) early detection; and subsequent referral with
Breakup by Category the help of remote specialists, even in settings,
where health resources are generally scarce. Our
efforts through
28% the platform were recognized by the CSR Journal
NCDs as one of the ‘Top CSR initiatives for cancer
23%
prevention and early detection on National
Infectio Cancer Awareness Day 2021.
us

NCDs and 51% of all conditions

infectious
diseases
account for
TransformAction 69
|
 gnancy
19%
P
r 7%
e
Musculoskeletal

5%
Gastrointestinal

4%
10% 2% 2% Anaemia
Others Skin ENT

70 | ESG Report
2022
 Biocon
Limited

• The Well Baby Clinics to improve local access to

cures for common childhood illnesses and to address
A cancer treatment NCDs (diabetes and hypertension), common
beneficiary from Varanasi cancers and others

Cancer was a scary word for me. I never thought

that even consuming paan (betel leaves) with
areca nuts could cause oral cancer, until I attended
a screening organized by the Biocon Foundation
and Homi Bhabha Cancer Hospital.

I was initially hesitant to undergo screening, but a

counseling session helped me realize the
significance of screening. The doctors identified
white patches in my mouth, which were symptoms
of oral cancer. I was explained that it was a
precancerous lesion, which could turn into cancer if
not treated.

I panicked and couldn’t come to terms with the fact

that I had been diagnosed with cancer. Since I was
struggling to repay the auto loan, I couldn’t think of
ways to afford the treatment. It was so comforting
to know that it was curable because the cancer
was detected at an early stage and treatment
would be provided free of cost. The screening,
which I was hesitant to attend earlier, changed my
perception about health and life. The cessation
counseling helped me overcome my habit. I am
extremely grateful to the organizations for taking up
such a noble initiative to save the lives of people
like me. I want to thank the entire team for being so
compassionate and patient with me.

Health clinics:

Biocon Foundation also operates clinics that

provide specialist diagnostic, management, and
counseling on a range of issues including
women and child health, nutrition, NCDs and
comorbidities.

• NCD Clinics to diagnose and manage type 2

diabetes and hypertension

• Geriatric Clinics for elderly health issues,

including chronic health conditions

• The Well Woman Clinics provide services to

deal with issues related to sexual and
reproductive health, nutrition, diet related
TransformAction 69
|
 malnutrition concentration was indicative of lack of aerobic
aquatic life. Water quality was calculated as
• Support in augmenting the COVID-19 care per the National
infrastructure at the Anekal General Hospital
in Bangalore.

In FY22, our outreach has expanded to 14,000

patients who have benefited from the services
of these clinics.

Mazumdar-Shaw Advanced Research Center

The former Vice-Chairman of Biocon, John Shaw,

along with Kiran Mazumdar -Shaw, our Executive
Chairperson, have been honored by University of
Glasgow by having the University’s new
research center named after them. The
Mazumdar-Shaw Research Centre will be home
to over 500 researchers, spanning across various
disciplines with far reaching impacts. Their
contribution of ` 580 million in 2019 has been
used to set up a new research hub within the
University campus and create a Professor Chair,
the Mazumdar-Shaw Chief of Molecular Pathology.

Environmental sustainability

Reviving Hebbagodi lake

In 2018, we executed a three-step bioremediation

process using advanced technologies and
implementing innovative solutions to revive the
Hebbagodi lake. We installed trash barriers and
bar screens to stop floating matter from
entering the water body. In addition, we placed
floating wetlands and also installed energy
efficient cascading aerators and submersible
mixers to increase dissolved oxygen and reduce
sludge in the water. We have been regularly
carrying out bioremediation to treat the organic
pollutants. As a result of these concerted
efforts, we successfully restored the ecosystem of
the dying 35-acre Hebbagodi lake.

Regular water quality audits are carried out by

NABL accredited laboratories, through sample
collection and analysis from various points
around the lake. In the year 2017, pre-
intervention assessment of water quality
suggested that several parameters indicative of
chemical, physical, and biological properties
were abysmally poor. The higher COD, BOD & TDS
represented the greater levels of water pollution
and the environmental concern. Nil DO
70 | ESG Report
2022
 Biocon
Limited

Sanitation Foundation Water Quality Index. A covering an area of 460 square meter, has been
comparison between the pre-and post- completed. The project will aim to plant 4,500 square
intervention levels of COD, BOD, TDS, Nitrates feet with 20 varieties of more than 4,000 shrubs,
and DO after our intervention showed a deploying drip irrigation techniques.
significant improvement in the water quality.
Between 2017 to 2022, we have spent over `
82 million towards the Hebbagodi lake
rejuvenation project.

Despite the challenges presented by the

pandemic, our efforts towards lake revival and
maintenance continued unabated to prevent the
waterbody from any degradation. We also
undertook a series of activities along with the
local community, to augment awareness towards
protection of the lake.

Hebbagodi Metro project:

In 2020, the Biocon Foundation partnered with

the Bengaluru Metro Rail Corporation Limited
(BMRCL) to finance the construction of a metro
station at Hebbagodi in Anekal Taluk, Bengaluru.
We pledged to contribute ` 650 million to fund
the construction of the Hebbagodi Metro Station
on Hosur Road and in FY22, over ` 32 Million
was invested in this project by both Biocon
Biologics and Biocon respectively.

The Hebbagodi Metro Station is part of

the new
18.82 km line from R V Road to Bommasandra,
being constructed under Phase II of the
Bengaluru Metro Rail Project. In recognition of
our efforts, the Government of Karnataka issued
an order in December 2020, renaming
Hebbagodi Metro Station to ‘Biocon Hebbagodi
Metro Station’ for a period of 30 years. Once
operational, the metro line is expected to see
an average daily ridership of over millions of
passengers, thereby reducing traffic congestion
and helping in lowering the environmental
impact from vehicular pollution.

Minsk Square landscaping:

To restore a historically important site at Minsk

Square, we initiated a project to create an
urban green space at the heart of Bengaluru.
The landscape design comprises hard-scape and
soft-scape features. Phase I of the project,
TransformAction 71
|
Rural development diverted towards pandemic management, our
health interventions addressed the need for
We work with partners in rural India and
prevention, screening, and control of common
join hands with like-minded organizations to
NCDs such as hypertension, diabetes, and
help improve the quality of learning
common cancer. Our support in setting up the
outcomes. In FY21, we invested to build
infrastructure stands to benefit over 60,000
new buildings at the government higher
patients who annually use the hospital facilities.
primary schools in Huskuru, Bengaluru and
Sira, Tumkuru. The improved infrastructure
will provide an enabling environment to the
students and is expected to positively
influence the learning outcomes.
Additionally, the school infrastructure
project enabled 500 students to avail
access to quality infrastructure.

“We were conducting classes in an old and

dilapidated school building, where walls and
ceilings had developed cracks, posing a risk
to the lives of the students. Our teachers
and students thank the Biocon Foundation
for reconstructing our school despite the
challenges posed by COVID-19. The
infrastructure has created a safe and
fearless learning environment. As the
students return to school, they are going
to
experience a friendly and conducive ambience.”
- Srinivasamurthy R, Headmaster,
Government Higher Primary School,
Huskuru

Regular engagements and interactions

among the local communities has created a
support network across various geographies
in Karnataka. We also undertake Baseline
studies and Focus Group discussions to
understand the needs and challenges of the
communities.

Covid-19 relief
During the reporting period, we undertook
the responsibility of augmenting the COVID-
19 care infrastructure at the Anekal General
hospital and supported the Government in
its pandemic response efforts across other
Primary Health Centres. With resources being
72 | ESG Report
2022
 Biocon
Limited

Biocon Academy biopharma companies, including Biocon.

The Biocon Academy is committed to building In addition to developing a talent pool for the
an ecosystem for biotech related skills in India. industry, we are empowering many faculty
We help create an enabling environment that members of the universities and colleges by
molds everyone into highly capable, forward- imparting industry training in biopharmaceutical
looking self-starters, equipped with the skills, technologies. We are working closely with the
experience and knowledge to move India Karnataka Science and Technology Academy
forward. Since November 2013, over 700
people have received rigorous academic
learning and world class industrial training on
applied aspects of various life sciences
disciplines at the Biocon Academy, and all of
them have earned placements in some of the
top biotech companies in India. The programs
we offer aim to empower biotechnology and
engineering graduates. Through the Biocon
Academy, we partner with esteemed
international education institutions such as Keck
Graduate Institute, California, to deliver
industry-oriented training programs for biotech
students.

To enrich student experience and learning

outcomes, we continue to implement innovative
learning methods such as industry-oriented
case study discussions and comprehensive
project-based learning programs. We have now
launched a unique program in Global
Regulatory Affairs (GRA) in partnership with the
JSS Academy of Higher Education and Research
(JSS AHER), Mysuru. This program is exclusively
structured for students to develop knowledge
on various regulatory practices, clinical
development processes, submission of filings,
regulation for drugs, biologics, and medical
devices. In addition to partly funding the
course fees, we sponsor facilities such as meals
and transportation, which enable students to
retain their focus on their training.

During FY22, 120+ students successfully

graduated from the Academy and found jobs
with leading biotech and biopharma companies
in India including the Biocon Group-Bangalore,
Chennai, Vizag and Hyderabad, Dr. Reddy’s
Labs, Hetero Drugs-Hyderabad; Intas
Biopharma-Ahmedabad and Baxter- Gurugaun.
We are proud to have maintained a 100 percent
placement record in leading biotech and

TransformAction 71
|
(KSTA), Association of Biotechnology Led
Enterprises (ABLE) and Biotecnika to organize
joint webinars and seminars, promoting
biotechnology initiatives across the country.
Over 20 faculty members from more than 10
universities and colleges across India and
Malaysia also received training under the Biocon
Academy Certificate Program in Faculty
Development. For our efforts, we were
awarded the ‘Smart Bio Award’ in 2021 by the
Government of Karnataka under the ‘Best Social
Enterprise/Institute’ category.

72 | ESG Report
2022
 Biocon
Limited

ESG Scorecard
Economic Performance:
Biocon Total refers to Biocon and Biocon Biologics (India and Malaysia).

*Syngene is not included

Economic Value Generated

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Total Revenue ₹ Million 51,114

56,849

Economic Value Distributed and Retained

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Total Operating cost ₹ Million 29,518 34,648
Total employee related expenses (salaries + benefits) ₹ Million 10,808 11,620
Payments to providers of capital ₹ Million 0 0
Payment to government ₹ Million 1,220 1,367
Community investments ₹ Million 97 114
Economic Value Retained ₹ Million 9,471 9,100
Data includes consolidated value excluding Syngene

Philanthropic Contributions
Category Unit Biocon Total Biocon Total
(FY21) (FY22)
CSR expense ₹ Million 98.6 113
Charitable donations % of total CSR 12 0
spend
Community Investments % of total CSR 88 100
spend
Political contributions ₹ Million 0 0

Research and Development

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Research & Development spending $ Million 75.56 78.37
Research & Development spending ₹ Million 5,531 5,950
R&D spending as percentage of Sales % 11.23 11

TransformAction 73
|
No. of R&D positions No. 721 1,057

74 | ESG Report
2022
 Biocon
Limited

Fines/Settlements/Complaints
Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Fines or settlements related to Anti-competitive ₹ 0 0
practices
Ongoing investigations related to anti-competitive No. None None
practices
Confirmed cases of Corruption & Bribery No. 1 0
Current involvement in any ongoing corruption No. None None
and bribery cases
Contributions to and spending for political ₹ 0 0
campaigns,
political organizations, lobbying, trade associations,
tax-exempt entities
No. of incidents of discrimination and harassment No. 1 5
No. of complaints related to Child labour/Forced No. 0 0
labour/
Involuntary labour
Class I product recalls No. 0 1
Class II product recalls No. 0 0
Regulatory agency inspections No. 4 6
Complaints concerning breaches of customer privacy No. 0 0
and
losses of customer data

Environmental Performance*

Material Consumption
Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Raw materials tonnes/annum 23,445 21,859
Associated materials tonnes/annum 6,536 6,164
Semi-manufactured materials tonnes/annum 187 -
Packaging materials tonnes/annum 84 132

TransformAction 73
|
Energy Consumption
Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Natural Gas MWh 201,198 226,790
Diesel MWh 16,492 22,755
Furnace oil MWh 233 0
Coal MWh 9,782 11,192
Wood Chips* MWh 1,581 1,665
HSD* MWh 212 206
LPG* MWh 2,083 1,546
Total Direct Energy MWh 231,581 264,154
Electricity purchased (from non-renewable sources) MWh 141,700 137,200
Electricity purchased (renewable sources) MWh 95,000 110,000
Total Indirect Energy MWh 236,700 247,200
Electricity purchased (renewable sources) MWh 95,000 110,000
Biomass based Energy* MWh 1,581 1,665
Total Renewable Energy MWh 96,581 111,665

*Only BBL Malaysia

GHG Saving Initiatives^

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Green power (purchased) tCO2 85,500 99,000
Furnace oil offset due to natural gas use in steam in tCO2 15,730 17,045
boiler
Boiler economiser induced natural gas savings tCO2 1,362 1,652
Total carbon footprint reduction tCO2 102,592 117,697

^ BL+BBL India Operations’

GHG emissions
Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Scope 1: Direct emissions tCO2 55,997 62,253
Scope 2: Indirect emissions tCO2 127,530 123,480
Total GHG emissions tCO2 183,527 185,733
GHG emission intensity tCO2 eq/Revenue in 3.59 3.27
Million ₹*
* Exchange rate used: INR 77.77 to USD 1

74 | ESG Report
2022
 Biocon
Limited

Emissions of ozone-depleting substances (ODS)

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
HCFC-22 or R-22 tonnes 0.15 0.7

Air Pollutant Management

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Particulate matter tonnes/ 19.20
(PM) Nitrogen annum
31.2**
Oxide (NOx) tonnes/annu
0.60
Sulfur Oxide m
0.76**
tonnes/
annum 13.58 9.4**
*Excludes BBL Malaysia
**BBL Malaysia: PM, NOx and SOx levels are monitored and are within the regulatory limit

Water Sourcing and discharge

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Municipal water supplies (or from other water million m3 1.74 1.71
utilities)
Fresh surface water (lakes, rivers, etc.) million m3 0.00 0
Fresh groundwater million m 3
0.00 0
Total Withdrawal million m 3
1.74 1.71
Discharge post treatment million m 3
0 0
Treated wastewater recycled % 100 100
*2 Sites in India (Hyd and Vizag) and Biocon Malaysia send wastewater to Common Effluent treatment plant (CETP) for further
treatment

Waste generation and disposal and method*

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Hazardous MT 17,147 24,748
Authorised BMW waste handler MT 30 160
Authorised disposal agency MT 1,059 8,548
Authorised e-waste recycler MT 3 10
Authorised recycler MT 10,109 10,463
Authorised reprocessor MT 23 157
Authorised TSDF MT 4,868 4,774

TransformAction 75
|
 incineration/co-processing MT 1,056 628
*BL and BBL (India+Malaysia)

76 | ESG Report
2022
 Biocon
Limited

Waste generation and disposal and method*

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Non-Hazardous MT 9,735 11,154
Authorised disposal agency MT 1,351 -
Authorised recycler MT 220 1,843
Composting MT 88 0
Co Processing MT 5,929 7,153
Recycling or reuse MT 2,147 2,158
*BL and BBL (India+Malaysia)

Social Performance

Employee Information
Category Employees Unit Biocon Total Biocon Total
(FY21) (FY22)
Male No. 124 137
Female No. 19 20
Senior management (L12+) <30 No. 0 0
30-50 No. 88 103
>50 No. 55 54
Male No. 2,910 3,107
Female No. 466 525
Middle management (L5-11) <30 No. 143 218
30-50 No. 3,105 3,322
>50 No. 128 92
Male No. 3,784 4,014
Female No. 869 986
Junior management (L1-L4) <30 No. 2,518 3,034
30-50 No. 2,114 1,955
>50 No. 21 11
Male No. 1,611 1,687
Female No. 460 469
Contractual employees <30 No. 1,001 948
30-50 No. 1,087 1,131
>50 No. 69 77

TransformAction 77
|
 Biocon
Limited

New Employee Hires

Category Employees Unit Biocon Total Biocon Total
(FY21) (FY22)
Male No. 52 34
Female No. 12 4
Senior management (L12+)+) <30 No. 0 0
30-50 No. 50 26
>50 No. 14 12
Male No. 571 713
Female No. 97 168
Middle management (L5-11) <30 No. 58 135
30-50 No. 607 739
>50 No. 3 7
Male No. 287 1,465
Female No. 52 422
Junior management (L1-L4) <30 No. 228 1586
30-50 No. 105 301
>50 No. 6 0

Employee Turnover
Category Employees Unit Biocon Total Biocon Total
(FY21) (FY22)
Male No. 17 34
Female No. 3 5
Senior management (L12+) <30 No. 0 0
30-50 No. 12 28
>50 No. 8 11
Male No. 302 709
Female No. 66 149
Middle management (L5-11) <30 No. 15 80
30-50 No. 342 761
>50 No. 11 17
Male No. 522 1,028
Female No. 120 265
Junior management (L1-L4) <30 No. 373 799
30-50 No. 268 491
>50 No. 1 3

TransformAction 77
|
Workforce Breakdown: Gender
Category Unit Biocon Total Biocon Total
(FY21) (FY22)
No. of women in total permanent workforce No. 1,354 1,531
Percentage of women in total permanent workforce % 17% 17%
(as % of
total permanent workforce)
No. of women in top management positions, i.e. No. 2 4
maximum
two levels away from the CEO or comparable
positions
Percentage of women in top management positions, % 0.02% 0.05%
i.e.
maximum two levels away from the CEO or
comparable
positions (as % of total top management positions)

Trainings Man Hours Total Training Hours by Average Training Hours by

Grade Grade
Category FY21 FY22 FY21 FY22
Senior management (L12+) 1,375 1,557 9.62 10.52
Middle management (L5-11) 91,861 67,366 27.21 18.64
Junior management (L1-L4) 159,957 109,341 34.38 21.95
Total 253,193 178,264 31 20.40
Total Training Hours by Average Training Hours by
Gender Gender
Gender Unit FY21 FY22 FY21 FY22
Male Hours 219,108 131,223 32 17
Female Hours 34,538 47,559 26 26

Parental Leave* FY 2020- FY 2021-

21 22
Category Unit Bioco Bioco Bioco Bioco
n, n n, n
Indi Biologic Indi Biologi
a s, a cs,
India India
Employees entitled for maternity leave No. 351 702 486 813

Employees that took maternity leave No. 18 30 25 28

Employees that returned to work in the No. 16 13 21 24

reporting
period after maternity leave ended
Employees that returned to work after No. 14 13 21 24
maternity
leave ended that were still employed 12
78 | ESG Report
2022
 Biocon
Limited

months after
their return to work

Rate of Return to work that took maternity % 89% 100% 84% 86%
leave
Retention rates of employees that took % 0 0 0 0
maternity
leave
*Parental leave includes maternity leaves only

TransformAction 79
|
 Biocon
Limited

Health and Safety Biocon Total (FY21) Biocon Total (FY22)

Category Unit Biocon Total Biocon Total

Fatalities No. 0 0

Near miss incidents No. 47 96

Occupational disease cases No. 0 0

Man hours worked No. 24,627,456 24,454,656

Total working days scheduled to be worked by No. 288 288

the
workforce
Injuries (Total) No. 53 37
Note: Only lost time injuries will be considered
here.
As per internal classification
Lost time injury frequency rate (LTIFR) Rate 2.15 1.51

Suppliers and Procurement spend

Category Unit Biocon Total Biocon Total
(FY21) (FY22)
Total Suppliers No. 1,308 1,194
Critical suppliers No. 304 296
Non-Critical Suppliers No. 1,004 898
Total Procurement spend Million ₹ 17,870 20,700
Procurement spend on Critical Suppliers Million ₹ 16,250 18,120
Procurement spend on Non-Critical Suppliers Million ₹ 1,620 2,580
Procurement spend on locally based suppliers Million ₹ 4,210 5,520
Procurement spend on locally based suppliers(%) % 24% 27%
No of Tier 1 suppliers identified for sustainability high- No. 0 0
risk
No of Non-Tier 1 suppliers identified for sustainability No. 0 0
high-risk

TransformAction 79
|
 Benefits provided to Permanent employees and
Biocon Total
Temporary employees* (FY22)
Category/Types of benefits provided Permanent Contract
Employees ors
Life insurance Yes No
Health insurance Yes Yes (for those who are not
covered under ESIC)
Accident insurance Yes Yes (covered under ESIC)

Parental Medical Insurance (including paternity

Yes Yes (covered under ESIC)
leave option from Biocon Biologics, Malaysia)
Disability Yes Yes (covered under ESIC)
Parental leave (**maternity leave or paternity leave) Yes Yes
Marriage leave (additional to Normal leaves allotted) No No
Bereavement leave (additional to Normal leaves allotted) Yes No
Leave for Haj (additional to Normal leaves allotted) No No
Leave for Baptism (additional to Normal leaves allotted) No No
Leave for Circumcision Ceremony (additional to
No No
Normal leaves allotted)
Retirement provision No No
Stock ownership *Yes No
Transportation Yes Yes
Housing No No
Food allowance Yes Yes
Extra paid holidays Yes Yes
Citizenship leave No No
Children Education Reimbursement Yes No
Higher Education Policy Yes No
Day care facilities Yes Yes
Employee Car Scheme policies Yes No
*For select cadres of employees
**Maternity, surrogacy and adoption

80 | ESG Report
2022
 Biocon
Limited

GRI Standards Index

GRI Classification References
GRI Standards Disclosures Report Section/ GRI
Classification
Chapters index
(reference
pages)
Organizational 102-1 Name of the About the 4
Profile organization
102-2 Report Our 6-9
Activities,
brands, Transformative story
102-3 6-8
products &
102-4 services 6-8
Our Transformative
102-5 4
Location of
102-6 story Our
headquarters Location 6-9
102-7 Transformative story
of operations 6-9
102-8 About the Report
Ownership and legal 46-49
Our Transformative
form
102-9 story Our 40-44, 79
Markets served
Transformative story
102-10 Scale of the
organization Transformi 40-44
ng the
Information on workplace
employees and
102-11 Partnership in Action,
other workers 30-37
ESG
102-12 Supply chain
Scorecard 20-23
Significant Partnership in
102-13
changes to the Action 40-43
organization and its
supply chain

Precautionary Principle Governance in

or
approach action
External
Transformation
Initiatives

progress
Membership
of in
association action
s Partnership in
action

102-14 Statement from Senior Statements 10-18

Strategy
decision maker from the
102-15 Key impacts, risks, and Leadership 20-23
TransformAction 81
|
 opportunities Transformational
progress
in Action
102-16 Values, Governance in Action 31-37
Ethics
principles,
and
standards, and
Integrity
norms
of behaviour
102-17 Mechanisms for advice Governance in Action 31-37
and concerns about
ethics
Governance 102-18 Governance Governance in 31-37
102-19 structure Action Governance 31-37
102-20 Delegating in Action Our 6-8
authority Transformative story
Executive-
level responsibility for
economic,
environmental,
and social topics

82 | ESG Report
2022
 Biocon
Limited

GRI Classification References

Classification GRI Standards Disclosures Report Section/ GRI
Chapters index
(reference
pages)
Governance 102-21 Consulting Materiality assessment 37
stakeholders
on economic, and stakeholder
environmental, and engagement
social
topics
102-22 Composition of the Governance in Action 31-37
highest governance
body
and its committees
102-23 Chair of the highest Governance in Action 31-37
governance body
102-24 Nominating and Governance in Action 31-37
selecting
the highest
governance
body
102-25 Conflicts of interest Governance in Action 31-37
102-26 Role of highest Governance in Action 31-37
governance body in
setting purpose,
values,
and strategy
102-27 Collective knowledge Governance in Action 31-37
of
highest governance
body
102-28 Evaluating the highest Governance in Action 31-37
governance body’s
performance
102-29 Identifying and Governance in Action 31-37
managing
economic,
environmental,
and social impacts
102-30 Effectiveness of risk Governance in Action 31-37
management
processes
102-31 Review of economic, Governance in Action 31-37
environmental, and
social
topics
102-32 Highest governance Governance in Action 31-37
body’s role in
sustainability reporting
102-33 Communicating critical Governance in Action 31-37
concerns

TransformAction 83
|
 102-35 Remuneration policies Governance in action 31-35
102-36 Process for determining Governance in action 31-35
remuneration
102-37 Stakeholders Governance in action 31-35
Involvement
in remuneration

84 | ESG Report
2022
 Biocon
Limited

GRI Classification References

Classification GRI Standards Disclosures Report Section/ GRI
Chapters index
(reference
pages)
Stakehold 102-40 List of stakeholder Materiality 37
er groups assessment
Engageme and
nt stakeholder
engagement
102-42 Identifying and Materiality assessment 37
selecting
stakeholders and stakeholder
engagement
102-43 Approach to Materiality assessment 37
stakeholder
engagement and stakeholder
engagement
102-44 Key topics and Materiality assessment 37
concerns
raised and stakeholder
engagement
Reporting 102-45 Entities included in About the 4
Practice the Total financial
102-46 statements Report About 4
Defining report
102-47 content and topic the Report 37
boundaries
List of material topics
Materiality
102-48 assessment -
and
102-49 Restatements stakeholder
of engagement
102-50
informati NA
102-51 on 4

Changes in 4
102-52 About the
reporting 4
102-53 Report About
Reporting period
the Report 4
Date of most
About the 4
102-54 recent
Report
report
Reporting cycle
About the 4
102-55
Contact point
102-56 Report About
for questions
regarding the the Report
81
report
-
Claims of
reporting in About the
accordance with the Report

TransformAction 83
|
 GRI
Standards GRI Index
GRI content NA
index External
assurance
Management 103-1 Explanation of About the Report 4
Approach the material topic
and its
boundary
103-2 The management About the Report 4
approach and its
components

84 | ESG Report
2022
 Biocon
Limited

GRI Classification References

Classification GRI Standards Disclosures Report Section/ GRI
Chapters index
(reference
pages)
GRI 200 Economic Standard Series
Economic Performance
Indirect Economic Impact
GRI 201: 201-1 Direct economic ESG Scorecard 72
Economic value generated and
distributed
Performance
201-3 Defined benefit plan ESG Scorecard 80
obligations and other
retirement plans

Procurement Practices
GRI 204:
204-1 Proportion of ESG Scorecard 79
Procureme
spending on
nt
local suppliers
Practices
Anti-corruption

GRI 205: Governance in Action 35

Anti-
205-1 Operations assessed
corruption
for risks related to Governance in Action 35
205-2 corruption
Communication
and training about
anti- corruption ESG Scorecard 73
205-3 policies and
procedures
Confirmed
Anti-competitive Behavior incidents of
corruption and
actions
taken

GRI 206:
Anti-
competitive 206-1 Legal actions for Governance in 35, 73
anti- competitive action,ESG
Behavior
behavior, antitrust, Scorecard
and monopoly
GRI 300 Environmental Standards Series practices

Materials
GRI 301: 301-1 Materials used by ESG Scorecard 73
Materials weight
or volume

TransformAction 85
|
Energy
GRI 302: 302-1 Energy consumption ESG Scorecard 73
Energy within the organization
302-3 Energy intensity ESG Scorecard 73
Water
GRI 303: Water 303-1 Water withdrawal by ESG Scorecard 75
source
303-2 Water ESG Scorecard 75
sources significantly
affected by the
withdrawal of water
303-3 Water recycled ESG Scorecard 75

86 | ESG Report
2022
 Biocon
Limited

GRI Classification References

Classification GRI Standards Disclosures Report Section/ GRI
Chapters index
(reference
pages)
Emissions
GRI 305: 305-1 Direct (Scope 1) GHG ESG Scorecard 74
Emissions emissions
305-2 Energy indirect (Scope ESG Scorecard 74
2)
GHG emissions
305-4 GHG emissions intensity ESG Scorecard 74
305-5 Reduction of GHG Responsible action 63
emissions towards environment
305-7 Nitrogen oxides (NOX), ESG Scorecard 75
sulfur oxides (SOX),
and other significant
air
emissions

Effluents and Waste

GRI 306:
306-1 Water discharge Responsible 58-64, 75
Effluents
by quality and action towards
and Waste
destination environment,
306-2 ESG
Scorecard
Waste by type
305-5 ESG Scorecard 75-76
and disposal
method
Water bodies Responsible 58-64
Environmental Compliance
affected by water action towards
307-1 discharges and/or environment
runoff

Supplier Environmental Assessment

GRI 307:
Environment
Non-compliance Responsible 58-64
al
with environmental action towards
Compliance
laws and environment
308-1 regulations

GRI 308:
Supplier
New suppliers Responsible 58-64, 79
GRI 400 Social Standards Series
Environment
that were action towards
al
Employment screened using environment,
Assessment
GRI 401: 401- ESG 76-
New employee hires
environmental
Employme 1 and employee
criteria Scorecard
Scorecard 77
nt turnover ESG 8
401- Benefits provided Scorecard 0
to full-time
employees that are
not provided to TransformAction 85
temporary or part- |
401- ESG 7
time
GRI Classification References
Classification GRI Standards Disclosur Report Section/ GRI
es Chapters index
(reference
pages)
Occupational Health and Safety
GRI 403: 403-1 Workers representation Transforming 55-56
Occupation our
al Health in formal joint
and Safety
workplace management–worker
health and safety
committees
403-2 Types of injury and rates Transforming 55-56, 79
our of injury, occupational workplace, ESG
Scorecard diseases, lost days, and
absenteeism, and
number of work-
related fatalities
403-3 Workers with high Transforming 55-56, 79
our incidence or high risk of workplace, ESG
Scorecard diseases related to their
occupation

Training and Education

GRI 404:
404-1 Average hours of ESG Scorecard 78
Training
training per year
and
per employee
Education
404-2
Programs for Transforming our 46-56
upgrading workplace
employee skills
and transition
404-3 assistance
Transforming our 48-49
programs
workplace
Percentage of employees
receiving
Diversity and Equal Opportunity regular performance
405-1 and career
development
reviews

Non-Discrimination
GRI 405:
Diversity of Governance in Action 31-35
Diversity
governance bodies
and Equal
and employees
Opportuni
ty

GRI 406: corrective actions

Non- taken
Discriminati 406-1 Incidents of
on discrimination and
86 | ESG Report
2022
Child Labor
408-1
 Biocon
Limited

ESG Scorecard

GRI 408:
Child Labor
Operations and Partnership in Action, 40-44, 79
suppliers at ESG
significant risk for Scorecard
incidents of child
labor

TransformAction 87
|
 Biocon
Limited

GRI Classification References

Classification GRI Standards Disclosur Report Section/ GRI
es Chapters index
(reference
pages)
Forced or Compulsory Labor
GRI 409: 409-1 Operations and suppliers Partnership in Action, ESG 40-44,
Forced or 79 at significant risk for Scorecard
Compulsory incidents of forced or
Labor compulsory labor

Human Rights Assessment

GRI 412:
412-1 Operations that Governance in action 30-35, 73
Human
have been subject ESG
Rights
to human rights Scorecard
Assessment
reviews or impact
412-2 assessments
Employee training
Governance in action 34
on human rights
policies or
procedures

GRI 413:
Local Communities
Local
Communitie 413-1 Operations with Transforming 66-71
s local community our
engagement, impact communiti
assessments, and es
413-2 development 66-71
programs
Operations Transforming
with significant actual our
Supplier Social Assessment and potential negative communiti
impacts on local es
414-1
communities

GRI 413:
Public Policy
Supplier
New suppliers that Partnership in Action, 40-44, 79
Social ESG
were screened
Assessment Scorecard
using social
criteria

GRI 415:
Public Policy
415-1 Political contributions ESG Scorecard 72

Customer Health and Safety

GRI 416: 416- Assessment of the Transforming 7
Customer 1 health and safety the 3
Health and impacts of workplace
Safety product and
service TransformAction 87
416- Transforming 7
categories |
2 the ESG
compliance concerning workplace, 3
GRI Classification References
Classification GRI Disclosur Report Section/ GRI
Standards es Chapters index
(reference
pages)
Marketing and Labeling
GRI 417: 417-1 Requirements for product Our Transformative story
Marketing and 6-7
Labeling and service information
and labeling
417-2
Incidents of non- ESG Scorecard 73
compliance
concerning product
and service
417-3
information and
labeling
Customer Privacy
Incidents of non- ESG Scorecard 73
418-1 complian
ce concerning
marketing
communications

Substantiated ESG Scorecard 73

GRI 418:
complaints
Custome
concerning
r Privacy
breaches of
customer privacy
and losses of
customer data

88 | ESG Report
2022
 Biocon
Limited

TransformAction 89
|
 Biocon
Limited

BRSR Index
Section A: General Disclosures
1.Details of the listed entity

Corporate Identity Number (CIN) of the Listed Entity L24234KA1978PLC003417

Name of the Listed Entity Biocon Limited

Year of incorporation 1978

20th KM Hosur Road, Electronic City, Bengaluru –

Registered office address
560 100, India

20th KM Hosur Road, Electronic City, Bengaluru –

Corporate
address 560 100, India

E-mail [email protected]

+91 80 2808
Telephon 2808 /
e
+91 80 4014

Website www.biocon.com

Financial year for which reporting is being done FY 2021-22

BSE Limited
Name of the Stock Exchange(s) where shares are listed
National Stock Exchange of India Limited

Paid-up Capital INR 600,30,00,000

Name and contact details (telephone, email

Mr. Mayank Verma
address) of the person who may be contacted in
Email: [email protected]
case of any queries on the BRSR report

Reporting boundary The reporting boundary for this BRSR Report includes
Biocon Are the disclosures under this report made on a standalone basis Limited (BL) and Biocon Biologics
Limited (India and Malaysia) (i.e. only for the entity) or on a consolidated basis (i.e. for the (BBL),
excluding Syngene International, for the period
entity and all the entities which form a part of its consolidated from 1st April, 2021 to 31st March, 2022.
The entities will financial statements, taken together). collectively be referred to as the ‘Company’ for the
length of

TransformAction 89
|
2.Products/services

2.1. Details of business activities (accounting for 90% of the turnover):

Please refer to page numbers 6 - 9 for an overview of the Company’s services which constitute over 90% of the turnover.*
*Research services of the Company are undertaken by subsidiary Syngene International Limited. Syngene is excluded from the remainder of this report.

2.2. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover):
S. Product/ NIC % of total turnover
No. Service Code* contributed
Manufacture of
1 021 100
pharmaceuticals, medicinal chemical
and botanical products
*As per National Industrial Classification – Ministry of Statistics and Programme Implementationmedicinal chemical and botanical products

3.Operations

3.1 Number of locations where plants and/or operations/offices of the

entity are situated:
Locatio Number of Number of Tot
n plants/offices offices al
3 Manufacturing Locations (1
Nation 1 2
al plant - Bengaluru, 2 plants - 8 1

United States of America,

Internation Switzerland, United Kingdom, 1 1
al United Arab Emirates, 1 2

3.2. Markets served by the entity:

(a) Number of locations

Please refer to page numbers 6 - 9 for information on the number of national and international locations the
Company has offices/ operations.

3.3 What is the contribution of exports as a percentage of the total turnover of the
entity?
Over 54% of the Company’s total revenue can be attributed to its earnings from exports.

(b) A brief on types of customers

The Company is invested in cutting-edge science, key research partnerships and global manufacturing scale to
expand its reach and develop products that address unmet patient needs. Its customers fall under two broad
categories:

Healthcare providers

The Company is focused on delivering high-quality therapies to partners and healthcare systems across the globe.

It has leveraged its unique strength in fermentation technology to develop a differentiated portfolio of generic
Active Pharmaceutical Ingredients (API) which are used in a variety of therapy areas, including cardiology,
immunosuppressants, anti-diabetics, multiple sclerosis and cancer. The APIs developed by the Company have
found application in high quality drugs that treat oncology,

90 | ESG Report
2022
 Biocon
Limited

cardiology, CNS and neurology, orthopedic, pulmonology, gastroenterology, nephrology ophthalmology, and
endocrinology conditions. The Company supplies statins, immunosuppressants, cardiovascular drugs and other APIs
to over 100 countries and has accomplished 33 filings and received 14 approvals for APIs globally.

Biocon operates its biosimilar business through its subsidiary Biocon Biologics Limited (BBL). We develop high-
quality, affordable biosimilars that can expand access to cutting-edge therapeutics for patients globally at our
R&D sites in Bengaluru and Chennai (India). These are manufactured at scale for both developed and
emerging markets in Bengaluru (India) and Johor (Malaysia). Our products are marketed globally through a
hybrid commercial model, wherein we have direct commercial presence in a few countries and in others, we
leverage partners such as Viatris to expand patient reach.

Patients

We discover, develop, and deliver affordable medicines that help transform patient lives. Patients’ health and
wellbeing are our top priority. Our products are helping enhance the healthcare process in both developed and
developing countries, furthering our goal of achieving health equity for all.

Our commitment is to deliver medicines to a vast proportion of people and ensure better patient outcomes.
Over the past 20 years, Biocon has leveraged India’s value advantage of scientific talent and advanced
manufacturing to deliver scale, speed and quality that enabled affordable access to complex therapies for
chronic conditions. Through our generics, biosimilars and novel biologics we have strengthened our value
proposition to reflect our four strategic pillars: accessibility, affordability, availability, and assurance.

Our global portfolio of APIs has catered to over 700 pharma companies, with an impeccable track record of
quality, safety, and reliability, for the past 20 years.

The Company’s biosimilar portfolio has benefitted over 5.3 million Patients worldwide in FY22.

Biocon’s subsidiary Biocon Biologics has launched a special program, ‘Mission 10 cents,’ to offer governments
of Low- and Middle-Income Countries (LMIC) (specifically in the Philippines and Tanzania) its products for less
than 10 U.S. cents a day.

4.Employees

4.1 Details as at the end of Financial Year: Employees and workers (including
differently abled):
For information on the employee force at the Company, please refer to page number 76 of this Report.
Note: The Company does not have any ‘Workers’ as defined in the guidance note on BRSR

4.2. Differently abled Employees and workers

Tot Male Femal
S. No Particulars e
al No. (B) % (B / A) No. (C)
(A % (C /
) A)

Differently abled employees

1. Permanent 2 2 100 - -
(D) %

Other
2. - - - - -
than
Permanent
(E)
3. 2 2 100 - -
Total % TransformAction 91
|
differently
 *Data excludes BBL Malaysia numbers
Note: The Company does not have any ‘Workers’ as defined in the guidance note on BRSR

92 | ESG Report
2022
 Biocon
Limited

4.3. Participation/Inclusion/Representation of women

Tot No. and percentage of

al Females
(A No. (B) % (B /
A)
Board of Directors* 9 2 22%

Key Management Personnel 4 1 25%

*Note: Dr. Kiran Mazumdar Shaw, Executive Chairperson and Mr. Siddharth Mittal, Managing Director & CEO, are members of
the Board of Directors and are also considered Key Managerial Personnel.

4.4. Turnover rate for permanent employees

Please refer to page number 48 & 77 of the Report for details on the turnover rate of the Company’s employees.

5.Holding, Subsidiary and Associate Companies (including joint ventures)

5.1. Names of holding / subsidiary / associate companies / joint ventures Does the
entity indicated at
Name of the Indicate whether
% of shares held by column A, participate
holding / subsidiary / holding/
listed entity in the Business
associate companies / Subsidiary/
Responsibility
joint ventures (A) Associate/
initiatives of the
Joint Venture
listed entity?
The % of shares held (Yes/No)
The company is associated with by the Company is
22 entities Of the 22 entities, 20 present in the Yes, Biocon Academy
are subsidiaries while independent financial (Non- Profit company),
Bicara is an associate statement subsidiary of the
and Neo Biocon s. Company, participates in
is a joint venture https://archive.bioco the BR initiatives of the
n. Company.
com/biocon_invrelatio
n_
subsidiary.asp

6.CSR Details
(i) Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No) -Yes

(ii) Turnover (in Rs.) - 17,382 Mn

(iii) Net worth (in Rs.) - 80,929 Mn

*Data for turnover and Net worth are standalone figures

TransformAction 93
|
 Biocon
Limited

7.Transparency and Disclosures Compliances

Complaints/Grievances on any of the principles (Principles 1 to 9) under the National

Guidelines on Responsible Business Conduct:
Grievance FY 2021-22 FY 2020-21
Redressal
Stakeholder Number of Number
Mechanism in Place
of group from whom Number of complaints
(Yes/No) (If Yes, Number
of complaints complaint is complaints filed
pending
then provide complaints
web- filed pending
received during the year resolution at during the year
resolution at
link for grievance
redress policy) * close of the close of the
year year

Communities Yes 0 0 0 0

Investors/
Yes 119 1 184 0
Shareholders

Employees
Yes 1 0 2 0
and Workers

Customers Yes 0 0 0 0

Value Chain Yes 0 0 0 0

Partners
Others
Yes *4 0 0 0
(Please
specify)

* Whistleblowing complaints

**Please note complaints that were material and substantial have been considered.

The Company’s grievance redressal mechanism has been detailed in its process for complaint/grievance redressal
- https://www.biocon.com/whistle-blower-integrity-policy/

TransformAction 93
|
7.1. Overview of the entity’s material responsible business conduct issues
Please indicate material responsible business conduct and sustainability issues pertaining to environmental
and social matters that present a risk or an opportunity to your business, rationale for identifying the same,
approach to adapt or mitigate the risk along-with its financial implications, as per the following format

Indica Financi
te Rationale al implications
Material In case of of the risk or
S. No. whether for identifying
issue risk, approach to adapt opportunity
risk or the risk (Indicate
identified or mitigate
opportuni / positive
ty opportunity or
(R/ negative
O) implicatio
ns)
1 Produc Risk All We have implemented a Negativ
t pharmaceutical system to ensure quality of e:
qualit companies are products and continuous In the case of
y constantly being compliance to regulatory poor product
evaluated on requirements. quality, Biocon
possible recalls, Additionally, through can face
product safety the pharmacovigilance process, reputational as
concerns. Biocon tracks responses to well as operational
actively address product related damage.
risks and continuously This may also
improve the products. lead to a
A dedicated pharmacovigilance decrease in
team tracks and reports customer
complaints received via a satisfaction
purpose-built web portal. and trust.
We also have a toll-free
number, publicly available on
the web portal for patients or
other stakeholders to report
complaints. All reports are
proactively investigated to
ensure that timely action is
taken where
necessary.
Further, all employees
undergo mandatory
pharmacovigilance
training.
2 Research Opportunity R&D investment At Biocon, a key area of Positiv
and has a positive focus is ‘Green Chemistry’ and e:
Developme impact on green we have implemented several Cutting
nt innovation initiatives for the same. These edge
ie: include transitioning from technological
technologies solvent based reactions to innovations can
which are water based reactions, using place Biocon at
developed harmless, greener solvents the forefront of
to reduce instead of hazardous solvents, industry- leading
the environmental enhancing our solvent recovery discoveries and
impact and ESG capabilities and overall, open new
performance of improving our processes to avenues for
an enterprise. maximize the incorporation of business
Therefore, all materials growth.
strategical used.
94 | ESG Report
2022
 Biocon
Limited

ly investing in
R&D and
disclosing
publicly on its
investments
allows internal
and
external
stakeholders
to
understand the
approach and
scale taken by
an
organization.

TransformAction 95
|
 Biocon
Limited

Indica Financi
te Rationale al implications
Material In case of of the risk or
S. No. whether for identifying
issue risk, approach to adapt opportunity
risk or the risk (Indicate
identified or mitigate
opportuni / positive
ty opportunity or
(R/ negative
O) implicatio
ns)
3 Access Opportunity Responsible At Biocon, our aim is to Positiv
& pricing for achieve health equity and e:
affordabili innovative and believe that everyone, Enabling access
ty generic across the globe, has the to affordable
medicines right to access affordable drugs and other
which and quality medicines. services can
take affordable Through our generics, support the
access, positive biosimilars and novel reach and
cost-benefit ratio, biologics businesses, we growth of
and overall consistently work towards Biocon, providing
healthcare costs enhancing our value a competitive
into proposition and deliver best-in- edge
consideration, class
have a high solutions to our
chance of patients.
impacting
Biocon’s reach
and favor
amongst
patients, as
compared to
competitors.
4 Environment Risk Biocon’s To limit the environmental Negativ
al commitment impact of the operations, e:
performan towards Biocon continuously strives to In the case of
ce protecting reduce the carbon footprint, non- compliance
the recycle resources, transition to with
natural renewable energy, adopt environmental
environment and responsible sourcing practices, norms and
conserving drive productivity across the regulations,
resources has value chain and adopt digital Biocon can face
been embedded solutions that reduce reputational
in our value inefficiencies damage as well
system. For more details on the as well as
Upholding initiatives undertaken, please adverse financial
these principles refer to: please refer to the repercussions
and complying chapter - “Responsible Action
with applicable towards Environment”
regulatory
requirements can
affect the overall
performance and
enhance Biocon’s
image with the
stakeholders.

TransformAction 95
|
96 | ESG Report
2022
 Biocon
Limited

Indica Financi
te Rationale al implications
Material In case of of the risk or
S. No. whether for identifying
issue risk, approach to adapt opportunity
risk or the risk (Indicate
identified or mitigate
opportuni / positive
ty opportunity or
(R/ negative
O) implicatio
ns)
5 Safe Risk As a Biocon implements robust Negativ
& responsible procedures and continuous e:
empoweri employer, it is process safety improvements The absence of a
ng our duty to at all the sites to show safe and
workplace create a safe commitment towards a zero- empowering
and healthy incident safety culture. There workplac
workplace that is are employee training and e could result in
free of injuries, protocols for preventing, adverse financial
fatalities reporting and addressing consequences such
and illness. behavior that is not in line with as fines and
In addition to the Business Principles and penalties.
this, it is standards, including sexual, Additionally, it
imperative to discriminatory or other could lead to
foster a misconduct. operational and
conducive For more details on the reputational
workplace that initiatives undertaken, please damage
attracts and refer to ‘Employee
retains talent by Health and Safety’.
enabling To inculcate an
empowerment, empowering workplace, we
growth, have developed stringent
flexibility, processes which focus on
remuneration enabling our employees to
and achieve their personal
purpose. aspirations as well as
their professional goals.
For more information please
refer to the chapter -
Transforming our
workplace
6 Digitizatio Opportunity Utilization of Biocon is investing in Positiv
n digital building a robust digital e:
technology to architecture that will support Digitization can
improve data platforms networks lead to improved
efficiency in across all functions. sale and
operations and ESG is at the core of Biocon’s efficiency across
quality digital transformation where operations which
management in the aim is to enhance quality can impact
the and compliance, augment Biocon’s
Pharmaceutical productivity through performance as
Industry is a clear enhanced operational compared to
opportunity for excellence and enable data peers.
Biocon. integrity through technology-
This led data transparency.
includes deploying More information on the
digital initiatives initiatives can be found across
to fully integrate the ESG Report
supply chains and for FY21-22
TransformAction 97
|
 improve
operational
processes,
making
them more
adaptive and
responsive.

98 | ESG Report
2022
 Biocon
Limited

Indica Financi
te Rationale al implications
Material In case of of the risk or
S. No. whether for identifying
issue risk, approach to adapt opportunity
risk or the risk (Indicate
identified or mitigate
opportuni / positive
ty opportunity or
(R/ negative
O) implicatio
ns)
7 Supply Risk In the The integrated supply chain Negativ
chain Pharmaceutical ensures uninterrupted medicine e:
sustainabili Industry, it availability to the customers, Disruption
ty is extremely patients, partners and across Biocon’s
imperative to healthcare systems globally. value chain can
ensure a stable Biocon relies on cost- adversely impact
supply chain to effective and sustainable the operations,
ensure business logistics and supply chain thus hampering
continuity. rationalisation to increase the supply of
Initiatives access, right from the stage of products and
must be procurement of raw materials increasing costs
undertaken to to the last-mile delivery of
anticipate, products to patients.
prevent and Biocon enforces a
mitigate any mandatory minimum level of
concerns that adherence towards
cause environmental compliance for
disruptions. our critical vendors through
periodic
site audits.
Additionally, a Supplier
Code of Conduct to guide
the value chain partners on
applicable laws,
regulations, policies and
procedures, as well as, the
behavioral and ethical
standards has been
developed.
For more information, please
refer to the chapter –
‘Partnerships in Action’
8 Communi Opportunity It is crucial The Biocon Foundation is Positiv
ty that Biocon the principal channel for the e:
engageme engages with the corporate philanthropy By
nt communities we undertaken by the empowering
operate in to Company. and uplifting
increase trust and The aim of this Foundation our
foster is to build resilient solutions surrounding
harmony. that enable underserved communities,
communities to live we can
better, every day. mitigate
The core areas of intervention future
are: grievances or
• Primary Healthcare concerns, thus
safeguarding
• Environmental
Sustainability the business
from any
TransformAction 97
|
 adverse
events
• Rural Development
• COVID-19 Relief

For more details on the

initiatives undertaken,
please refer to the
chapter – Transforming
our
Communities

98 | ESG Report
2022
 Biocon
Limited

Indica Financi
te Rationale al implications
Material In case of of the risk or
S. No. whether for identifying
issue risk, approach to adapt opportunity
risk or the risk (Indicate
identified or mitigate
opportuni / positive
ty opportunity or
(R/ negative
O) implicatio
ns)
9 Inclusion and Opportunity This aspect Numerous steps have Positiv
diversity addresses a been undertaken to build a e:
company’s gender-inclusive workplace, A pool of
ability to ensure which includes an extended diverse
that maternity leave, part-time workforce from
its culture, opportunities for returnees, different
hiring and gender sensitization sessions genders, ages
promotion and women’s health initiatives. and ethnic
practices The Company also has several diversity, will
embrace distinct developmental enable Biocon to
representation programs in place, focused on develop, expand
from a diverse the Company’s female and mitigate
and inclusive employees, operational risks.
workforce geared towards preparing
across all levels of them for managerial and
the organization leadership roles.
(board, senior, The Company has an ‘Equal
mid and junior Pay for Equal Work’ practice in
levels). place, where employees are
compensated based on their
merit, irrespective of the
gender
they identify with.
More information can be
found in the chapter –
Transforming the
Workplace
10 Ethica Risk To ensure the At Biocon, the principles of Negativ
l smooth integrity, transparency, e:
governanc functioning of the accountability and ethics Absence
e company, Biocon resonate throughout the of adherence
has implemented organization. with the
clear systems Professional management policies of the
and defined roles teams and independent Boards Company on
and for Biocon Limited, Biocon business conduct
responsibilities of Biologics Limited and Syngene and ethical
concerned International Limited have been governance can
personnel for built to allow better governance lead to
managing topics across the Biocon Group. reputational as
related to ethics well as
By implementing global best
and integrity operational
practices in corporate
(e.g. anti-bribery damage.
governance and risk
and corruption,
management, we ensure
anti- money
that the Group consistently
laundering, code
preserves and
of conduct,
enhances value.
whistle blowing
etc.). For more details, please refer
to the chapter –
TransformAction 99
|
 Governance in Action

10 | ESG Report
2022
0
 Biocon
Limited

Section B: Management and Process Disclosures

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place
towards adopting the NGRBC Principles and Core Elements.

S. No. Principle Description

Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical,
P1
Transparent and
Accountable

P2 Businesses should provide goods and services in a manner that is

sustainable and safe

P3 Businesses should respect and promote the well-being of all employees, including those in their value
chains

P4 Businesses should respect the interests of and be responsive to all its

stakeholders

P5 Businesses should respect and promote human rights

P6 Businesses should respect and make efforts to protect and restore the
environment
Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is
P7
responsible
and transparent

P8 Businesses should promote inclusive growth and equitable

development

P9 Businesses should engage with and provide value to their consumers in a responsible
manner

TransformAction 99
|
Disclosure Questions P P P P P P P7 P P
1 2 3 4 5 6 * 8 9

1. Policy and management processes

1. 1. Whether your entity’s policy/policies cover Y Y Y Y Y Y N Y Y
each principle and its core elements of the NGRBCs.
(Yes/No)
1.2 Has the policy been approved by the Board? Y Y Y Y Y Y N Y Y
(Yes/No)
1.3. Web Link of the Policies, if available Y Y Y Y Y Y N Y Y

1.4. Whether the entity has translated the policy Y Y Y Y Y Y N Y Y

into procedures. (Yes / No)
1.5.Do the enlisted policies extend to your Yes, the Company’s Supplier Code of Conduct largely
value chain partners? (Yes/No) includes the above-mentioned principles, and the value chain
partners are expected
1.6.Name of the national and international to adhere to the requirements outlined.
codes/ certifications/labels/standards (e.g. - Environmental Management System (ISO
Forest Stewardship Council, Fairtrade, 14001)
Rainforest Alliance, Trustea) standards (e.g. - Occupational Health & Safety Management
SA 8000, OHSAS, ISO, BIS) mapped to each System
principle. ** (ISO
45001)
- Good Manufacturing Practice (GMP) compliance
certification for the Company’s facilities across
Bengaluru, Hyderabad and
Visakhapatnam in India, and Malaysia

1.7.Specific commitments, goals and targets set

Please refer to Chapters - ‘Transforming patient lives’,
by the entity with defined timelines, if any.
‘Partnership in action’, ‘Transforming the workplace’,
‘Responsible action towards environment’ &
‘Transforming our communities’ for an in-depth
description of our actions and commitments towards
1.8.Performance of the entity against the fulfilling the
specific commitments, goals and targets NGBRC principles.
along-with reasons in case the same are not
Please refer to chapters ‘Transforming patient lives’,
met.
‘Partnership in action’, ‘Transforming the workplace’,
‘Responsible action towards environment’ &
‘Transforming our communities’ to get an overview of
our performance against our efforts towards fulfilling the
NGBRC
principles.

2.Governance, leadership and oversight

2.1.Management’s statement
Please refer to page numbers 10 - 19 for statements from our leadership.
2.2.Details of the highest authority policy/policies
responsible for implementation and
2.3.Does the entity have a specified Committee of the Board/
oversight of the Business Responsibility
100 | ESG Report
2022
 Biocon
Limited

Director responsible for decision making on

sustainability related issues? (Yes / No). If yes, The Business Responsibility (BR) policies are broadly
provide details. managed by the Board of Directors, Chief Executive
Officer and the concerned
departmental head(s).

Please refer to page number 14 of the Report for information

on Board
Committees on ESG
*The Company plays a strong role in public policy advocacy through regular engagement with specific external stakeholders
including industry associations, government bodies and regulatory departments. However, the Company does not have a
formal advocacy policy

**Link to the Company’s ISO 14001 & ISO 45001 certifications: http://www.biocon.com/biocon_aboutus_ehspolicy.asp

TransformAction 10
| 1
 Biocon
Limited

2.4.Details of Review of NGRBCs by the

Company:
Indicate whether review Frequenc
was undertaken by y (Annually/ Half
Subject for Review Director / Committee of yearly/ Quarterly/
the Board/ Any Any other –
other Committee please specify)

The Corporate Social Responsibility Committee of

Performance against above the Board assesses the Business Responsibility (BR)
policies and follow up action performance of the Company on a half yearly basis
and reports to the Board. The Board assesses the
report on BR on an annual basis.
Compliance with statutory
The Business Responsibility report is being published
requirements of relevance to the
annually as part of the Company’s annual report in
principles, and rectification of any non-
compliance with the provisions of SEBI Listing
compliances
Regulations, which can be accessed at
www.biocon.com.

Has the entity carried out independent

No, the Company does not conduct an independent
assessment/ evaluation of the working of its
assessment by external agencies. But all Company
policies by an external agency? (Yes/No). If yes,
policies are regularly monitored and reviewed by
provide the name of the agency.
respective policy owners

2.5.If answer to question (1.1) above is “No” i.e. not all Principles are covered by a policy, reasons to be stated:

The Company considers all the principles

The entity does not consider the Principles
material to the business. It does not currently conduct
material to its business (Yes/No)
independent third-party
assessments of its policies.
The entity is not at a stage where it is in a position
to formulate and implement the policies on
specified principles (Yes/No) No
The entity does not have the financial
No
or/human and technical resources available
It is planned to be done in the next financial year (Yes/No) No

Note on P7: While the Corporation may share its expertise to

Any other reason (please help in the formulation of public policy, it does
specify) not directly engage in lobbying or advocacy activities
and hence, does not
have a specific policy for this purpose.

TransformAction |
101
Section C: Principle Wise Performance Disclosure
Principle 1: Businesses should conduct and govern themselves with integrity,
and in a manner that is Ethical, Transparent and Accountable
Essential Indicators
1.Percentage coverage by training and awareness programmes on any of the Principles during the financial
year:

Segment Total number of

Topics / principles Percent of
training and
covered under the persons in respective
awareness
training and its category covered by
programmes
impact the awareness
held
programmes
Board of Directors
13 Business model and 100%
overview of business
units, Technical
specification, building
strategy and Regulatory
Key Managerial Personnel policies and
1 82% (BL)
(BL) updates 90% (BBL)
1 Talent Assessment
(BBL) for customized
development
journey
Employees other than BoD (BL) Trainings cover topics
including BBL values, 93% (BL)
and KMPs*
vision and Company 90% (BBL)
29 (BL)
culture.
135 (BBL)
The topics covered
under training include
Talent Assessment,
mandatory & Functional
SOP Training,
Interpersonal skills &
Leadership development
and Business specific
functional training (such
as Lean 6 Sigma,
Quality
Refresher,
CRE, etc.)
(BL)

Workers The company does not categorize any employee under the worker category.

*Data for employees excludes BBL Malaysia numbers

102 | ESG Report

2022
 Biocon
Limited

2.Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid
in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement
agencies/judicial institutions, in the financial year, in the following format:

Monetary
NGRBC Name of the Amount (In Brief of the Has an appeal
INR) Case
Principle regulatory/ been
preferred?
Enforcement (Yes/No)
agencies/
judicial
institutions

Penalty/ Fine

Settlement
Nil

Compounding

fee
Non-Monetary
NGRB Name of Brief of the Has an appeal
C the Case been preferred?
Principl regulatory/ (Yes/No)
enforcement
agencies/
judicial
Imprisonme
nt Nil
Punishment

3.Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in
cases where monetary or non-monetary action has been appealed.

Nil.

4.Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in
brief and if available, provide a web-link to the policy.

The Company has a Code of Conduct which further highlights the Company’s commitment to do business
with integrity and its zero-tolerance approach towards bribery and corruption. It is applicable to all
operations, regardless of local business practices (https://www.biocon.com/code-of-conduct/)

5.Number of Directors/KMPs/employees/workers against whom disciplinary action was

taken by any law enforcement agency for the charges of bribery/ corruption.

FY 2021- FY 2020-
22 21
Director

s KMPs
Ni Ni
Employee l l

Worker
s
TransformAction |
103
6.Details of complaints with regard to conflict of interest:

FY 2021- FY 2020-
22 21
Number of complaints received in relation to issues of
Conflict of Interest of the Directors
Ni Ni
Number of complaints received in relation to issues of l l
Conflict of Interest of the KMPs

7.Provide details of any corrective action taken or underway on issues related to fines /
penalties /action taken by regulators/ law enforcement agencies/ judicial institutions, on cases
of corruption and conflicts of interest.

Not applicable.

Leadership Indicators
1.Awareness programmes conducted for value chain partners on any of the Principles during the financial
year:

Total number of Topics / principles covered under the %age of value chain
awareness partners covered trainin under the awareness
programmes
The Company has helda ‘Supplier g programmes
The SCoC provides necessary The Biocon’s good practices
Code of Conduct’ (SCoC) that
guidance on topics of training to be document has been shared
provides guidance to value chain
undertaken. The Biocon’s Good with all key KSM/
partners. The SCoC contains
practices covers information intermediate vendors.
critical information on
related to Sustainability,
applicable laws, regulations,
management of Greenhouse gas,
policies and procedures. It also
natural resources and waste
provides direction on the
management.
behavioral and ethical standards
to be met.

2.Does the entity have processes in place to avoid/ manage conflict of interests involving
members of the Board? (Yes/No) If Yes, provide details of the same.

Please refer to page numbers 30 - 36 of the report for details on the processes set in place for conflicting management.

104 | ESG Report

2022
 Biocon
Limited

Principle 2: Businesses should provide goods and services in a manner that is

sustainable and safe

Essential Indicators
1.Percentage of R&D and capital expenditure (capex) investments in specific technologies to
improve the environmental and social impacts of product and processes to total R&D and capex
investments made by the entity, respectively.

Biocon Limited (Amount in Details of improvements in environmental and social impacts

Mn INR)
FY 2021- FY 2020-
22 21
R&D 90 1,22 For details on environmental and social benefits
6 3 driven by the Company, please refer to Chapters -
Cape 2,85 1,31 (‘Responsible action towards the environment’) and –
x 2 2 (‘Transforming patient lives’).
Biocon Biologics (Amount in
Mn INR)

R&D 5,863 4,383

Capex 8,183 10,399

2.Does the entity have procedures in place for sustainable sourcing? (Yes/No) If yes, what
percentage of inputs were sourced sustainably?

Please refer to page numbers 40 - 44 and 79 for overview of our procedures in place for ensuring responsible
and local sourcing. We also have set systems in place to periodically evaluate our suppliers, which are
mentioned in these pages.

3.Describe the processes in place to safely reclaim your products for reusing, recycling and
disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous
waste and (d) other waste.

Please refer to page number 58-65 and 73-76 of the Report for details on the Company’s waste management processes.

4.Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes
/ No). If yes, whether the waste collection plan is in line with the Extended Producer
Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to
address the same.

Our waste collection and management plan in our manufacturing facilities is in line with applicable central and
state regulations. The Company does not have a formal EPR system in place. Steps taken to responsibly collect
and dispose of the various types of waste generated via its operations have been detailed in response to Q.3
above.
 TransformAction | 105

106 | ESG Report

2022
Leadership Indicators
1.Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its
products (for manufacturing industry) or for its services (for service industry)? If yes,
provide details in the following format?

Boundary for which Whether Results

Name of
Product/Service the Life Cycle conducted by communicated in
Perspective
Cradle to/ independent public domain
N
Assessment was external agency (Yes/No) If yes,
Vlidagliptin gate Cradle
conducted (Yes/No) o
provide the web-link.

Mycophenolate to gate N N

mofetil Lenalidomide Cradle to o o

Rosuvastatin gate N N

o
The Company has a Life Cycle Assessment concept in place for our key products considering consecutive and
interlinked stages of a product (or service) system, from raw material acquisition or generation from natural
resources to final disposal.

2.If there are any significant social or environmental concerns and/or risks arising from
production or disposal of your products / services, as identified in the Life Cycle Perspective /
Assessments (LCA) or through any other means, briefly describe the same along-with action
taken to mitigate the same.

Name of Product / Description of the risk / Action

Service concern Taken
Ni NA
Vlidagliptin

l NA
Mycophenolate mofetil

Ni NA
Lenalidomide

l NA
Rosuvastatin
Ni
3.Percentage of recycled or reused input material to total material (by value) used in
production (for manufacturing industry) or providing services (for service industry).

Indicate input Recycled or reused input material to total

material material*
FY 2021- FY 2020-
22 21
Process Solvents 70% 52.5%
*Use of recycled/reused material to total material is not tracked at Biocon Biologics.

4.Of the products and packaging reclaimed at end of life of products, amount (in metric
106 | ESG Report
2022
 Biocon
Limited

tonnes) reused, recycled, and safely disposed.

Please refer to page numbers 58-65 for details on waste management through reuse, recycle and other forms
of disposal undertaken by the Company.

5.Reclaimed products and their packaging materials (as percentage of products sold) for each product
category.

The Company’s waste collection and management plan in its manufacturing facilities is in line with the
applicable central and state regulations. The Company is also currently evaluating EPR applicability in its
business value chain.

TransformAction |
107
 Principle 3: Businesses should respect and promote the well-being of all
employees, including those in their value chains

Essential Indicators
1.Employees

a. Details of measures for the well-being of employees.

Please refer to page numbers 46-53 of the Report for details on employee benefits provided by the Company

b. Details of measures for the well-being of workers:

The Company does not have any ‘Workers’ as defined in the guidance note on BRSR.
2.Details of retirement benefits*:

FY 2021-22 FY 2020-
21
Benefits No. of No. of Deducted No. of No. of Deducted
employees workers and and
covered as covered as a % deposited employees workers deposited
a % of of total with covered covered with
total workers the as a % of as a % of the
employe authorit total total authorit
es y employe workers y
(Y/N/N.A es (Y/N/N.A
.) .)
PF 100% 100% Y 100% 100% Y

Gratuity 100% 100% Y 100% 100% Y

ESI 100% 100% Y 100% 100% Y

for applicable for
employees applicable
(whose gross is employees
less than 21k (whose gross
per month is less than
21k per
month
Others- please - - - - - -
specify
*Please note the data coverage includes India employees.

3.Accessibility of workplaces
Are the premises / offices of the entity accessible to differently abled employees and workers,
as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether
any steps are being taken by the entity in this regard.

Yes

4.Does the entity have an equal opportunity policy as per the Rights of Persons with
Disabilities Act, 2016? If so, provide a web-link to the policy.

The Company has a Code of Conduct which covers equal opportunity for all employees
https://www.biocon.com/docs/Code- of-conduct-2021.pdf

5.Return to work and Retention rates of permanent employees and workers that took parental leave:

Please refer to page number 78 of the Report for details on the Company’s Return to work and Retention rate.
108 | ESG Report
2022
 Biocon
6.Is there a mechanism available to receive and redress grievances for the following Limited
categories of employees and workers?

Yes, the Company has a mechanism to receive and redress grievances.

TransformAction |
109
 If yes, give details of the mechanism
in brief.

Category of Mechanism for grievance redressal

employees and
workers The mechanism comprises of the following steps:

Permanent • The Integrity Committee determines whether the concern or complaint

Workers actually pertains to an unethical/non-compliant activity.
• If the enquiry indicates further action, it is carried out by the
Investigation Committee nominated by the Integrity Committee.
Other than • The investigation would be conducted in a fair manner, as a neutral fact-
Permanent finding process and without presumption of guilt.
Workers • Depending on the seriousness of the matter, the Integrity Committee may
refer the matter to the Audit Committee with the proposed disciplinary
action/counter measure.
Permanent • The Audit Committee may decide the matter as it deems fit. In such
Employees cases, Integrity Committee shall ensure direct access for Whistleblower to
the Chairperson of the Audit Committee.
• In case of dissatisfying solution by the Integrity Committee, employee may
Other than reach out to the Chairman of the Audit Committee.
Permanent
Employees

7.Membership of employees and worker in association(s) or Unions recognised by the listed entity:

The Company is not associated with any associations or Unions.

8.Details of training given to employees and workers:

FY 2021-22 FY 2020-21
Category Total On On Skill Total On On
Health upgradation (D) Skill
(A) and upgradati
safet Health on
y and
measur safety
es measur
es %
Employee No.(F)
% (B / % (F /
s No. (E / No. (C) % (C / A) No. (E)
(B) A) D)
D)
Male 7,250 6,281 87% 5,565 77% 6,782 5,222 77% 3,377 50%

Female 1,541 1,260 82% 953 62% 1,359 1,036 76% 489 36%

Total 8,791 7,541 86% 6,518 74% 8,141 6,258 77% 3,866 47%

*Data excludes BBL Malaysia figures

 Biocon
Limited

108 | ESG Report 2022

TransformAction |
111
 Biocon
Limited

9.Details of performance and career development reviews of employees and worker*

FY 2021-22 FY 2020-21

Category Total (A) No. (B) % (B / A) Total (C) No. (D) % (D / C)

Employees

Male 7,10 5,748 81% 6,673 5,375 81%

0
Female 1,499 1,138 76% 1,288 990 77%

Total 8,599 6,886 80% 7,961 6,365 80%

*The company does not categorize any employee under the worker category.

For more details on our Talent and Organization Development Strategy, please refer to page nos 46-56 of the Report.

10. Health and safety management system

a.Whether an occupational health and safety management system has been implemented by the entity?
(Yes/ No).

Yes, the Company has a well-established occupational health and safety management system in place, detailed
on pages 55-57 of the Report.

If yes, what is the coverage of such a system?

The system has 100% coverage. All internal and external stakeholders of the Company Group, including
personnel associated with its Joint Ventures, suppliers, contractors and other stakeholders like NGO, are
covered as part of the Company health and safety system.

b.What are the processes used to identify work-related hazards and assess risks on a routine
and non-routine basis by the entity?

For details on the Company’s risk management identification and control process, please refer to page
numbers 55-57 of the Report.

For all workplace hazards, the Company conducts routine process safety risk assessments. It has the requisite
permits in place for undertaking non-routine work-related hazards. Integrated process safety management
systems ensure all existing processes and new developments are assessed for risk. Process safety studies such as
Process Hazard Analysis, Equipment Safety Study through techniques including HAZOP, What-if and Risk Matrix are
conducted by cross functional teams. Detailed risk-based assessments are conducted regularly along with
extensive audits to evaluate our health and safety performance at the site level.

c.Whether you have processes for workers to report the work-related hazards and to remove
themselves from such risks?

Several channels are in place for the Company’s workers to report concerns related to health and safety at the
workplace. These include:

• Making use of the Whistleblower policy to report any kind of harmful condition in the workplace.

• Raising concerns during the periodic departmental level safety meetings. Based on the concern/s raised an
action plan, with a strict timeline and a dedicated responsible person, is identified to ensure timely
resolution.

• Following the Standard Operating Procedure on ‘Incident reporting and investigation’

TransformAction |
109
 • In the event of an incident at the site, the workers are required to immediately make a report to the
plant head. The event is analysed by the Investigating team, consisting of cross functional departments,
which is responsible for taking appropriate action

110 | ESG Report

2022
 Biocon
Limited

The Company has also implemented the Hazard Identification and Risk Assessment (HIRA) system to identify
work-related hazards followed by routine risk assessment. We organize regular safety committee meetings to
provide a forum for management, employees and contract workmen to come together to identify and resolve
health and safety problems. The committee meets once every three months and consists of members who
represent employees from all units and departments.

d.Do the employees/ workers of the entity have access to non-occupational medical and healthcare
services?

Yes, the Company’s employees have access to non-occupational medical and healthcare services. Additionally,
the company has well established occupational health centers in its facilities with a competent team of
paramedics and doctors. Periodical examinations of employees are conducted to detect the initial stage of
any occupational disease. Workers’ access to non- occupational medical and healthcare services are
facilitated through various initiatives driven by the HR and EHS team.

11. Details of safety related incidents, in the following format:

For details on the Company’s health and safety track record over the past year, please refer to page number 79 of the
Report.

12. Describe the measures taken by the entity to ensure a safe and healthy workplace.

Please refer to page numbers 55-57 of the Report for details on the measures set in place by the Company to
ensure a safe working environment for all its employees.

13. Number of complaints on the following made by employees and workers

FY 2021-22 FY 2020-
21
Filed during Pendin Remarks Filed during Pendin Remark
the year g resolution the g s
at the year resoluti
end of year on at
the end
of
year
Working Conditions 0 0 - 0 0 -

Health & Safety 0 0 - 0 0 -

14. Assessments for the year

% of your plants and offices that were assessed (by entity

or statutory authorities or third parties)

Health and safety practices 100%

Working Conditions 100%

15. Provide details of any corrective action taken or underway to address safety-related
incidents (if any) and on significant risks / concerns arising from assessments of health &
safety practices and working conditions.

Hazard identification and risk assessment (HIRA) is employed to identify work-related hazards and assess risks
on a routine and non-routine basis. These processes are periodically subject to internal and external audits as
part of EHS Management systems. As part of the audit, competency of persons is also checked to see if
TransformAction |
111
he/she is aware of the standard operating procedure and trained in HIRA. As an outcome of HIRA, for
unacceptable risks, remediation actions are defined by proposing implementation of controls as per hierarchy
of controls.

112 | ESG Report

2022
 Biocon
Limited

Leadership Indicators

1.Does the entity extend any life insurance or any compensatory package in the event of
death of (A) Employees (Y/N) (B) Workers (Y/N).

Yes, the Company provides Group Term Life Insurance and other applicable benefits to their employees.

2.Provide the measures undertaken by the entity to ensure that statutory dues have been
deducted and deposited by the value chain partners.

All statutory compliances related to MSME vendors have been instituted. The Company procures raw materials
from approved vendors, both national and international. Additionally, a periodical audit is also conducted of
all critical suppliers on business sustainability parameters. The company has also instituted a checks and
balances system that ensures that the company’s business partners adhere to national codes on EHS and
labor practices.

3.Provide the number of employees / workers having suffered high consequence work related injury / ill-
health
/ fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and
placed in suitable employment or whose family members have been placed in suitable
employment:

No employee or worker has suffered high consequence work related injury/ill-health or fatality during the reporting
period.

4.Details on assessment of value chain partners:

% of value chain partners (by value of business done with

such partners) that were assessed

Health and safety conditions 100%: All business partners of the Company are
trained to adhere and comply with EHS norms
Working conditions and labor practices.

TransformAction |
111
Principle 4: Businesses should respect the interests of and be responsive to all its
stakeholders

Essential Indicators
1. Describe the processes for identifying key stakeholder groups of the entity.

Please refer to page number 36 of the Report for the process followed by the Company to identify and
interact with its key stakeholders.

2. List stakeholder groups identified as key for your entity and the frequency of
engagement with each stakeholder group:

Stakeholder Group Whether identified Channels of Frequency of Purpose and scope

as Vulnerable & communication engagement of engagement
Marginalized including key
Group
(Yes/No) topics and
concerns
raised during such
engagement

Government and No By Email, through Event driven and as Regarding ANDA/

regulatory authorities phone, In person, need basis DMF/Query response
through meetings submissions, GDUFA
(visual and/or face to & BLA compliance
face) activities, clarification
on
guidelines and advice
on
technical/regulatory
points, controlled
correspondence,
Pre-ANDA meeting,
CARES ACT,
Marketing
Application
submissions, Follow
ups, Discussions,
Query
response submissions
for regulatory
approvals/
permissions,
Post approval
variation
submissions/
Fee payment
correspondence,
Scientific advice

NGOs No Direct Event driven and as Provide support to

Engagement at need basis NGOs for social
the project site, upliftment
CSR
activities and
project team Ensure communities
we operate in are
112 | ESG Report
2022
 Biocon
Limited

engagement, visit
to NGO facilities supported through a
network
and
of
offices
NGOs Creating

shared value

TransformAction |
113
 Biocon
Limited

Stakeholder Group Whether identified Channels of Frequency of Purpose and scope

as Vulnerable & communication engagement of engagement
Marginalized including key
Group
(Yes/No) topics and
concerns
raised during such
engagement

Academia No Meetings, thought Event driven and as Transfer of knowledge

leadership need basis through
events, engagement
campus with students
and
events
universities
Recruitment and
hiring
of freshers

Employees No Townhalls, emails, Regular and on a Providing employees

employee continuous with adequate
engagement basis training and
surveys, grievance development for
career
mechanisms,
progression
training activities,
and appraisals Ensuring
employees are
aligned with
organizational
values and code
of conduct

Addressing employee
grievances
Customers Yes, based Instilling health
on predefined Regular and and safety
criteria such as Customer on a practices in the
income, gender, etc. feedback continuous organization
forms, basis
Ensuring
emails,
customer
telephone satisfaction and
calls needs
are met

Suppliers Resolving customer

No grievances

Regular and Providing

on a affordable
Audits, continuous and
meetings, emails, basis accessible
healthcare
initial screening
Ensuring business
ethics and
alignment with
organizational
TransformAction |
113
 values Ensure
quality of
material is met
Integration of
ESG aspects into
supplier
operations

114 | ESG Report

2022
 Biocon
Limited

Stakeholder Group Whether identified Channels of Frequency of Purpose and scope

as Vulnerable & communication engagement of engagement
Marginalized including key
Group
(Yes/No) topics and
concerns
raised during such
engagement

1. Local community Not all stakeholder Pamphlets / Fortnightly/ Monthly Topics of

Community engagement:
2. Local NGOs groups are considered Meetings meetings
3. Panchayat vulnerable. 1. Building
awareness
4. City Municipal Council towards health
5. Local Education (In the local services
officials community,
6. Local Health officials the company work 2. Sensitization
7. Front-line Healthcare with the lower socio- workshops on
workers economic section of preventive health
8. Civil Society Institutions society) 3. Lake management
9. Local environmentalists updates
10.Residents Welfare 4. Civic issues
Associations 5. Capacity Building
on relevant
topics in health /
education
Local community Yes, based CSR activities, Regular and
on predefined local on a Ensuring community
criteria such as community continuous growth
income, gender, etc. visits basis and development
with regards to
employment,
education,
healthcare,
Investors etc.
No
- Calls/In Person Quarterly/ Enhancing reputation.
Meetings (one Annually, Event To discuss
on one/group) based and need about business
- Annual based performance and
General outlook, details of
Meeting the announced
- Through Press events and to
Releases and discuss about
website concerns/issues (if
Shareholders - Publishing any)
No Annual Report
- Investor
Presentations Annual, Quarterly,
Need
Shareholde Basis
r meets, annual and To discuss
sustainability about business
reports, performance and
communication of outlook, details of
TransformAction |
115
 financial results the announced
through emails, events and to
media and news discuss about
concerns/issues (if
any)

Ensure transparency
and
accountability

116 | ESG Report

2022
 Biocon
Limited

Principle 5: Businesses should respect and promote human rights

Essential Indicators
1.Employees and workers who have been provided training on human rights issues and
policy(ies) of the entity, in the following format:

Category FY 2021-22 FY 2020-21

Employees* Total (A) No. % (B / A) Total (C) No. of employees % (D / C)
of covered (D)
employe
es
covered
(B)

Permanent 6,839 6,298 92% 6,731 6,417 95%

Other than
1,846 1,785 97% 1,741 1,660 95%
permanent

Total 8,685 8,083 93% 8,472 8,077 95%

employees

*Data excludes BBL Malaysia numbers

2.Details of minimum wages paid to employees and workers, in the following format:

Category FY 2021- FY 2020-

22 21
Employees Total (A) Equal More Total (D) Equal More
* to minimum than to minimum than
wage minimum wage minimum
wage wage
% (B / % % (E / % (F
No. (B) No. (C) (C / No. No. /
A) D)
(E) (F)
A) D)
Permanent Male Female 7,503 3,560 47% 3,943 53% 6,406 3,394 53% 3,012 47%

Other than permanent 6,340 2,948 47% 3,392 53% 5,644 3,018 53% 2,626 47%

Male 1,163 612 53% 551 47% 762 376 49% 386 51%

Femal 1,846 990 54% 856 46% 1,741 606 35% 1,135 65%
e
1,433 814 57% 619 43% 1,329 450 34% 879 66%
*Data excludes BBL Malaysia numbers.
413 176 43% 237 57% 412 156 38% 256 62%

TransformAction |
115
3. Details of remuneration/salary/wages (Amount in Mn INR), in the following format:

Biocon Limited:

Male Female
Number Median remuneration/ salary/wages Number Media
of n remuneration/
respective category salary/wages of
respective
category
Board of
Directors
(BoD):
Executive 1 42.20 1 24.60
Directors
Non-Executive,
Non- 1 4.20 - -
Independent
Directors

Non-Executive,
Independent 4 4.87 1 4.68
Directors

Key Managerial
2 7.10 0 NA
Personnel

Employees other
2,819 0.59 380 0.61
than BoD and KMP
*Mr. John Shaw stepped down effective from July 22, 2021 and Mr. Eric Mazumdar was appointed effective from November
1, 2021, hence the details for both of them are not covered.

Biocon Biologics Limited

Male Female
Number Median remuneration/ salary/wages Number Media
of n remuneration/
respective category salary/wages of
respective
category
Board of
Directors
(BoD):
Executive Directors 1 47.50 1 25

Non-Executive,
Non- *1 2.70 - -
Independent
Directors

Non-Executive,
Independent 4 6.07 1 5.54
Directors
Key Managerial
2 27.5 - -
116 | ESG Report
2022
 Biocon
Limited

Personnel
Employees
3,516 0.73 782 0.6
other than BoD
and KMP
*Mr. Thomas Jason Roberts was appointed effective from November 15, 2021

TransformAction |
117
 Biocon
Limited

4.Do you have a focal point (Individual/ Committee) responsible for addressing human
rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes, there is a Compliance Officer who looks after all human right related grievances.

5.Describe the internal mechanisms in place to redress grievances related to human rights issues.

Integrity committee is made available to address such issues consisting of CEO, CFO and Head HR who delegate
the investigation to relevant stakeholders.

The Company has a set procedure to address all complaints and grievances received:

• The Company’s Integrity Committee determines whether the concern or complaint received pertains to
an unethical/non- compliant activity.

• If the enquiry indicates further action, it is carried out by the Investigation Committee nominated by the
Integrity Committee, which consist of the CEO, CFO and Head HR.

• The investigation is conducted in a fair manner, as a neutral fact-finding process and without presumption of guilt.

• Depending on the seriousness of the matter, the Integrity Committee may refer the matter to the Audit
Committee with the proposed disciplinary action/counter measure.

• The Audit Committee may decide the matter as it deems fit. In such cases, the Integrity Committee shall
ensure direct access for Whistleblower to the Chairperson of the Audit Committee.

• In case of dissatisfying solutions by the Integrity Committee, employees may reach out to the
Chairman of the Audit Committee.

6.Number of Complaints on the following made by employees and workers:

Please refer to page number 73 of the Report for information related to Human Rights related cases/complaints.

TransformAction |
117
7.Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment
cases.

The company have Whistle Blower policy & Code of Conduct elaborating formation of committee to address
cases related to discrimination. Additionally, a POSH committee to address harassment related cases. Apart from
this, the code of conduct details the process to be followed in case any such instance happens.

The company has an Integrity and Whistleblower policy which covers measures to protect the complainant:

• If any Whistleblower feels that he/she is experiencing any kind of retaliation, victimization or
discrimination in nature of intimidation, pressure to withdraw the complaint or threats for reporting,
testifying or otherwise participating in the investigation proceedings, he/she should report the
matter to the Integrity Committee.

• As with complaints of unethical/non-compliant activities, such actions of retaliation, victimization or

discrimination too will be treated as misconduct and upon notification and the Integrity Committee will
immediately take appropriate action to prevent/ rectify the retaliation, including. For more details, please
refer to the Company’s policy - https://www.biocon.com/docs/Biocon- Integrity-and-Whistle-Blower-
Policy_2020.pdf)

• The Company also has a POSH committee which addresses harassment related cases.

• Apart from this, the Company’s Code of Conduct details the process to be followed in case of any
discrimination or harassment cases.

8.Do human rights requirements form part of your business agreements and contracts? (Yes/No)

Yes.

9.Assessments of the year

% of your plants and offices that were assessed (by entity or statutory
authorities or third parties)
Child labour
Forced/
involuntary
labour
Sexual Assessment has been done atleast once in all entities by the independent
harassment internal auditor. All the compliances are tracked on an ongoing basis using a workflow,
which covers all the sites/entities.
Discrimination
at workplace

Wages
Others –
please specify

10. Provide details of any corrective actions taken or underway to address significant risks /
concerns arising from the assessments at Question 9 above.

No significant gaps identified as part of the reviews carried out. The company has a process to track the
closure of non-critical observations (If any) identified as a part of such reviews.

118 | ESG Report

2022
 Biocon
Limited

Leadership Indicators

1.Is the premise/office of the entity accessible to differently abled visitors, as per the
requirements of the Rights of Persons with Disabilities Act, 2016?

Yes.

2.Details on assessment of value chain partners.

100%: All business partners of the company are trained to adhere and comply with EHS norms and labor practices.

Principle 6: Businesses should respect and make efforts to protect and restore the
environment

Essential Indicators

1.Details of total energy consumption (in Joules or multiples) and energy intensity, in the following
format:

Please refer to page number 74 of the Report for details on the Company’s energy consumption.

2.Does the entity have any sites / facilities identified as designated consumers (DCs) under the
Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose
whether targets set under the PAT scheme have been achieved. In case targets have not been
achieved, provide the remedial action taken, if any.

Not Applicable

3.Provide details of the following disclosures related to water, in the following format:

Please refer to page number 75 of the Report for details on the Company’s water consumption.

4.Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details
of its coverage and implementation.

Yes, the Company has a zero liquid discharge system consisting of Multiple Effect Evaporation (MEE) and Vertical
Thin Film Dryer (VTDF). Water is treated in a biological treatment system, followed by a three-stage reverse
osmosis system. All water is then recycled for non-process purposes. The system has 100% coverage (only
within the Indian operations of the Company).

5.Please provide details of air emissions (other than GHG emissions) by the entity, in the following
format:

Please refer to page number 75 of the Report for details on the Company’s air emissions.

6.Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its
intensity, in the following format:

Please refer to page number 74 of the Report for details on the Company’s GHG emissions.

7.Does the entity have any project related to reducing Greenhouse Gas emission? If Yes, then provide
details.

Yes, the Company has several initiatives in place to reduce its GHG emissions. It has switched to natural gas,
instead of using furnace oil, to produce steam. The Company is also committed to increasing its share of

TransformAction |
119
 renewable energy in its energy mix, via purchase of green energy from the grid as well as installing onsite
solar technologies and procurement of wind energy.

120 | ESG Report

2022
 Biocon
Limited

Additionally, implementation of energy-efficient boilers have led to a reduction in fuel consumption. Some
examples for energy efficient measures adopted by the Company include:

• Installation of energy efficient centrifugal air compressors;

• Installation of LED lighting to replace fluorescent lamps;

• Power Trading through Indian Energy Exchange;

• Installation of energy efficient air blower motors;

• Installation of solar powered lighting;

• Installation of waste steam recovery system;

• Partial usage of Biomass briquettes as an alternative to coal

For more information, please refer to the chapter “Responsible action towards environment”.

8.Provide details related to waste management by the entity:

Please refer to page number 75, 76 of the Report for details on the Company’s waste generation and management
processes.

9. Briefly describe the waste management practices adopted in your establishments. Describe
the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in
your products and processes and the practices adopted to manage such wastes.

Please refer to page numbers 62-65 of the Report for details on the Company’s waste management practices.

10. If the entity has operations/offices in/around ecologically sensitive areas (such as
national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots,
forests, coastal regulation zones etc.) where environmental approvals / clearances are
required, please specify details in the following format.

No Company offices are located in/around ecologically sensitive areas.

11. Details of environmental impact assessments of projects undertaken by the entity based
on applicable laws, in the current financial year:

Nil

12. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in
India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control
of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details
of all such non-compliances, in the following format:

The company is compliant with all national and state regulations.

TransformAction |
121
 Biocon
Limited

Leadership Indicators

1.Provide break-up of the total energy consumed from renewable and non-renewable sources.

Please refer to page number 74 of the Report for details on the Company’s break-up of total energy consumed

2.Provide the following details related to water discharged:

Please refer to page number 75 of the Report for details on the water discharged.

3.If the entity has undertaken any specific initiatives or used innovative technology or solutions
to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste
generated, please provide details of the same as well as outcome of such initiatives, as per the
following format:

Please refer to page numbers 58-65 of the Report for initiatives/interventions undertaken by the Company to
improve resource efficiency, reduce emissions/effluent discharge/waste generated.

4.Does the entity have a business continuity and disaster management plan? Give details in 100 words/
web link.

The Company’s Disaster Management system covers both natural disasters such as earthquakes and floods as well
as manmade disasters such as bomb attacks among others with key mitigation measures in place. The
authority to implement mitigation manners lies with the Site Controller, Incident Controller, Central Utility In
charge and Shift Engineer in a structured manner. In case of a bomb threat, control measures as per the On
Site Emergency Plan will be initiated by the Site Controller.

The Company’s Information Technology (IT) team has implemented a Disaster Recovery capability which helps
the organization to regain use of critical systems and IT infrastructure instantly in emergency situations and
minimize the impact on business operations.

5.Disclose any significant adverse impact to the environment, arising from the value chain
of the entity. What mitigation or adaptation measures have been taken by the entity in
this regard?

We identify and evaluate the actual or potential aspects and impacts to the environment and climate change
related, whether adverse or beneficial, from its activities, services and facilities through aspect impact
assessment which is a part of our EHS Management Systems. During the evaluation process, significant
impacts to the environment are determined which inturn addresses climate change impacts as well. We
constantly check on existing or future regulations, among others on climate-related issues (e.g. emission trading
schemes, energy efficiency requirements, reporting requirements, climate-related taxes etc.). Based on this,
the businesses are informed on new developments and possible risks.

TransformAction |
121
Principle 7: Businesses, when engaging in influencing public and regulatory
policy, should do so in a manner that is responsible and transparent

Essential Indicators
1.a. Number of affiliations with trade and industry chambers/ associations. - 11

b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such
a body) the entity is a member of/ affiliated to.

Name of the trade and industry Reach of trade and industry

S. chambers/
No. chambers/ associations
1 associations
Federation of Indian Export Organisation (State/National) -

2 (FIEO) Service Export Promotion -

3 Council (SEPC) -

4 Export Promotion Council EOU’S and SEZ’s State

5 (EPCES) Bangalore Commerce & Industry -

6 Chambers (BCIC) Confederation of Indian State

7 Industry (CII) -

8 Hyderabad Management Association (HMA) -

9 The Federation of Telangana Chambers of Commerce -

and
Industry
10 -
(FTCCI) Bulk Drug Manufacturers
11 Association (BDMA) -

2.Provide details of corrective action taken or underway on any issues related to anti-
competitive conduct by the entity, based on adverse orders from regulatory
authorities.

Nil

122 | ESG Report

2022
 Biocon
Limited

Principle 8: Businesses Should Promote Inclusive Growth and Equitable Development

Essential Indicators

1.Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on
applicable laws, in the current financial year.

While the Company does not have a mandatory requirement of conducting SIA of its projects, it conducts
internal assessments and identifies the impacts achieved. The details of the assessments are further shared
during the CSR meetings.

2.Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is
being undertaken by your entity, in the following format.

Not Applicable.

3.Describe the mechanisms to receive and redress grievances of the community.

Sources of Adverse event information/ Complaints/ Medical Information queries:

The Company has set up mechanisms to address the grievances, contextualized for specific community
programs. The strategy to address this is through structured monitoring and evaluation of all programs, with
assessment of stakeholder perceptions, either through regular surveys by the Company’s Foundation team or
third-party impact assessment.

The main grievance of the life sciences student community is the lack of adequate practical skills that is
required in the industry. Biocon Academy plays an active role in reducing the existing skill deficit and is
working on transforming students into industry- ready professionals.

4.Percentage of input material (inputs to total inputs by value) sourced from suppliers*:

FY 2021- FY 2020-
Directly sourced from MSMEs/ small 22 21
producers 25% 15%
Sourced directly from within the
district and neighboring districts 25% 15%

*Data is not captured within BL. Above information is

only for BBL.

Leadership Indicators
1.Provide details of actions taken to mitigate any negative social impacts identified in the Social
Impact Assessments (Reference: Question 1 of Essential Indicators above)

The Company is not mandated to conduct SIA through a third-party. However, internal assessments are done
for the projects implemented. During recent assessments, the Company has identified potential areas where
negative impact could occur (e,g, Lake management, staff concerns in eLaj clinics, etc,) and necessary steps
have been taken to rectify the impact. In the year under consideration, no negative has been identified.

2.(a) Do you have a preferential procurement policy where you give preference to
purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No)

The Company has always strived to work alongside and develop the small and medium enterprises around its
area of operation. The Company procures a considerable part of its goods and avails services from local and

TransformAction |
123
 small vendors, particularly those located around its manufacturing locations. 15-20% of its total supplier base
are small and medium enterprises. There is also a strong corporate directive to develop sourcing capabilities
locally. This enables the Company to achieve multiple benefits like:

124 | ESG Report

2022
 Biocon
Limited

a) Shorter turn-around times for delivery.

b) Promoting Vendor-Managed Inventory, closer to our facilities.

c) Quicker resolution of issues pertaining to material quality.

d) Contribute to the local economy, thereby enhancing sustainability of our operations. Additionally, we
aid the long-term capacity planning for such vendors by sharing forecasts for up to 12 months.

3.Details of beneficiaries of CSR Projects:

Please refer to page number 66-71 of the Report for details on the Company’s CSR projects.

Principle 9: Businesses should engage with and provide value to their

consumers in a responsible manner

Essential Indicators
1.Describe the mechanisms in place to receive and respond to consumer complaints and feedback.

Sources of Adverse event information/ Complaints/ Medical Information queries:

• We receive queries via various methods like telephone calls received on Biocon’s toll free no., emails
received at Drug Safety mailbox ([email protected]), Fax, any postal mails received at Biocon
offices e.g. MedWatch forms received from US FDA etc.

• All AE/ PQC/ MI collection modalities are periodically tested. Further required reconciliation is performed on a periodic
basis.

• MICC call handlers managing the toll free numbers send the information to Drugsafety Mailbox or to the
PQC department depending on their assessment of the type of report.

• All MedWatch forms received as postal mail at 485 US HIGHWAY 1 S Suite B305 ISELIN NJ 08830 are
managed by a designated employee at the US office and these are converted into a scanned pdf and
sent to the Drugsafety mailbox.

• All kinds of information received via different methods in the Drugsafety mailbox are tracked & monitored on all
business days.

2.Turnover of products and/ services as a percentage of turnover from all products/service

that carry information about:

As a percentage to total turnover

Environmental and social parameters relevant to the

product Safe and responsible usage 100%
Recycling and/or safe disposal

TransformAction |
125
 Biocon
Limited

3.Number of consumer complaints in respect of the following:

FY 2021-22 Remarks FY 2020-21 Remarks

Received Pending Receive Pendin
during the resolution d during the g
year at end of year resolution
year at end of
year
Data privacy 0 0 - 0 0 -

Advertising 0 0 - 0 0 -

Cyber-security 0 0 - 0 0 -
Delivery of
16 5 - 10 0 -
essential
services
Restrictive
0 0 - 0 0 -
Trade
Practices
Unfair Trade
0 0 - 0 0 -
Practices

Other 0 0 - 0 0 -

4. Details of instances of product recalls on account of

safety issues:
Number Reasons for
Recall
Voluntary recalls 1 -

Forced recalls Nil -

5.Does the entity have a framework/ policy on cyber security and risks related to data privacy?
(Yes/No) If available, provide a web-link of the policy.

The Company respects the privacy of all individuals and confidentiality of the personal information it holds
about them. Identified as a progressively critical risk, due to the increased adoption of the remote working
model over the course of the COVID-19 pandemic, key mitigation measures were put in place to support
business continuity and ensure safety of operations.

The Company’s IT infrastructure and information security management system is certified to ISO 27001:2013 and
has undergone external third-party audits. This is supplemented with third-party vulnerability analyses
including stimulated hacker attacks.

The manner in which the Company collects, uses, protects or otherwise has been provided in detail in the
Company Privacy policy (Privacy policy). In collecting, using or storing personal data, each employee must
comply with the following:

• Data is obtained from the individual with level of consent required by local laws or internal policies
including where personal data is obtained from third parties

• Data collected is adequate, relevant and used solely for the purpose for which it is collected

TransformAction |
125
 • Personal data is used in accordance with relevant published Privacy laws

• Personal data is kept confidential and secure

126 | ESG Report

2022
 Biocon
Limited

All employees of the Company undergo annual awareness training on information security/cyber security.
Special sessions are also conducted over the course of the year on critical focus areas. A clear escalation matrix
has been established for employees to report suspicious activities in a timely manner. Information security/
cyber security are also included as a parameter for employee performance evaluation.

6.Provide details of any corrective actions taken or underway on issues relating to advertising,
and delivery of essential services; cyber security and data privacy of customers; re-occurrence
of instances of product recalls; penalty
/ action taken by regulatory authorities on safety of products / services.

We take proactive steps in case any issue arises pertaining to any one of these categories. Corrective actions are
also taken to prevent recurrences of similar instance.

Disclaimer

The contents of this report are intended to provide accurate and authoritative information in relation to the subject
matter covered. Information regarding medical products or devices mentioned in the report is not intended to endorse,
advertise, recommend or even act as an alternative to consulting qualified doctors or healthcare professionals. Nothing
contained herein should be construed as an endorsement or be relied upon as the basis for making a decision without
consulting a healthcare professional.
TransformAction |
127
128 | ESG Report
2022
Biocon Limited
20th KM Hosur Road, Electronic City, Bengaluru – 560
100, India Telephone: +91 80 2808 2808
Email: [email protected]
Website: www.biocon.com

Scan this QR Scan this QR

code to code to
download the download the
ESG Report. Annual Report.